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Abstract
Background: Asthma is characterised by symptoms and variable airflow 
obstruction as a result of airway inflammation. Obesity is defined as the 
accumulation of excessive body fat over daily metabolic demands resulting in 
a body mass index (BMI) over 30Kg/m2. Both are increasing in prevalence 
and have been epidemiologicaily linked. This has led to suggestions that 
asthma severity may be influenced by adverse metabolic effects of excess 
adipose tissue or alterations to the mechanics of breathing in obesity.
Whether the asthma severity can be improved by medical weight loss is less 
clear. In this thesis I aim to explore the hypothesis that "Medical weight loss 
improves asthma severity in obese asthmatics.,,
Methods: Obese subjects with a prior physician diagnosis of asthma on 
inhaled medication were randomised to either a medical weight loss (dietician) 
or a control group. Measures of generic and disease specific health related 
quality of life, airway inflammation and bronchial responsiveness were 
measured at baseline, 3 and 6 months using Short Form-36, St George’s 
Respiratory Questionnaire and the Impact of Weight on Quality of Life - Lite 
questionnaires plus bronchial responsiveness to methacholine avoiding deep 
inspiratory manoeuvres, exhaled nitric oxide and induced sputum differential 
cell counts.
Results: 397 subjects were screened for obesity and asthma. Of 91 subjects 
tested for bronchial responsiveness 36.3% did not demonstrate bronchial 
responsiveness and were excluded. There was no significant difference in 
disease specific Health Related Quality of Life between those with and without 
significant bronchial responsiveness. There was a significant correlation 
between HRQoL and BMI but no relationship with other measures of asthma 
severity. 51 patients with obesity and asthma with bronchial 
hyperresponsiveness were randomised into the dietician group (26) and 
control group (25). Both groups achieved weight loss, reaching significance in 
the dietician arm at 3 and 6 months with no significant difference between 
groups. Similar proportions of patients achieved clinically significant weight 
loss (>5% baseline) in both groups. HRQoL scores improved at 3 and 6 
months with no significant differences between groups and no correlation with 
BMI or % weight lost. There was no significant difference between groups for 
induced sputum differential cell counts, exhaled nitric oxide or bronchial 
responsiveness. There was also no correlation between change in weight and 
these variables.
Conclusion: In a population of obese asthmatics on medication there was a 
significant effect on health related quality of life influenced by BMI rather than 
asthma severity. Moderate weight loss was achieved with medical 
intervention, but there were no clear relationships between BMI, markers of 
airway inflammation or airway responsiveness and weight loss did not 
improve measures of asthma severity. The effect of obesity on asthma is 
complicated and further studies are required to investigate the interaction 
between lung volumes, symptoms and inflammation.
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Chapter 1. Introduction
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1.1 Overview
Obesity is a risk factor for the development of asthma1. Possible 
mechanisms include the effects of obesity on the mechanical aspects of 
respiration, symptoms and also the effect of an induced systemic 
inflammatory state associated with obesity which may influence the local 
respiratory tract inflammatory processes leading to airway narrowing through 
bronchial responsiveness2.
Work is needed to understand these processes in more detail, primarily 
by studying changes in airway responsiveness, inflammatory markers and 
symptoms that occur with weight change.
Many studies have been cross sectional and have relied on subjective 
measures to obtain a diagnosis of asthma3. Furthermore, longitudinal weight 
loss studies have generally been based on relatively small numbers of 
patients undergoing surgical weight loss procedures without objectively 
diagnosing asthma4"7.
This research proposes to explore the effect of obesity on symptoms 
and quality of life, airway responsiveness and non invasive markers of airway 
inflammation in subjects with objectively proven asthma. It also explores how 
these variables relate to medically achieved weight loss comparing an 
intervention group with a control.
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1.1.1 Hypotheses:
1. Impairment in health related quality of life (HRQoL) in obese 
asthmatics is better explained by the degree of obesity rather than 
measures of asthma severity such as airway hyper­
responsiveness.
2. A higher BMI leads to increases in asthma severity measured by 
airway responsiveness which improves with weight loss.
3. Change in BMI in obese asthmatics will be associated with 
changes in HRQoL.
4. Obese asthmatics are more likely to lose weight when receiving a 
specific weight loss programme than asthmatics offered standard 
weight loss advice.
5. Change in BMI in obese asthmatics will be associated with 
changes in measures of airway inflammation.
6. Change in BMI in obese asthmatics will be associated with 
changes in airway responsiveness and specific airway 
conductance.
24
1.2 Asthma
The Health Survey for England gave an overall prevalence of a 
combined variable of recent wheeze, asthma diagnosis ever and treatment for 
asthma of 8.1% 8 and the global prevalence of asthma ranges from 1% to 
18% of the population in different countries 9'10 (GINA 2006).
Asthma is a disease of the airways and diagnosis is clinical.11 Although 
there is no agreed definition of asthma, the International Consensus Report 
describes asthma as “a chronic inflammatory disorder of the airways... in 
susceptible individuals inflammatory symptoms are usually associated with 
widespread but variable airflow obstruction and an increase in airway 
response to a variety of stimuli. Obstruction is often reversible, either 
spontaneously or with treatment”12.
The Global Initiative for Asthma uses a descriptive definition of asthma 
as “Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a role. The chronic inflammation is associated 
with airway hyper-responsiveness that leads to recurrent episodes of 
wheezing, breathlessness, chest tightness, and coughing particularly at night 
or in the early morning. These episodes are usually associated with 
widespread, but variable airflow obstruction within the lung that is often 
reversible either spontaneously or with treatment.” This lack of a working 
definition for asthma presents problems for the study of asthma13 and the 
identification of asthma includes a variety of methods.
The fundamental problem in asthma is narrowing of airways caused by 
hyper-responsiveness of airway smooth muscle, airway wall thickening and 
mucous hypersecretion which can lead to recognizable symptoms and signs.
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The driving factor for these changes is airway inflammation usually driven by 
an allergic type response mediated by IgE, mast cells and eosinophils14. 
Various clinical tests can detect these factors.
Asthma shares many symptoms in common with other diseases of the 
respiratory system but also in other systems such as cardiovascular disease. 
Features of an airway disorder such as cough, wheeze and breathlessness 
should be corroborated where possible with measurement of airflow 
limitation15.
As asthma is a multifactorial condition then we need multiple measures to 
monitor its severity. Asthma severity can be monitored by symptoms, tests of 
bronchial responsiveness and measures of airway inflammation. To 
understand these processes it is necessary to explain the pathology of the 
condition.
1.2.1 Symptoms.
Symptoms of asthma are common amongst a variety of diseases but 
the character of symptoms can indicate a diagnosis of asthma. These include: 
wheeze, shortness of breath, chest tightness and cough. The characteristics 
that suggest asthma as a diagnosis being: variability, intermittent, worse at 
night and provocation by triggers or exercise15.
Other factors to consider for a diagnosis of asthma include a personal 
or family history of asthma or other atopic conditions, deterioration after 
exposure to triggers and worsening of symptoms after taking aspirin / non­
steroidal anti-inflammatory medication or the use of (3-blockers.
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1.2.2 Signs.
As asthma is an episodic disease, signs may be absent for most of the 
time. However, during exacerbations, patients may have wheeze which is 
usually diffuse, polyphonic, bilateral and particularly expiratory. Lung function 
will be reduced with an obstructed pattern on spirometry and a reduced peak 
expiratory flow12.
1.2.3 Pathology.
There is widespread acknowledgement that asthma is caused by a 
chronic inflammatory response in the airways13 and this leads to the 
pathological and clinical features of asthma. The syndrome of asthma arises 
from a number of poorly understood inducing stimuli, such as allergens and 
chemicals, in a group of patients who are in some way genetically 
predisposed16. The patient with asthma is ‘primed’ or at risk of severe 
bronchospasm if exposed to trigger factors and may show markedly 
heightened responses to direct bronchoconstrictor agents17.
Histological specimens from lungs of asthmatics show shortening of 
the airway musculature and inflammatory oedema of the whole airway, 
particularly the submucosal layer18. There is thickening of the epithelial 
basement membrane and damage to the bronchial epithelial lining with 
desquamation that exposes the epithelial basement membrane. Excessive 
mucus production occurs due to hypertrophy and hyperplasia of submucus 
glands and goblet cells. The muscularis layer shows smooth muscle cell 
hypertrophy and hyperplasia and there is microvascular dilatation in the 
adventitial layer. All layers of the airway reveal intense infiltration from
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inflammatory and immunological cells in the form of granulocytes, especially 
eosinophils with evidence of degranulation and disgorgement of highly 
histotoxic products such as major basic protein (MBP). There are also 
infiltrations of chronic inflammatory mononuclear cells, including T 
lymphocytes, particularly CD4+ cells19.
1.2.4 Asthma and inflammation.
Asthma is characterised by a specific pattern of inflammation that is 
largely driven via immunoglobulin (Ig)E-dependent mechanisms20. The airway 
wall is oedematous and infiltrated with inflammatory cells, which are 
predominantly eosinophils, lymphocytes, activated mast cells and T- 
lymphocytes. There is vasodilatation, plasma exudation, oedema and 
sensitisation with activation of sensory nerves.
Although most asthmatics are atopic, some have normal total and 
specific IgE and negative skin tests. This “intrinsic" asthma is usually late in 
onset and more severe21. It has a similar pathophysiology to allergic asthma 
with evidence of local IgE production, possibly directed at bacterial or viral 
antigens22. The inflammation leads to increased symptoms directly by causing 
cough and chest tightness by activation of airway sensory nerve endings and 
also indirectly by increased airway hyper-responsiveness. This inflammation 
persists over many years and can cause a chronic inflammatory state.
More recently different inflammatory phenotypes and endotypes23 of 
asthma have been identified by cluster analysis of a heterogenous population 
with different asthma characteristics including inflammatory profiles24,25.
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1.2.5 Inflammatory cells.
The precise role of all inflammatory cells is unknown and no single cell 
can account for the complex pathophysiology of allergic disease, but some 
cells predominate26. Mast cells in airway smooth muscle27 secrete cytokines, 
such as interleukin (IL)-4 and tumour necrosis factor (TNF)-a28. Macrophages 
derived from blood monocytes activated by low affinity IgE receptors 
(FceRII)29, 30 produce many different products, including a large variety of 
cytokines and have an impaired anti-inflammatory role in asthma31'34. 
Dendritic Cells are specialised macrophage-like cells that promote 
differentiation of T-helper (Th)2 cells and eosinophilia important in the allergic 
response .
Eosinophils are characteristic of allergic inflammation and there is a 
correlation between eosinophil counts in peripheral blood or bronchial lavage 
and airway hyper-responsiveness38. Several mediators are involved in the 
migration of eosinophils from the circulation to the airway and prolong survival 
by avoiding apoptosis. Neutrophils are a more prominent cell type in airways 
and induced sputum of patients with more severe asthma39'41 possibly due to 
rapid kinetics of neutrophil recruitment or steroid use42'44, however it is 
possible that neutrophils are actively recruited in severe asthma, with 
increased levels of IL-8 due to increased levels of oxidative stress40,45. The 
role of neutrophils is unknown but it is possible that they may be associated 
with reduced responsiveness to corticosteroids.
T-Lymphocytes coordinate the inflammatory response by release of 
specific patterns of cytokines, resulting in recruitment and survival of 
eosinophils and in the maintenance of mast cells in the airways46. Other cells
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are present such as B-Lymphocytes that secrete IgE47 and Basophils 
whose role is uncertain48.
Lastly, platelets are activated and aggregated by Th2-mediated 
inflammation49, whilst structural cells may also be an important source of 
inflammatory mediators50"52.
1.2.6 Inflammatory mediators.
Various mediators are involved in asthma which produce the effects of airway 
smooth muscle contraction, increased microvascular leakage, increased 
airway mucous secretion and the attraction of inflammatory cells including 
lipid mediators such as cysteinyl-leukotrienes, RAF and prostaglandins which 
are potent constrictors of human airways and also have weak inflammatory 
effects53"65. Cytokines such as IL-4, IL-5, IL-12, il-13 and IL-18 released from 
inflammatory cells are important in chronic inflammation and play a critical 
role in orchestrating the type of inflammatory response56,57. Chemokines 
including eotaxins, RANTES and MCP-4 are involved in the recruitment of 
inflammatory cells in asthma58 acting in sequence in determining the final 
inflammatory response and increasing airway hyper-responsiveness59"61. 
Reactive oxygen species causing oxidative stress result in increased 
concentrations of 8-isoprostane (a product of oxidised arachidonic acid) in 
exhaled breath condensates45 and increased ethane (a product of oxidative 
lipid peroxidation)62. Endothelins induce airway smooth muscle cell 
proliferation and promote a profibrotic phenotype and may therefore play a 
role in the chronic inflammation in asthma63"66. Finally nitric oxide is produced
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by NO synthases in several cells and this will be explored in more detail 
below67,68.
1.3 Markers of asthma severity 
Measurement of inflammation in asthma.
I shall concentrate on two of the least invasive ways to measure 
inflammation in asthma as they have been employed in the methods. These 
are measurement of exhaled nitric oxide and the use of induced sputum.
1.3.1 Biology of Nitric Oxide
Nitric oxide (NO) is formed by the oxidation of the terminal guanidinium 
nitrogen on the amino acid i-arginine via an oxygen and nicotinamide adenine 
dinucleotide phosphate (NADPH) dependent mechanism producing L-citruline 
and nitroxyl (NO-)69 catalysed by the enzyme nitric oxide synthase (NOS)70. 
NOS is present in three isoforms, two constitutive and one inducible: 1.) 
constitutive neuronal NOS (NOS I or nNOS); 2.) inducible NOS (NOS II or 
iNOS); and 3.) constitutive endothelial NOS (NOS III or eNOS). All forms are 
expressed in the airways71"75. The constitutive form of NOS is released within 
seconds by a Ca2+ and calmodulin-dependent mechanism producing small 
amounts of NO in the range of fentomolar or picomolar concentrations after 
receptor stimulation by selective agonists. The inducible form is produced 
over a longer period in larger amounts (nM) after induction by proinflammatory 
cytokines at a pretranslational level. This may be many hours after stimulus 
and may continue for hours or days. Cytokines such as tumour necrosis 
factor-a (TNF-a), interferon-y (IFN-y), and interleukin (IL)-1(3 can stimulate
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expression of iNOS76 as well as exogenous factors such as bacterial toxins, 
virus infection, allergens, environmental pollutants, hypoxia, tumours77'79 
which can be reduced by corticosteroids80.
The bioactivity of NO is divided into NO mediated/cGMP dependent 
such as smooth muscle relaxation and cGMP independent such as virus 
killing. The high level of NO released by iNOS has an effect as an immune 
effector molecule in killing tumour cells81, in halting viral replication82, and in 
eliminating various pathogens. NO may also inhibit pathogen virulence and 
replication by S-nitrosylation of cysteine proteases83. The release of NO 
activates soluble guanylyl cyclase and causes an increase in intracellular 
cGMP84 and endogenously formed NO produces most of its effects by this 
mechanism. NO can also activate or inhibit other enzymes and NO itself can 
inhibit NOS activity directly or as a result of inhibition of the induction of 
iNOS85.
NO is a highly reactive molecule and small amounts produced by 
constitutive enzymes are removed safely by reaction with haemoglobin, 
however when produced in larger amounts reactions of NO with other free 
radicals can lead to the production of toxic reactive nitrogen species e.g. 
nitrogen dioxide, peroxynitrite and dinitrogen trioxide which can produce toxic 
effects by potent oxidative actions86,87
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1.3.2 Exhaled Nitric Oxide and measurement
Nitric oxide (NO) as a marker of inflammation, can be measured in the 
exhaled breath in ppb by chemiluminescence analysers88 and has been found 
to be increased in asthmatics compared to non-asthmatics89. It has also been 
shown to be useful in monitoring asthma to guide treatment90.
The chemiluminescence reaction is based on the findings that ozone 
reacting with NO yields excited N02 which emits infrared light, which is directly 
proportional to the original NO levels, and the light (photons) can be counted 
by a photomultiplier tube91. NO-free inspired air must be used when exhaled 
NO measurements are performed to avoid possible effects of outdoor air 
pollution and NO in ambient air. Exhaled NO measurements can be affected 
by a number of factors and the avoidance of many of these confounding 
factors should be attempted prior to measurement92.
The measurement of exhaled nitric oxide (eNO) is dependent on 
expiratory flow93 and thus measurements must be standardised as suggested 
by international guidelines for the measurement of NO in adults and 
children94'96. The levels of NO in exhaled air are dependent on 1.) production 
of NO by cells in the airways of lung parenchyma, 2.) diffusion of NO into the 
capillary circulation, and 3.) alveolar ventilation and bronchial airflow.
NO measured from the mouth is from a combination of sources: the 
lower respiratory tract, nasal97, NO from salivary N02' and gastric 
regurgitation98,". Nasal NO can potentially contaminate gasphase NO during 
exhalation manoeuvres96,100 and therefore expiratory resistance to close the 
soft palate with raised mouth pressure is used during exhaled NO
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measurements in spontaneously breathing subjects94,96. To measure airway 
NO the plateau phase is taken after excluding the dead space92.
It has been shown that NO production and expiratory NO can be 
predicted by a two-compartment model of the lung (Fig 1.), consisting of a 
nonexpansible compartment of the conducting airways and an expansible 
compartment of respiratory bronchioles and alveoli101. The model shows that 
both compartments contribute to exhaled NO and the relative contributions of 
airways and parenchyma can be separated by analysis of the relationship 
between exhaled NO output (nl/s) against expiratory flow rate (ml/s).
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Fig 1. legend, Schematic of 2-compartment model for nitric oxide (NO) 
pulmonary exchange. First compartment represents relatively nonexpansile 
conducting airways; second compartment represents expansile 
alveoli. Each compartment is adjacent to a layer of tissue that is 
capable of producing and consuming NO. Exterior to tissue is a layer 
of blood that represents bronchial or pulmonary circulation and 
serves as an infinite sink for NO. V E and V I, expiratory and 
inspiratory flow, respectively; CE and Cl, expiratory and inspiratory 
concentration, respectively; Cair and Calv, airway and alveolar concentration, 
respectively; Vair and Valv, airway and alveolar volume, 
respectively; Jt:g,air and Jt:g,alv, total flux of NO from tissue to air and 
from alveolar tissue, respectively; t, time; V, volume.
Fig. 1. Two compartment model of nitric oxide production in the 
airways101 (Reproduced from: Tsoukias NM. George SC. A two-compartment 
model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 
1998;85(2):653-66.) Permission not required.
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1.3.3 Exhaled NO and asthma
Exhaled NO has been shown to be raised in atopic asthma when 
compared to controls89, and the source of NO is mostly generated in the lower 
airways102 mainly by iNOS in airway epithelial and inflammatory cells72. There 
is a strong association between elevated levels of eNO and skin prick test 
scores, total IgE103, and blood eosinophilia104 in mild asthma. It has also been 
shown to be an indicator of asthma control105 and asthma severity106. Thus 
eNO has been used to monitor asthma exacerbations107 and the effect of anti­
inflammatory therapy106. Corticosteroids may influence the levels of eNO by 
the reduction in asthmatic inflammation and also by direct inhibitory effects on 
iNOS itself. Oral and inhaled corticosteroids have been shown to result in a 
rapid and dose dependent reduction in exhaled NO108.
NO levels may increase before any significant changes in other 
parameters, such as lung function and sputum eosinophils, and may therefore 
serve as an early warning of loss of control.
Exhaled NO in asthmatics is correlated with airway hyper­
responsiveness to methacholine109, as well as peak flow variability110 and is 
also associated with eosinophilic inflammation as determined in blood104, 
urine111, bronchoalveolar lavage110, and sputum112.
Exhaled nitric oxide has also been shown to be increased by other 
chest diseases such as mild-moderate COPD, rhinitis, bronchiectasis, active 
pulmonary sarcoidosis, active fibrosing alveolitis, acute lung allograft rejection 
and acute viral lung infection. Exhaled nitric oxide is also affected by active 
smoking and levels are decreased in smokers compared with non-smokers.
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To conclude; eNO is a novel non-invasive biomarker reflecting airway 
eosinophilic inflammation in asthma.
1.3.4 Induced sputum differential cell counts and asthma.
Inflammation of the airways can be assessed through biopsies 
obtained via bronchoscopy, this is however an invasive technique, involving a 
procedure that is uncomfortable to the patient and also carries a small risk of 
complications. Assessing the induced sputum of patients is a less invasive 
method for obtaining information about the underlying airway inflammation in 
the airways of asthmatics113. The inflammation in asthma is mainly 
eosinophilic114 which is steroid responsive115,116. Other types of inflammation 
may be present such as neutrophilic24 which is less likely to respond to steroid 
treatment and different phenotypes of asthma have been identified based on 
symptoms and predominant cell types in induced sputum25. Pin et al117 
showed raised numbers of eosinophils and metachromatic cells in the sputum 
fraction from asthmatics compared with healthy subjects using a protocol 
based technique to induce sputum. This has also been shown to be 
reproducible and valid114. The technique has been refined to improve cell 
viability, reduce squamous contamination and provide reproducible differential 
cell counts and has also been shown to be safe, even in the presence of 
moderate to severe exacerbations118. Induced sputum ceil counting is 
therefore established as a valuable tool in investigating airways disease.
Guidelines on methodology have been developed to obtain sputum by 
induction with hypertonic saline and standardise its examination119. A 
standardised method was shown to result in successful sputum induction in
37
76% of normal and asthmatic subjects who cannot produce sputum 
spontaneously117 and if performed carefully with salbutamol premedication 
and FEV-i monitoring is relatively safe even in those with airways disease113.
Once sputum is obtained it must be processed to obtain cells for a cell 
count and supernatant for measurement of fluid phase components. 
Dithiotreitol (DTT) is used in the process to improve cell dispersion120,121. This 
is a sulphydryl reagent that produces mucolysis by opening disulphide bonds 
which crosslink glycoprotein fibres and maintain sputum in its gel form121. 
Although this makes cell differentiation easier and quicker, it must be noted 
that it may affect the measurement of certain fluid phase components in the 
supernatant115,122"124.
There is some discussion surrounding the selection of sputum from the 
whole expectorate in that some of the mediators may be lost when saliva is 
excluded, however the quality of cytospins are better and significant dilution of 
mediators may happen in saliva.
Normal ranges for sputum cell counts have been published113 (table 1.) 
and it has been shown that in asthmatics, eosinophils and metachromatic 
cells are increased114, plus there is also a slight increase in the numbers of 
neutrophils. These sputum cell counts are highly repeatable with within 
subject repeatability of sputum eosinophil counts in subjects with asthma 
being such that 95% of repeated measures lie within the twofold range of the 
original measurement.
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Cell Normal range 
Median Interquartile range
Total cell count 
(x106/ml)
3.1 4.0
Eosinophils (%) 0.5 1.1
Neutrophils (%) 24.1 26.8
Macrophages (%) 62.9 30.2
Lymphocytes (%) 1.3 1.6
Table 1. Normal ranges for sputum total cell count and differential inflammatory cell 
counts derived from 10 normal subjects113
There is a weak relationship between the severity of asthma as 
defined by lung function, airway responsiveness or symptoms and the sputum 
eosinophil count125 and studies have shown that induced sputum can be used 
to monitor asthma control and guide treatment126.
There has been conflicting evidence of correlation between functional 
airway parameters and sputum inflammatory cells and markers127 although 
asthmatics with higher baseline sputum eosinophilia are more likely to 
exacerbate and a change in sputum eosinophilia correlates well with reduction 
in airway function heralding an exacerbation rather than symptom scores128.
In chronic stable asthma compared to healthy subjects there are raised 
numbers of CD4* T lymphocytes expressing surface activation markers, 
reduced natural killer cells and raised B lymphocyte counts that correlate with 
sputum eosinophil counts. There are increased levels of secretory 
immunoglobulin IgA. Increased levels of cysteinyl-leukotrienes relate to 
asthma severity and a number of proinflammatory cytokines (IL-1b, IL-5, IL-6, 
TNFa, RANTES and IL-8) are raised with the reduction in levels of the anti­
inflammatory cytokine IL-10. Levels of matrix metalloproteinases (MMPs) 
have also been shown to be raised 129.
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During asthma exacerbations high numbers of neutrophils have been 
found130, as well as high eosinophil counts that fall with treatment116.
Sputum eosinophil counts and levels of ECP are related to the severity of 
asthma131 and this has been shown for neutrophil counts also40. Sputum 
eosinophil counts have also been shown to be significantly inversely 
associated with methacholine and adenosine bronchial responsiveness132,133. 
The role of eosinophils in the sputum of asthmatics has some doubt following 
the demonstration that sputum eosinophilia can be reduced by anti-IL-5 
antibodies without reducing airway hyperresponsiveness134. There has been 
noted a group of asthmatics with a neutrophil predominant sputum differential 
cell count with evidence of symptoms, variable airflow obstruction with a 
sputum eosinophil cell count <1.9% described as non eosinophilic asthma. 
These patients are less likely to respond to inhaled corticosteroids and 
highlight that the type of inflammatory response in symptomatic patients may 
be heterogenous and more complex than previously thought24.
Treatment strategies based on titrating treatment to induced sputum 
eosinophil counts have shown improvements in exacerbation rate and this 
further suggests that these measures are useful in monitoring asthma severity 
although there is little evidence that this is reflected in other traditional 
measures of asthma control such as FEV1, symptoms, AHR and SABA 
use126.
In summary sputum eosinophil counts may be useful in the diagnosis 
of asthma, predicting the response to corticosteroids, monitoring treatment 
and predicting exacerbations of disease129. They are therefore a useful
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measure of asthma control as a marker of inflammation of the airways and a 
useful tool in assessing airway inflammation in research studies.
1.4 Lung function and airway obstruction.
Respiratory physiology can be measured in a number of ways to 
measure airflow, lung volumes and bronchial responsiveness. These can be 
affected variably in asthma and can range from normal to abnormal 
depending on whether the disease is controlled14.
Static lung volumes are shown below in fig (2).
Maximal Inspiration
End Inspiration
End Expiration
Maximal Expiration
TLC - Total Lung Capacity, IC - Inspiratory capacity, FRC - Functional 
Residual Capacity, VC - Vital Capacity, IRV - Inspiratory Reserve Volume, 
TV - Tidal Volume, ERV - Expiratory Reserve Volume, RV - Residual 
Volume.
Fig. 2. Static lung volumes
In asthma these can be normal, however in those with airway 
narrowing due to airway smooth muscle activation, increased airflow 
obstruction and gas trapping there can be increases in residual volume (RV),
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expiratory reserve volume (ERV) and total lung capacity (TLC)135. This can be 
measured using a spirometer into which the subject exhales from TLC until 
RV. This can measure the volume of air expelled over time resulting in the 
vital capacity (VC). Using body plethysmography in which a subject is 
enclosed in a sealed box and pressures measured at the mouth and outside 
the body, the TLC and FRC can be derived using Boyles law. From this all 
other measures including inspiratory reserve volume (IRV), expiratory reserve 
volume (ERV) and residual volume (RV) can be derived136.
The characteristic feature of asthma is airway obstruction due to 
smooth muscle contraction, hypertrophy, remodelling, airway oedema and 
mucous plugging11. This can be measured by tests of airflow such as peak 
expiratory flow rate which is reduced in asthma and spirometry which 
measures volume exhaled over time137. The forced expiratory volume in 1 
second (FEV-i) is reduced in uncontrolled asthma which can reverse with 
bronchodilators and the ratio with forced vital capacity (FVC) or FEVi/FVC 
ratio is reduced as well as the flow at mid expiration or FEF25-75 or MMEF138. 
The peak expiratory flow rate can be measured serially over days by the 
patient and the variability of day to day peak flows can be used as a measure 
of asthma control with increased variability indicating worse control.
These ventilatory function tests reflect changes in airway resistance 
(Raw) and its reciprocal, airway conductance (Gaw) which can also be 
measured using body plethysmography139 by measuring the pressure at the 
mouth and air flow. These in themselves can be affected by lung volumes and 
therefore it is important that measures are carried out to agreed and 
standardised protocols17. Airway resistance can be increased at lower lung
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volumes due to a reduced airway diameter and vice versa, however specific 
airway conductance (sGaw) is expressed as conductance per unit of lung 
volume and therefore takes this into account140,141.
It is important that tests of expiratory flow rates are performed with a 
deep breath to total lung capacity and maximal effort is used by the subject. 
Measures of airway resistance are measured dependent on lung volume and 
are measured indirectly using body plethysmography at the same time as 
measuring lung volume to derive sGaw. In asthma, Raw is increased and its 
reciprocal Gaw and sGaw are decreased accordingly.
As asthma is characterised by variable airflow obstruction it is 
important to note that the changes in airway physiology described can vary 
from obstructed to normal and therefore it is important to check for variability 
in these measures. If airflow obstruction is noted then the measurements, if 
repeated after the application of a bronchodilating agent will return to normal. 
Alternatively if the measures are normal then a bronchoconstrictor challenge 
test can be performed as described in the next section17.
It is important to note however, that a process of airway remodelling 
can take place in asthma in which the airway wall is thickened, smooth 
muscle is increased, mucous glands are increased, surface tension increases 
with increased inflammatory exudate and thickening of the reticular basement 
membrane occurs. These changes can become irreversible leading to fixed 
airflow obstruction that resembles chronic obstructive pulmonary disease that 
some describe as a chronic obstructive pulmonary disease-asthma overlap19.
Lastly, transfer factor of the lung for carbon monoxide (TLCO) is a 
measure for the ease of molecules of carbon monoxide molecules to cross
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from alveolar gas to the circulation. This is assessed using a single breath 
technique where a subject exhales to RV then inspires a test gas including 
carbon monoxide (CO) to TLC and holds their breath before exhaling into a 
sample bag. The change in CO can be used to calculate the TLCO adjusted 
for haemoglobin. The TLCO in asthma can be normal or increased due to 
hyperaemic airways and increased perfusion of the apices of the lungs due to 
increased pulmonary arterial pressure142.
1.4.1 Airway responsiveness
Airway obstruction may be absent in well treated or mild asthmatics, 
however these patients may demonstrate increased smooth muscle tone or 
increased bronchial reactivity. Asthmatic airways become sensitive and stimuli 
can result in smooth muscle contraction and airway narrowing. This is the 
basis of bronchial challenge testing and the severity of responsiveness to 
challenge can be a marker for asthma and asthma severity or control14.
Reversible airway obstruction as a result of hyper-responsiveness of 
bronchial wall smooth muscle is therefore characteristic of asthma and 
bronchial hyperesponsiveness is responsible for recurrent episodes of 
wheezing, breathlessness, chest tightedness, and coughing. This can be 
measured using bronchial provocation challenge testing, non-selectively, 
either directly or indirectly by exposing the airways to various stimuli14, indirect 
challenges involve the use of chemical stimuli to initiate one or more of the 
intermediate steps leading to bronchoconstriction and direct challenges 
involve the use of substances such as muscarinic agonists (e.g. 
methacholine) to directly stimulate receptors on airway smooth muscle.
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Challenge testing can be used to assist with making a diagnosis and to 
assess asthma control or severity, however airway hyper-responsiveness 
(AHR) to methacholine is not synonymous with asthma and its severity is not 
synonymous with asthma severity. Despite this the measurement of bronchial 
hyper-responsiveness to methacholine is accepted as a way of assessing 
asthma severity in clinical trials and a way of tracking change with 
intervention .
There is a correlation between asthma severity and the severity of 
AHR144,145 which improves with anti-inflammatory therapeutic strategies such 
as inhaled steroids146. There is a modest correlation between the severity of 
direct AHR and airway inflammation with mainly eosinophils or metachromatic 
cells147. There is also an increased response to direct stimuli with 
nonasthmatic airflow obstruction closely related to the severity of chronic 
bronchial obstruction felt to represent a geometric issue with regard to airway 
diameter148.
There is felt to be two components to AHR, a variable and fixed 
component with the variable component being able to change with 
improvement in airway inflammation and the fixed component being related to 
structural and functional changes in the airway termed airway remodelling149. 
Although AHR is felt to be related to eosinophilic airway inflammation, some 
studies have dissociated the relationship between eosinophils and AHR. 
Studies using Mepolizumab an anti-interleukin-5 agent found that patients that 
had a reduction in eosinophils continued to have AHR and symptoms134.
Historically, for diagnostic purposes asthma challenge tests target a 
significant change in FEV-i with a 20% fall in FEV-i being considered a positive
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test and an arbitrary cut off to exclude significant bronchial responsiveness for 
most research studies set at 8mg/ml using increasing doses of methacholine.
Standardised methods have been developed to perform methacholine 
challenge tests150, a doubling concentration of methacholine is administered 
with assessment of the FEVi. The dose of methacholine calculated to induce 
a 20% drop in FEVi is used to define bronchial responsiveness and is termed 
PC2o. Alternatively airway constriction can be measured Using body 
plethysmography which can avoid deep inhalations to measure increase in 
airway resistance or its reciprocal, specific airway conductance (sGaw) and 
the cut off of a 45% drop in sGaw is used to produce PC45 which equates to 
PC2o. Two standardised methods are also described to administer 
methacholine, one requires deep inhalations and the other a tidal breathing 
method.
The speed or intensity of response to a bronchoconstricting agent has 
been shown to have a better relationship with HRQoL related to severity of 
asthma151. The slope of the dose-response curve has been shown to be more 
useful in identifying patients with asthma152 and in maintaining a better 
relationship with the degree of oxidative stress of patients153. This stems from 
the observation that a plateau is reached in the dose response curve of non 
asthmatic individuals that is not present in asthmatics. As this cannot be 
measured safely in asthmatic subjects the slope of the dose response can be 
used instead. Therefore bronchial responsiveness of asthmatics can be 
expressed in terms of the provocative concentration to cause a 20% drop in 
FEV1 from baseline and also the strength of the response to a provocative 
stimuli.
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It is important to note the caveat that increased bronchial 
responsiveness may not indicate “asthma” as bronchial hyper-responsiveness 
can be induced in normal subjects by restricting chest expansion and 
therefore eliminating the bronchoprotective effect of smooth muscle stretch in 
airways .
1.4.2 Airway remodelling and chronic obstructive pulmonary disease /
asthma
As described briefly above, asthma traditionally is thought of as being a 
reversible airway obstruction characterised by eosinophilic airway 
inflammation. However it has also been noted that in some cases asthma may 
be present with fixed airflow obstruction secondary to airway remodelling as a 
result of chronic airway inflammation. This results in narrowing due to 
increased airway wall thickness. This can be due to increased smooth muscle 
thickness, increased inflammatory infiltrate causing increased airway stiffness, 
epithelial goblet cell hyperplasia and metaplasia. Thickening of the lamina 
reticularis occurs and proliferation of airway blood vessels and nerves. These 
changes are less responsive to corticosteroids and it can be difficult to 
determine the difference between asthma with airway remodelling and chronic 
obstructive pulmonary disease which has a different aetiology155. The two 
diseases may be differentiated by examination of histology from bronchial 
biopsy specimens and by determining a typical history such as a significant 
past history of smoking.
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1.5 Symptoms and Health related quality of life in asthma.
Health related quality of life (HRQoL) is used to refer to the “physical, 
psychological, and social domains of health, seen as distinct areas that are 
influenced by a person’s experiences, beliefs, expectations, and 
perceptions”156. HRQoL reflects an individual’s subjective evaluation and 
reaction to health or illness157 rather than a medical professionals evaluation. 
Tools such as the Short Form 36 (SF 36)158 have been developed to measure 
HRQoL in subjects and therefore to try to quantify this for research purposes. 
HRQoL is recognised to be multidimensional and tools generally measure the 
functional ability, physical, emotional and social wellbeing of individuals159,16°. 
As HRQoL is generally poorly related to functional measures of asthma 
control such as lung function and markers of inflammation they are useful 
complimentary sources of information in research to evaluate the patient’s 
own perception of asthma on their quality of life.
Asthma is known to affect the HRQoL of patients and increased 
severity of asthma can have a greater impact on this measure, although the 
reciprocal relationship can occur with those with a worse quality of life having 
worse asthma control161. Measuring HRQoL in asthma is also difficult as it can 
be affected by other factors that may be important such as comorbidity162, and 
social circumstance: for this reason more specific tools to measure quality of 
life such as the St Georges Respiratory Questionnaire and Juniper Asthma 
Quality of Life Questionnaire have been developed to have greater sensitivity 
to detect changes related to a change in respiratory status163,164.
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1.5.1 The Short Form 36 (SF 36)
Ware, the developer of the SF 36 emphasised that health has 
dimensionality - physical health, mental health, everyday functioning in social 
and role activities, and general perceptions of well-being- and can range from 
the negative states of disease to more positive states of well being159.
The Short Form-36160,165 is referred to as a generic measure of 
quality of life which represents eight of the most important health concepts 
included in the Medical Outcomes Study which was a large scale test of the 
feasibility of self-administered patient questionnaires and generic health 
scales for those with chronic conditions, including the elderly158. It is self 
administered, includes one multi-item scale measuring each of eight health 
concepts and the scores for the SF-36 are also represented as summary 
scores for physical health and mental health. Further explanation of the SF-36 
questionnaire is described in chapter 2.
1.5.2 The St George’s Respiratory Questionnaire
The SGRQ is designed to measure health impairment in patients with 
asthma and Chronic Obstructive Pulmonary Disease and therefore has been 
designed to explore those aspects of HRQoL that were identified to be 
specific to respiratory disease rather than generic163. It is therefore more 
responsive to changes in relation to a change in respiratory disease. There 
are other questionnaires such as the Juniper Asthma Quality of Life 
Questionnaire (AQLQ)164 that are specific for asthma, however in a study or 
comparison between the two166, in overall terms, not one of these instruments 
behaved better than the other and therefore the SGRQ has been used in this
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study. Cough and wheeze have been shown to correlate with SGRQ symptom 
score and 6-min walking distance and MRC dyspnoea grade correlates with 
activity score. There are also significant correlations with FEV1, FVC, 
dyspnoea, anxiety and depression.
It is in two parts which includes 16 questions. Part 1 consisting of 
questions 1 to 8 produces the symptoms score, and part 2, consisting of 
questions 9 to 16, the activity and impact scores. A total score is also 
produced.
1.6 Obesity and its measurement
The prevalence of obesity is increasing worldwide 167 and this has 
many consequences for healthcare and the health of individuals. Obesity is 
associated with many comorbidities 168 including cardiovascular disease, 
diabetes, obstructive sleep apnoea and gastroesophageal reflux disease. 
Recently there has been interest in its possible relationship with asthma 1.
Obesity can be defined as an accumulation of excessive body fat, well 
over the daily metabolic requirements of facultative energy storage in the form 
of triglycerides. It can be assessed in a number of ways 169 which measure 
different aspects of obesity such as total or regional adiposity. Weight per se 
is a poor measure of obesity as this measures adipose tissue as well as 
muscle and other lean tissue as a whole. Body mass index (BMl) is a more 
useful measure as it takes height into account. BMl is calculated by dividing 
weight (Kg) by the height (m) squared. A BMl >30kg/m2 is accepted as 
obese. BMl <18.5 underweight, 18.5-24.9 healthy, 25-29.9 overweight and 
>40 morbidly obese.
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Waist circumference is at least as good an indicator of body fat as BMI 
and is the best predictor of visceral fat. Waist-hip ratio was introduced on the 
assumption that it would predict fat distribution better than waist 
circumference alone. Subsequent research, however, showed that it did not. It 
is also noted that due to a greater measurement error for waist circumference, 
body weight is the best measure to use for monitoring change170.
Other methods of measurement include densitometry employing the 
principle of water displacement, imaging with CT, or MRI which give the best 
assessment of visceral fat although these are less easy to perform. 
Bioimpedence is another method that crudely estimates total body water as a 
component of lean mass and therefore an estimate of fat mass can be 
obtained however there is no evidence that bioimpedence analysers are 
better than waist circumference in measuring body fat in adults.
In this study we have employed a combination of these methods to 
assess obesity in our population.
As shown later, adipose tissue is now thought to be metabolically 
active and obesity is now thought of as a low grade inflammatory state.
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1.7 Obesity and the lung
1.7.1 Historical aspects
Hutchinson171 was the first to describe the effect of weight on 
pulmonary function in 1846 when describing the use of his spirometer as he 
was able to accurately record lung volumes with a reproducible technique for 
the first time. He noted that with increasing weight, vital capacity increased, 
remained stable and then reduced. He postulated that this was likely to be 
due to ‘the mere circumstance of fat preventing the mobility of the thoracic 
boundaries’. Realizing the importance of this relationship he stated that ‘the 
examination of corpulent persons must not be compared with those not 
corpulent, though in all other aspects the same.’
Much early interest in the 1950’s of a condition of obesity 
hypoventilation, later to be given the term ‘Pickwickian Syndrome’ stemmed 
from a paper by Kerr and Lagen in 1936172. They ‘refer especially to a type of 
obesity which appears to be exogenous in origin, arising in persons whose 
dietary habits lead to a caloric intake beyond their daily requirements’. They 
describe reduction of tidal volume, and vital capacity due to changes in 
posture plus kyphosis and coin the term orthostatic dyspnoea, going on to 
describe the likely consequences of this in the form of polycythaemia and 
cyanosis. The first actual use of the term ‘Pickwickian Syndrome’ was by 
Bickelmann et al173 in 1956 who also acknowledge the ‘first modern and 
scientific description’ of this syndrome by Seiker et al174 in 1954 who 
described four patients with similar symptoms and signs related to obesity. 
Seiker reported a 20% decrease in total lung volume and a 50% decrease in 
expiratory reserve which decreased on recumbency to 150cc or 17% of the
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average normal value. They postulated that extreme obesity markedly 
reduces the functional residual capacity and also stated that weight reduction 
corrected the abnormalities. Bickelmann’s paper goes on to describe 
extensive pulmonary function tests on their patient both before and after 
weight reduction. These tests revealed low total vital capacity, expiratory 
reserve volume, residual volume, functional residual capacity and total lung 
volume which all increased with weight reduction with an increase in 
maximum breathing capacity.
Since then we have further understanding of the effects of weight on 
the lung.
53
1.7.2 Current understanding: Lung volumes.
As noted above compartmentalisation of gas within the lung can be 
described as per fig 3. below.
Maxima! Inspiration
End Inspiration
End Expiration
Maximal Expiration
TLC - Total Lung Capacity, IC - Inspiratory capacity, FRC - Functional 
Residual Capacity, VC - Vital Capacity, IRV - Inspiratory Reserve Volume, 
TV - Tidal Volume, ERV - Expiratory Reserve Volume, RV - Residual 
Volume.
Fig 3. Static lung volumes
Obesity can affect these volumes to varying amounts175 and this can 
depend on the severity of obesity generally measured as BMI.
As already described, the effect of obesity is a general reduction of all 
lung volumes in these individuals. More recently however the extent to which 
these volumes are affected has been investigated in more detail: Jones and 
Nzekwu176 found a significant inverse linear relationship between BMI for VC, 
TLC and RV although TLC and RV are not affected until the BMI becomes 
very large. In contrast FRC and ERV are affected more dramatically at lower 
BMI and exponentially when BMI becomes greater than 40 kg/m2.
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As lung volumes diminish, so the small airways also diminish in size 
thus as ERV reduces with increasing BMI, lung volumes come close to RV 
bringing individuals close to closing volume177, at which point the volume of 
the lung is so small that airways close and gas trapping occurs so that no 
more gas volume can be expelled140,178.
Another important observation is that obese individuals tend to breathe 
at low tidal volumes with higher respiratory rates when compared to those 
with normal BMI179.
When investigating spirometric values there is conflicting information 
with some studies reporting preserved FEV1/FVC ratios with reduction in both 
components180 and others have reported reduced FEV1/FVC ratios181.
The distribution of fat has been shown to be important in its effect on 
lung volumes. FVC, FEV1 and TLC have been shown to be affected by 
subscapular skinfold thickness182,183 after removing the effects of BMI and 
FVC has also been shown have a negative association with fat% and is more 
affected by central adiposity when measured as waist/hip ratio184. Cotes et 
ai185 found that fat% and fat free mass index had different contributions to 
lung volumes with fat % contributing to RV and ERV, and hence to FRC, VC 
and TLC with a negative sign. FFMI contributed negatively to ERV and hence 
FRC but made a positive contribution to IC, TLC, FEV1 and FVC. More 
recently abdominal height has been shown to affect pulmonary function186.
Another contributor to effects on lung function and volumes is body 
position which can have a greater effect in the obese individual due to the 
increased pressure from abdominal contents and redistribution of blood 
cephalically187,188 upon becoming supine. FVC reduces on sitting in obese
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subjects which is not shown in normal subjects189 and also on becoming 
supine along with TIC and VC. One group however has shown an increase in 
FRC on assuming a supine position from sitting, possibly due to increased fat 
in the abdomen pushing up the diaphragm190.
These changes in lung volumes are thought to be a combination of 
changes in abdominal pressure, changes in lung compliance, increased blood 
volume and increased fat content of the thoracic cavity some of which will be 
covered later.
There have also been suggestions that gender186 may have an 
influence on changes in lung volumes, possibly due to changes in fat 
distribution, however this is not clear.
56
1.7.3 Compliance.
The following figure (Fig 4.) shows an example of the volume pressure 
or compliance curve of the respiratory system191. Obesity is thought to affect 
this system in many ways.
transmural pressure ( Prs, Pew, Pj )
TLC - Total lung capacity, Vr - Volume at rest, RV - Residual Volume, cw - 
chest wall, L - Lung, rs - Respiratory system, Prs - Pressure respiratory 
system, Pew - Pressure chest wall, PL - Pressure lung.
Fig 4. Pressure Volume curve of the respiratory system191
Usually the point of FRC lies on the straight part of the compliance 
curve so that a small change in pressure results in a relatively large change in 
volume. As has been described already, however the lung volumes in obesity 
are lower with a lower FRC as BMI increases. As a result of this the FRC lies 
on a point of the compliance curve below the straight portion of the curve i.e. 
below the inflection point191. This flatter part of the curve results in less 
volume change of the lung in proportion to a change in pressure.
Total respiratory compliance is therefore related to vital capacity and 
Pelosi192'195 showed that a lower respiratory system compliance is caused by 
a decreased lung and chest wall compliance with predominance from the lung
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component that may be due to increases in both elastic and resistive work192" 
195. Chest wall eiastance is significantly correlated with decreased end- 
expiratory lung volume as a result of increased BMI due to changes in the 
elastic properties of the lung, vascular engorgement188, changes in the 
surface lining i.e, changes in surfactant and collapse of alveoli196. Chest wall 
compliance may also be reduced due to increased adiposity around the ribs, 
diaphragm and abdomen or limited movement of ribs due to thoracic kyphosis 
or lumbar lordosis from excessive abdominal fat content192.
1.7.4 Resistance
Airway resistance is dependant on airway calibre, which is reduced at 
lower lung volumes197. A strong association between BMI and lung volume 
and airway calibre has been shown and therefore in obesity as lung volume 
decreases there is increased airway resistance198,199. This increased airway 
resistance has been shown by plethysmography and forced oscillation 
technique (FOT)198. There is evidence however that changes in airway 
resistance in obesity cannot be explained by changes in lung volumes alone 
as airways have been found to be narrower than expected on the basis of 
lung volume and other factors are involved199.
Reductions in lung volumes with reduced airway diameter and 
reduction in smooth muscle stretch over time can lead to alterations in smooth 
muscle function with a change from rapidly cycling actin-myosin cross-bridges 
to slow cycling latch bridges leading to airway narrowing by smooth muscle200.
Airway resistance also increases as obese subjects move to a supine 
position from sitting due to vascular engorgement as blood moves cephalically
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and the diaphragm moves up with areas of atelectasis and alveolar collapse 
contributing to increased airway resistance188.
The involvement of the upper airways such as in obstructive sleep 
apnoea may have an effect on airway resistance as the effort of breathing in 
through a narrowed upper airway can cause airway collapse201.
The increase in total respiratory resistance in obesity has been shown 
to be almost entirely due to increased pulmonary resistance with maximum 
resistance of the lung up to three times higher in obese subjects than normals 
as a result of increased airway resistance and an increase in additional 
resistance of the lung caused by stress relaxation or time constant inequalities 
within the respiratory system tissues192.
Maximum resistance of the chest wall has been shown to be higher but 
not significantly so in the obese group with no correlation between chest wall 
resistance and BMI194
Relative contributions of the lung and chest wall to the maximum 
resistance of the respiratory system were similar between normal and obese 
subjects which suggests that the increase is probably due to decreased lung 
volumes rather than airway narrowing.
Therefore in summary, increased resistance in the lung is due to a 
number of factors including reduced airway diameter secondary to reduction 
in lung volumes, loss of deep inspiration effects on smooth muscle, collapse 
of small airways, vascular engorgement and the effects of the upper airways.
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1.7.5 Ventilation - Perfusion
Usually, the ventilation and perfusion of areas of the lung are well 
matched, however in obesity this may be altered202.
As already stated, there is a tendency to small airway closure and gas 
trapping due to the low lung volumes associated with obesity. This can lead to 
areas of atelectasis and underventilated areas of lung. This coupled with the 
increased blood volume and vascular engorgement associated with obesity 
can lead to ventilation - perfusion mismatch. The distribution of perfusion has 
been shown to be more uniform from top to bottom of the lung in obesity than 
in normal subjects, possibly due to increased perfusion pressure and Holley et 
al203 showed that ventilation to lower zones can become seriously impaired 
when breathing at low lung volumes in some obese subjects with this being 
more closely related to ERV than to the degree of obesity.
It has been demonstrated that DLCO can be reduced in obesity204 
although some have reported normal values181. There have also been reports 
of raised DLCOA/A205 thought to be due to vascular engorgement of 
ventilated areas.
1,7.6 Exercise and work of breathing
A combination in the change of airway mechanics and oxygen 
demands can affect exercise and the work of breathing in obese individuals.
At a constant respiratory rate, the work of pulmonary ventilation during a 
single breath increases with tidal volume and respiratory rate206. Obese 
subjects breathe at lower lung volumes and have a reduced FRC which may 
partly explain increased respiratory work involved in these subjects. Obese
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subjects have a higher energy cost of breathing shown by a greater drop in 
V02 from spontaneous breathing and after intubation, ventilation and 
paralysis207. Increases in respiratory resistance can also increase respiratory 
work and may account for increased V02.
The increase in total respiratory work in obese subjects mainly consists 
of work done upon the lung, however in the case of obesity hypoventilation 
this increase in work is spread between the thorax and the lungs208. Excess 
tissue in the obese patient is metabolically active leading to increased oxygen 
demand at rest and an increased resting metabolic rate. Also the sheer fact of 
carrying increased body weight increases metabolic demands generally209.
When examining 02 uptake and C02 production during exercise, 
obese subjects maintain a consistently higher level than normal subjects with 
an increase linearly with work intensity210. As exercise increases, 02 
consumption, pulmonary ventilation, and breathing frequency increase: this 
occurs more rapidly in the obese compared to non obese. Minute ventilation 
increases faster with increased work intensity and this leads to a significantly 
greater ventilation equivalent for 02 (VE/02). The maximum amount of
oxygen available per kilogram of body weight decreases as obesity
• 210increases .
There is a significantly lower V02max (ml/kg/min) in obesity, however 
as a percent predicted V02 max based on ideal body weight, 
cardiorespiratory functional capacity is similar to the non obese204.
In obese individuals there is a fall in end expiratory lung volume (EELV) 
until ventilatory threshold (VTh) due to recruitment of expiratory muscles 
increasing workload then a rise back to resting levels at peak exercise. End
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inspiratory lung volume (EILV) shows similar patterns to EELV during exercise 
and obese subjects approach TLC during maximal exercise producing large 
increases in the oxygen cost of breathing204.
Some obese subjects experience expiratory flow limitation during 
exercise not present during rest which can limit exercise capacity shown by 
increases in thoracic pressure at rest, VTh, and peak exercise produced by a 
likely combination of reduced lung volumes, expiratory flow limitation and 
expiratory resistive work204.
In summary a combination of factors are involved to increase 
respiratory work in obese subjects: greater oxygen demands from 
metabolically active tissues and moving a greater mass, increased work 
required to move against higher respiratory resistance and a less compliant 
respiratory system and increased ventilation from faster and lower tidal 
volumes. Finally limitation of the ability to reduce EELV and increase EILV 
against flow limitation and a lower TLC all increase work of breathing in the 
obese.
1.7.7 Bronchial responsiveness
One of the hallmarks of asthma is the presence of bronchial 
responsiveness or the responsiveness of the airway smooth muscle to 
contract in the face of a stimulus. This leads to reversible airway obstruction 
and wheeze.
It has been shown that breathing at low lung volumes and avoiding 
deep inspiration can lead to increased airway responsiveness154 and
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theoretically this should occur in obesity as these subjects breathe at low lung 
volumes with small but rapid TV.
Litonjua211 was the first to investigate the risk of onset of airway hyper­
responsiveness measured by methacholine challenge in relation to BMI. They 
showed a U shaped distribution with those with the lowest and highest 
quintiles for BMI being more at risk of developing AHR. They also showed that 
there was a relationship with the rate of increase per year in BMI and the 
onset of AHR. Increased airway responsiveness with increased BMI has also 
been found by others also212.
There is also evidence to the contrary - Schacter et al213 investigated 
obese subjects with questionnaire analysis for the presence of wheeze, 
asthma diagnosis and medication and performed methacholine challenge 
testing. They found obesity to be a risk factor for recent asthma, wheeze and 
medication use as measured by questionnaires but did not find it to be a risk 
factor for airway hyper-responsiveness. Other investigators have found a 
similar relationship180'214'216.
1.7.8 Effects of weight change
It has been shown that weight gain is an important predictor of decline 
in FEV1 and FVC in men and women with some suggestion that this 
relationship is stronger in males216. There are few studies which investigate 
other respiratory volumes over time to describe other changes with weight 
gain.
Studies involving weight loss have shown improvement of lung 
volumes after weight loss with increase in FEV1, FVC, ERV, FRC and TIC
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217,218. There was no change in DLCO or RV219. Resistance reduced as did 
ventilation due to a reduction in tidal volume, in subjects undergoing surgical 
weight loss the above were noted plus there were also increases in 
respiratory muscle strength and endurance as shown by increases in Plmax, 
PEmax and PmPeak/ Plmax ratio217.
Subjects who previously showed closing volume above FRC reversed 
this ratio after weight loss 219. Any hypoxaemia prior to weight loss tends to 
improve and carbon dioxide tension tends to fall. This has been shown not to 
correlate with the amount of weight loss and thus the change in closing 
volume and recruitment of areas of the lung correcting the ventilation 
perfusion mismatch may be important218.
Resting 02 uptake (V02), 02 cost of work (E02), resting ventilation 
and ventilatory cost of work (EV) have all been shown to decrease with weight 
loss. 002 recovery time after work (C02RT) decreased and 002 output of 
work (EC02) rose slightly. The reduction in EV and EC02 appears to be due 
to a reduction in the 02 cost of breathing 209
The effect of weight loss on lean body mass and muscle structure and 
function is complex 220, with weight loss reducing energy stores and reducing 
muscle bulk, however the reduction in surrounding adipose tissue improving 
convection of heat, increased capillary density and shorter diffusing distance 
with improved glucose tolerance can improve the efficiency of muscle work 
with the appropriate consequences for the respiratory system. Muscle 
endurance has also been shown to improve following weight loss due to 
changes in substrate utilisation by muscles.
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1.8 Biochemical changes and inflammation in obesity.
As previously discussed in relation to asthma, many inflammatory 
mediators are involved within the respiratory system including the balance 
between Th1 and Th2 pathways and their associated inflammatory pathways. 
Studies in humans and animals have identified important biological mediators 
which may have an influence on airway inflammation in obesity and adipose 
tissue appears to exhibit a significant overlap in function with T lymphocytes 
and macrophages.
Adipose tissue produces and releases a number of cytokines and 
hormone like proteins such as leptin, IL-6, TNF-a, IL-8, plasminogen activator 
inhibitor-1, TGF-(31, CRP and adiponectin 221-222) all of which may be of 
importance for the association between obesity and health complications 
leading to a systemic proinflammatory state.
Protein levels of cytokines such as IL-6 and TNF-a are found to be 
elevated in plasma as well as in the adipose tissue of obese subjects, and 
weight loss is associated with changes in these adipose tissue-derived 
cytokines. The importance of this source of inflammatory cytokines has been 
shown by investigating the arterio-venous difference in IL-6 over the 
abdominal subcutaneous adipose tissue depot in the basal situation 223. IL-6 
was found to be released in the circulation in a sufficient concentration to elicit 
endocrine effects.
Leptin, a protein coded by the obese {ob) gene is involved in some 
pathophysiological aspects and is a central mediator of inflammation in 
obesity. It shares structural homology with long-chained helical cytokines, 
such as IL-6, and has been shown to recruit and activate monocytes and
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macrophages, and promote angiogenesis 224 Serum leptin concentration is 
increased in obesity and is strongly correlated with total body fat mass 225 and 
there are indications of a resistance to the effect of leptin in obesity 226.
Leptin is also important for normal lung development, serving as a 
critical mediator of the differentiation of lipofibroblasts to normal fibroblasts 
and of pulmonary surfactant phospholipid synthesis. Obese mice that are 
genetically leptin deficient {ob/ob) demonstrate profound pulmonary 
hypoplasia. Genetically obese ob/ob and db/db mice, as well as Zucker fatty 
rats, have mutations in the leptin or leptin receptor gene, but no equivalent 
mutations have been detected in the majority of humans with obesity 227.
The adult lung displays particularly high levels of putative functional 
leptin receptor as well as its splice variants. Bergen et al228 demonstrated that 
the lung as a whole and fetal type II cells in particular express functional leptin 
receptors and respond to leptin stimulation by increasing precursor 
incorporation into DSPC, a specific marker for pulmonary surfactant, 
suggesting synthesis of this phospholipid is increased and that leptin may 
have a role in pulmonary maturation.
Exogenous leptin has been shown to modulate allergic airway 
responses in mice, independent of obesity 229. Increased leptin levels in mice 
have been shown to increase airway hyper-responsiveness and increases 
serum IgE after inhaled ovalbumin challenge. This is not seen with inhaled 
phosphate buffered saline although BAL cell counts or lung tissue cytokine 
mRNA expression is not affected. Nonallergic immune function can also be 
affected as exogenous leptin can enhance bacterial clearance, killing and 
leukotriene synthesis in a murine pneumococcal pneumonia model 23°.
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Overfeeding wiid-type lean mice can lead to increased leptin levels and these 
show increased antigen-induced T-cell responses, increased mitogen 
increased splenocyte IFN-y production, and increased number of tracheal 
mast cells compared with lean control animals, although ovalbumin-specific 
immunoglobulin levels were paradoxically reduced in obese mice versus lean 
control mice 231. These studies suggest that leptin appears to have an 
important immunomodulatory role that is relevant to airway function and 
immune response, independent of body mass.
Ob/ob mice which are leptin deficient also show increased AHR with 
increased BAL levels of CC chemokine eotaxin after exposure to ozone and a 
predominant Th1 inflammatory phenotypic response with elevated levels of IL- 
6 and the neutrophil chemoattractants macrophage inflammatory protein 2 
(MlP-2) and KC compared to normal mice 232. Exogenous leptin may alter 
airway immune response differently between obese and lean animals, 
dependent on factors such as endogenous leptin concentrations, receptor 
number or affinity, or other concurrent modifications of inflammatory 
pathways.
Increased levels of eotaxin expression have been found in obese mice 
and also in humans which was reduced with weight loss by caloric restriction 
or bariatric surgery 233. The source of the eotaxin is at least in part related to 
adipose tissue.
Oestrogen may also have an influence on airway inflammation and 
may explain the possible gender influence on asthma and obesity.
Guler et al225 showed a significant but weak correlation between log 
IgE and log leptin levels among asthmatic children and Sood et al234 showed
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that serum leptin concentrations were associated with current asthma in 
adults. Lastly Sin and Man 235 showed a strong inverse relationship between 
FEV1 and serum leptin. Thus indicators suggest that biomarkers of obesity 
may be important in respiratory disease.
Also of note is a decreased level of the adipokine adiponectin in 
obesity which has been shown to have anti-inflammatory properties in the 
airways.
1.8.1 Induced sputum and obesity
There is little information on sputum cell counts in relation to BMI 
available. A retrospective review of a large database (727 subjects) by Todd 
et al showed that BMI did not correlate with any cell count including total and 
differential counts: total, neutrophils, eosinophils, lymphocytes and 
macrophages. In asthmatics there were higher numbers of sputum 
eosinophils however again there was no correlation between BMI and 
counts236. Thus there was no correlation between any measure of cellular 
inflammation in the airway and BMI.
Basyigit et al237 found no correlation between sputum levels of TNF- 
alpha and BMI also and in a study by Salerno et al238 in obstructive sleep 
apnoea, there was no significant correlation between BMI and any cellular 
components of induced sputum.
1.8.2 Exhaled NO and obesity
We know little about the effects of obesity on exhaled nitric oxide and 
few studies so far have presented results regarding the possible relationship
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between body mass index and exhaled nitric oxide. Obesity has been shown 
to be an inflammatory state222 which may be reflected in increased biomarkers 
of inflammation such as exhaled NO. It has been suggested that levels of 
exhaled nitric oxide increase with increasing BMI239, however in asthmatics 
this relationship does not occur, possibly due to the masking effect of 
asthmatic inflammation240. There are suggestions however, that as BMI 
increases further into the obese range i.e. above 30kg/m2 the levels of eNO 
become reduced likely due to changes in airway physiology and levels of eNO 
have been shown to increase following surgically induced weight loss4.
The release of proinflammatory cytokines from adipose tissue such as 
IL-6 has the potential to modulate the T-helper 2 immunity which is present in 
asthma and as a result may be associated with an increase in exhaled nitric 
oxide. This is expanded in the next section241.
1.8.3 Possible link between systemic and local inflammation in obesity
As noted above adipose tissue releases a number of substances that 
can lead to a systemic inflammatory state such as IL-6, TNF-a, IL-8, PAI-1, 
TGF-|31, CRP, leptin and adiponectin. This increased systemic inflammation 
could lead to an increase in local airway inflammation through interaction with 
CD4+ lymphoctes which can produce cytokines that lead to airway cellular 
inflammation and are important in asthma where they have been shown to 
produce Th2 cytokines242 that can lead to an increase in IgE. Flowever some 
have noted an increase in neutrophils rather than eosinophils in obesity 
suggesting that there may be an increase in Th1 inflammation driven by IFN-y 
and leptin, this is also shown by a reduction in exhaled nitric oxide - a marker
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of eosinophilic airway inflammation - as BMI increases. The link between 
systemic and airway inflammation is little understood and work is required to 
explore this further. It is known that the asthma syndrome can consist of a 
number of inflammatory phenotypes, therefore either of these mechanisms 
are plausible to explain a possible link between the systemic inflammatory 
state leading to the local inflammation present in asthma. Studies so far 
however have not been able to show a definite association between airway 
and systemic inflammation in asthmatic obese subjects although this has 
been shown in obese non-asthmatic individuals2,241.
1.9 Quality of life and obesity
As previously stated above, health related quality of life is used to refer 
to the “physical, psychological, and social domains of health, seen as distinct 
areas that are influenced by a person’s experiences, beliefs, expectations, 
and perceptions”156, HRQol reflects an individual’s subjective evaluation and 
reaction to health or illness rather than a medical professionals’ evaluation157. 
Obesity has been shown to worsen HRQol in many dimensions as measured 
by generic questionnaires such as the SF-36 and HRQol improves with 
weight loss243. As for asthma, disease specific HRQol questionnaires have 
been developed to be more sensitive to changes related to changes in weight. 
One such questionnaire is the Impact of Weight on Quality of Life-Lite 
questionnaire244.
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1.9.1 Impact of Weight on Quality Of Life-Lite (IWQOL-Lite)
The IWQOL-Lite is the short form of the IWQOL which was the first 
instrument specifically developed to assess the effects of the obese condition 
on the quality of life of persons who are seeking treatment for this condition244. 
It was designed around issues expressed by patients attending an intensive 
treatment programme for obesity at the Duke University Diet and Fitness 
Centre. Patient expressed dissatisfaction with various aspects of their lives 
due to obesity which covered health and physical functioning, 
social/interpersonal life, work, mobility, self-esteem, sexual life, activities of 
daily living, and comfort with food. The Task Force on Developing Obesity 
Outcomes and Learning Tools (TOOLS) was convened by the North 
American Association for the Study of Obesity and this was charged with 
choosing outcome measures to be used by clinicians and researchers. They 
recommended the use of the IWQOL-Lite in clinical practice and in research 
studies on obesity245.
The IWQOL-Lite is a 31 item questionnaire that begin with the phrase, 
“because of my weight...”. They are separated into 5 domains: Physical 
esteem (11 items), self-esteem (7 items), sexual life (4 items), public distress 
(5 items) and work (4 items). There is also a total score. Each item has 5 
response options as follows: (1=”never true”, 2=”rarely true”, 3=”sometimes 
true”, 4=”usually true", and 5=”always true.”)
1.9.2 SGRQ and obesity in asthma
There is little data on the influence of BMI in asthma on the respiratory 
specific health related quality of life measured by the SGRQ. Two studies
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have shown improvement in SGRQ with weight loss2,246 although the change 
in SGRQ scores did not correlate with amount of weight lost.
1.10 Asthma and obesity
There are many ways that obesity may affect the respiratory system as 
I have already demonstrated through the effects on respiratory mechanics, 
the influence of adipose tissue on inflammation and there are also 
suggestions of a shared genetic basis for susceptibility to both asthma and 
obesity247. Studies have related increasing rates of obesity with increasing 
incidence of asthma and linked the two. It is difficult to ascertain whether there 
is a true influence of obesity on asthma as the definition of asthma may vary 
between studies. Some rely on the subjects self reporting of symptoms 248 or 
a physicians diagnosis of asthma and it has been shown that up to a third of 
patients with a diagnosis of asthma may not have the disease249. Also some 
studies rely on self reported height and weight to obtain BMI rather than those 
directly measured and it has been shown that subjects can underestimate 
weight and overestimate height250 although other studies that use measured 
height and weight still show a significant association with BMI and asthma.
Nevertheless cross sectional studies involving large numbers of 
subjects have demonstrated an increased prevalence of asthma in obesity 251~ 
253. And the reported odds ratios for incident asthma in obese or extremely 
obese compared with normal weight individuals range from 1.0 to 3.5 254
As with most cross sectional studies, direction or causality may be 
difficult to establish as asthma may increase the risk of becoming obese due 
to the use of corticosteroids and reduced activity. Also obesity and asthma
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may also be independently associated with other unmeasured confounding 
conditions, such as obstructive sleep apnoea or gastroesophageal reflux 
disease 255,256.
Some prospective studies have found an increased risk of developing 
asthma with increasing BMI and most have shown a steady dose-response 
relationship with incident asthma and increasing BMI, and the majority also 
demonstrate the effect to be stronger in women than men although this is 
controversial3. Many of these longitudinal studies also control for diet and 
physical activity, strengthening the conclusion that it is obesity itself, and not a 
lack of exercise or dietary factors, that is associated with asthma257. Again 
studies have varied in whether height and weight is self reported or measured 
but in either case the majority of prospective studies have reported that 
obesity is a risk factor for the development of a new diagnosis of asthma. The 
odds ratio is between 1.1 and 3.0 comparing lowest and highest BMI 
categories3.
Paediatric studies show heterogeneity in the strength and direction of 
the relationship between asthma and obesity258. With differences reporting 
links between asthma and obesity between boys and girls varying between 
studies, this may be accounted for by differences in the way obesity is 
measured.
A recent meta-analysis 254 of seven studies in adult subjects with a 
primary outcome of incident asthma using BMI as a measure of overweight 
with at least one year follow up found that compared with normal weight, 
overweight and obesity conferred increased odds of incident asthma, with an 
odds ratio of 1.51. A dose response effect of elevated BMI on asthma
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incidence was observed. Comparing normal weight with overweight the OR 
was 1.38 and normal weight with obese OR was 1.92. There was no 
significant difference between men and women. Not all studies agree with the 
direction of causality and one study has shown that obesity was not a risk 
factor for subsequent asthma but asthma was a risk factor for subsequent 
obesity259.
As mentioned above, it is difficult to be clear whether the relationship 
between asthma and obesity exists in many of these studies as many rely on 
a diagnosis made from symptoms or physician reported diagnosis. However, 
the effects of obesity on the respiratory system can lead to symptoms of 
breathlessness which may be mistaken for asthma260. Some have shown that 
there is an increased risk of wheeze and breathlessness but not bronchial 
responsiveness213 which may suggest that not all subjects that respond 
positively to questions of symptoms may have asthma and we must treat 
these studies with caution.
1.10.1 Weight loss studies
Weight loss secondary to bariatric surgery has been shown to improve 
the clinical status of many morbidly obese patients with asthma, with 
resolution of the condition and improvements in number of attacks, medication 
use, hospitalisation and severity score for up to 90% of patients3. Also data 
from the Swedish Obese Subjects Intervention Study found reductions in the 
cost of medications to treat asthma in a surgically treated group but not in a 
conventionally treated group of obese patients 261. Some of these early 
studies are limited to lack of control groups and a lack of testing of pulmonary
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function or bronchial reactivity. More recent studies however with control 
groups have shown improvements in pulmonary function and asthma control 
with reductions in exacerbations plus rescue medication use but not exhaled 
nitric oxide suggesting that improvement in status is likely due to improvement 
in lung mechanics rather than inflammation241. This has been shown more 
recently also with weight loss after surgery failing to show improvements in 
inflammatory markers such as eosinophils in bronchoalveolar lavage fluid 
although there was an improvement in bronchial responsiveness2. However it 
is important to note bariatric surgery is usually carried out on the very obese 
(BMI>40Kg/m2) and may not be applicable to the general population.
Weight loss studies secondary to dietary intervention or dietary 
intervention plus behavioural change have also been carried out. 
Improvements in FEV1, FVC, dyspnoea, use of rescue medication, number of 
exacerbations, and health status have been shown with a weight loss of 
14.5% in 8 weeks in a pivotal clinical trial in which Stenius-Aarniala et al246 
recruited 38 obese subjects into an open, randomised parallel group study. 
This included an eight week, very low-energy diet plus a control group. The 
same group showed improvement in day to day REF variability, morning REF 
and FEV1, mid-expiratory flow, airway resistance (Raw) and FRC with mean 
weight loss of 13.7Kg in 14 obese patients with asthma. Another study with a 
weight loss of 14% showed improvements in day to day peak flow variation, 
FEV1, FVC, ratio of forced midexpiratory flow rate to FVC, FRC, ERV and 
resting minute ventilation262. One study has shown improvements in FEV1, 
FVC and total lung capacity, but no significant change in bronchial reactivity
213
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1.11 Current study
The studies described in this thesis were designed to examine the 
effects of weight loss on asthma severity in obese individuals with a previous 
diagnosis of asthma, on treatment. This is a case control study examining 
various mechanical aspects of the respiratory system, mainly focussing on the 
effects of airway calibre and bronchial reactivity, inflammatory markers of 
asthma within the respiratory system and symptoms.
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Chapter 2 Methods and study design
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This study was an open, randomised, parallel group study investigating 
the effects of weight loss using a meal replacement strategy combined with a 
behavioural program to encourage long term weight maintenance, versus 
simple dietary advice on symptoms, respiratory function and immunological 
markers of asthma severity. This was a mechanistic study and therefore 
duration was six months to allow maximal weight loss in the intensive 
intervention group and to minimise the chance of dropouts.
Ethical approval was obtained from Sefton Local Ethics Committee 
(04/Q1508/51) and the trial was registered with the International Standard 
Randomised Controlled trial Number register (ISRCTN 54432221). All 
subjects gave written informed consent.
2.1 Selection of subjects
This study was powered to investigate weight loss in patients based on 
the study by Stenius-Aarniala et al who investigated the effect of weight loss 
on asthmatics and achieved a 14.5% weight loss with dietary intervention 
compared to 0.3% in a control group246. It was designed to recruit eighty 
subjects with half randomised to intensive treatment and the others to simple 
dietary advice. Allowing for a dropout rate of 5 patients per group, 25 subjects 
per group were required to demonstrate significant changes in body weight, 
assuming a 14Kg change in weight with a SD of 15Kg; 30 subjects per group 
should be sufficient to show a change in PEER (based on previously 
published studies at the time of the study inception showing clear differences 
in body weight and measures of asthma severity with 19 subjects per group.
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This suggested that this sample size should be adequate for the primary 
outcome of improvement in bronchial responsiveness).
2.2 Pre-screening subjects for inclusion
I wished to include subjects with asthma and a Body Mass Index > 30 
Kg/m2. Subjects were recruited from clinics at University Hospital Aintree and 
also by poster and newspaper advertisements in the local press. Subjects 
were asked to contact the department by telephone if they had been given a 
diagnosis of asthma by a physician, were taking medication and were 
overweight. When the subjects contacted the department they were screened 
for inclusion and exclusion criteria outlined below and if appropriate were 
invited to the department for a screening visit to investigate suitability for the 
study.
For the purposes of the study asthma was excluded if the subject did 
not achieve a 20% drop in baseline FEVi with doubling doses of methacholine 
up to 32mg/ml using the 5 breath dosimeter method or did not show 
reversibility in FEVi to nebulised salbutamol of > 15% of baseline.
Other inclusion and exclusion criteria are as follows:
Inclusion criteria:
• Obesity (body mass index > 30 Kg/m2)
• Age 18-65 years. Male or Female
• Asthma requiring treatment with at least an inhaled 
corticosteroid and an inhaled (B-agonist
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Exclusion criteria:
• Subjects on long-term oral corticosteroid therapy (previous use 
for acute exacerbations, but not within three months of study 
entry was permitted)
• Diabetes mellitus
• Pregnancy or breastfeeding
• History of major eating disorder (anorexia or bulimia nervosa)
• History of food allergy or allergy to constituents of Slimfast
• Major psychiatric disease (including current use of 
antidepressants)
• Current smokers
• Uncontrolled thyroid disease (patients on stable thyroxine 
replacement could be included)
• History of severe cardiac, hepatic or renal disease, malignancy, 
or any other condition that might, in the opinion of the 
investigators preclude completion of the study.
2.3 Groups - Randomisation
Groups were randomised following screening at the baseline visit by 
opening sequential envelopes stratified by gender containing a pre-prepared 
envelope containing a card with group A (dietician) or group B (control) 
printed on it. Randomisation was prepared in a 1:1 ratio by the statistics 
department at the University of Liverpool based 80 subjects stratified to 
ensure equal numbers of male and female patients in each group. The 
investigators were blinded to the process of envelope preparation.
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2.4 Intervention
2.4.1 Dietician (meal replacement) group
The study investigators were not involved in the intervention at any 
point to ensure that they could not influence the study and therefore reduce 
the risk of bias. This group was assessed by a study dietician, their energy 
needs calculated and were given advice on diet using meal replacements; 
they were provided with sufficient Slimfast™ meals (drinks/bars. Slim.Fast; 
Slim.Fast Foods Company, West Palm Beach, FL) to provide up to 3.35 MJ 
(800 kcals) per day. An eating plan, incorporating meal replacement products 
with an energy deficit of at least 2.09MJ (500 kcal) per day was negotiated 
with the subject. Subjects were allowed to select a meal of their choice for the 
evening meal, up to a total of 5.02-6.28MJ (1200-1500 kcal) per day. Subjects 
also entered a programme of dietary management designed to encourage 
long term behavioural change. This was developed for use in Aintree Hospital 
weight management unit based on regular (two weekly) visits to a dietician for 
three months, and monthly visits thereafter. Areas covered include dietary 
history, nutritional education, advice about physical activity, identifying the 
stage of change and dealing with barriers to change, motivating change, and 
coping strategies to deal with challenging or difficult situations.
Following the first three months subjects were allowed to introduce a 
second meal of their choice but continued with at least one meal replacement 
for the duration of the study
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The following protocol was used by the dietician:
Assessment Appointment
□ Measure of weight and calculation of energy requirements
□ Weight and dieting history
□ Reasons for wanting to lose weight
□ Social information
□ Current activity levels
□ Current dietary patterns (typical day)
□ If motivation seems low then assess importance and confidence and 
consider using ambivalence grid
Information exchange -(information usually given at this appointment):
□ Rate of weight loss and 10 % target
□ How to take meal replacements
□ Daily eating plan
□ Food portion guide
□ Additional Meals
□ Snacks and drinks
□ Food diary
□ Slimfast® preference chart
Discuss Slimfast® choices and give samples (enough to last 2 weeks) of ones 
subject thinks they may like. Ask them to complete preference chart and bring 
to next appointment.
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Follow up appointments
Review every 2 weeks for 3 months then monthly for 3 months thereafter.
□ Weight Check
□ Provision of sufficient slimfast® for the next 2 weeks - & note what 
given
□ Review of progress including whether taking slimfast® as advised & if 
following eating plan
□ Asking re hunger and cravings & any lapses
□ Review of food diaries
□ Review of any lifestyle goals set at previous appointments
□ Negotiating goals for lifestyle change
□ Information exchange (can use agenda setting chart)
□ If motivation seems low consider assessing motivation and confidence 
and / or using ambivalence grid
□ Other advice/ support as appropriate
2.4.2 Control group
Those subjects randomised to receive conventional advice were given 
a standard leaflet on healthy eating (British Heart Foundation - Healthy 
Eating), and advised that weight loss might help their asthma; they were not 
given further advice on weight loss for the duration of the study.
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2.5 Asthma management
No intervention was made to the subjects’ asthma treatment 
throughout the study and treatment continued according to the British 
Thoracic Society Guidelines15. Subjects were educated regarding correct 
inhaler technique and given advice regarding adjustment of treatment, and 
when to seek advice from the physician or emergency department if required 
at the initial visit. Subjects were asked to complete a 2-week asthma diary 
card recording morning and evening PEFR as the best of three consecutive 
measurements using a mini-Wright peak flow meter for two weeks prior to 
each visit. Asthma symptoms and rescue medication were also recorded.
2.6 Procedures and rationale
2.6.1 Measuring height, weight and % fat mass
Height and weight were measured in meters with the patient in 
stockinged feet using a calibrated wall mounted stadiometer and in kilograms 
using calibrated weighing scales respectively. Body mass index (BMl) was 
calculated with the following equation: weight in Kg / height in meters2 = BMl 
(Kg/m2).
%Fat mass was measured using a Quadscan body composition & fluid 
measuring device (Bodystat®). Subjects were asked not to eat or drink from 
the night prior to their visit, had no alcohol or caffeine consumption 24hours 
prior to their visit and refrained from exercise 12 hours prior to the visit. 
Patient age, height, weight and sex were entered into the device and the 
subject was asked to lie in a comfortable, relaxed position with the arms and 
legs spread slightly so that no parts of the body were touching one another.
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Self-adhesive disposable electrodes were attached to the right hand and right 
foot in order to avoid battery current passing through the side of the body 
where the heart is situated. Red (injecting) leads were connected to 
electrodes placed just behind the finger and the toe and black (measuring) 
leads were connected to electrodes placed on the right wrist and right ankle. 
Once the subject was lying in the supine position, 4-5 minutes elapsed before 
commencing a measurement to ensure that fluid levels have stabilised in the 
body.
Results of Fat% and Lean% of total body weight were recorded from 
the device which is calculated from a regression equation programmed by the 
manufacturer. Fat and lean mass are determined due to the two 
compartments having a different impedence or ability to conduct electricity 
with the body’s lean component having less impedence than the fat 
component.
These anthropometric values were recorded at each subject visit.
2.6.2 Questionnaires, patient peak flow diaries and symptom diaries
Patient health related quality of life was assessed with the following 
questionnaires: Generic quality of life with the Short Form - 36 (SF-36), 
Respiratory specific quality of life with the St George’s Respiratory 
Questionnaire (SGRQ) and Weight related quality of life with the Impact of 
Weight on Quality of Life - Lite (IWQOL - Lite) copies of these are included in 
Appendix A. At each visit patients were asked to self complete the 
questionnaires following anthropometric measurements but before any other 
intervention. Subjects were allowed to ask questions of the investigators if
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they were unsure of how to answer any questions but the investigators took 
care not to influence the response.
The questionnaires were issued at all visits and results calculated as 
per methods recognised by their respective developers.
2.6.3 Quality of Life Questionnaires
2.6.3.1 The Short Form 36 (SF 36) (UK version)
The United States Task Force on Developing Obesity Outcomes and 
Learning Standards (TOOLS) recommends utilizing the SF-36 as the generic 
measure of choice in obesity research (Anne Wolf, NAASO meeting 2000) 
(Koiotkin 2001 obese rev) because it is comprehensive, brief, consistent with 
current guidelines and psychometrically sound. It is not age, disease, or 
treatment specific and assesses health-related quality of life outcomes known 
to be mostly affected by disease and treatment.
Ware, the developer of the SF 36 emphasised that health has 
dimensionality - physical health, mental health, everyday functioning in social 
and role activities, and general perceptions of well-being and can range from 
the negative states of disease to more positive states of well being.
The Short Form-36 is referred to as a generic measure of quality of life 
which represents eight of the most important health concepts included in the 
Medical Outcomes Study which was a large scale test of the feasibility of self- 
administered patient questionnaires and generic health scales for those with 
chronic conditions, including the elderly. It includes one multi-item scale 
measuring each of eight health concepts: (1) physical functioning, (2) role 
limitations due to physical health problems, (3) bodily pain, (4) general health,
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(5) vitality (energy/fatigue), (6) social functioning, (7) role limitations due to 
emotional problems, and (8) mental health (psychological distress and 
psychological well being). Information about these health status scales is 
summarised in table 2.
Concepts No. of 
items
No. of 
levels
Meaning of scores: Low Meaning of scores: High
Physical
functioning
10 21 Limited a lot in performing 
all physical activities 
including bathing or 
dressing due to health
Performs all types of 
physical activities 
including the most 
vigorous without 
limitations due to health
Role-Physical 4 5 Problems with work or 
other daily activities as a 
result of physical health
No problems with work or 
other daily activities as a 
result of physical health
Bodily pain 2 11 Very severe and 
extremely limiting pain
No pain or limitations due 
to pain
General Health 5 21 Evaluates personal health 
as poor and believes it is 
likely to get worse
Evaluates personal health 
as excellent
Vitality 4 21 Feels tired and worn out 
all of the time
Feels full of pep and 
energy all of the time
Social Functioning 2 9 Extreme and frequent 
interference with normal 
social activities due to 
physical or emotional 
problems
Performs normal social 
activities without 
interference due to 
physical or emotional 
problems
Role-Emotional 3 4 Problems with work or 
other daily activities as a 
result of emotional 
problems
No problems with work or 
other daily activities as a 
result of emotional 
problems
Mental Health 5 26 Feelings of nervousness 
and depression all of the 
time
Feels peaceful, happy, 
and calm all of the time
Reported Health 
Transition
1 5 Believes general health is 
much better now than one 
year ago
Believes general health is 
much worse than one 
year ago
Table 2. Healt 
HRQoL quest!
i scales and explanation of domains for the Short Form 36 
onnaire
The questionnaire has proven useful in surveys of general and specific 
populations, in comparing the relative burden of disease, and in differentiating 
the health benefits produced by a wide range of instruments.
The questionnaire is self administered and subjects were excluded if 
they were unable to read the questionnaire. It was administered before the 
subject was asked about other health questions and concurrent illnesses so 
that any discussion of health problems did not influence the subject’s
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answers. The subject was instructed to read the instructions on top of the first 
page and choose the response that best represented how they felt. The 
questionnaire was answered by the subject themselves and spouses, or other 
family members, or visitors, were asked not to assist in completing the 
questionnaire. Once the questionnaire was completed the investigators 
checked for any missing answers and checked with the subject if they missed 
the question by accident and to complete the missing answer or asked if there 
was any other reason for not completing the questionnaire.
The SF-36 items and scales are scored so that a higher score indicates 
a better health state. After data entry, items and scales were scored in three 
steps:
(1) item recording, for the 10 items that require recoding;
(2) Computing scale scores by summing across items in the same 
scale (raw scale scores);and
(3) Transforming raw scale scores to a 0-100 scale (transformed scale 
scores).
Scoring was performed using an excel spreadsheet programmed with the 
scoring algorithm outlined in the SF-36 Health Survey Manual & Interpretation 
Guide.
Norms for the general U.S. population are shown in table 3.
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Physical
functioning
Role-
physical
Bodily
Pain
General
Health
Vitality Social­
functioning
Role-
Emotional
Mental
Health
Total 84.15
(23.28)
80.96
(34)
75.15
(23.69)
71.95
(20.34)
60.86
(20.96)
83.28
(22.69)
81.26
(33.04)
74.74
(18.05)
Males 87.18
(21.29)
86.61
(30.88)
76.88
(22.97)
73.48
(20.02)
63.59
(20.04)
85.23
(21.28)
83.28
(31.31)
76.37
(17.16)
Females 81.47
(24.6) (36.20)
73.59
(24.25)
70.61
(21.50)
58.43
(21.47)
81.54
(23.74)
79.47
(34.43)
73.25
(18.68)
Table 3. Normative scores for the SF36 HRQoL questionnaire for the 
general population (US) means (sd) given
The scores for the SF-36 can also be represented as summary scores 
for physical health and mental health. The eight SF-36 scales define distinct 
physical and mental health clusters. It is known that 80 to 85 percent of the 
reliable variance in the eight SF-36 scales is accounted for by physical and 
mental components of health and this suggests that psychometrically-based 
summary measures can reduce the number of statistical comparisons 
required in analyzing SF-36 data from eight to two without substantial loss of 
information. Therefore the mental component summary (MCS) and physical 
component summary (PCS) component measures were constructed using 
principle components analysis factor analytical method.
2.6.3.2 The St George’s Respiratory Questionnaire (SGRQ)
The SGRQ is a respiratory specific Health Related Quality of Life 
questionnaire designed to measure health impairment in patients with asthma 
and Chronic Obstructive Pulmonary Disease. There are other questionnaires 
such as the Juniper Asthma Quality of Life Questionnaire (AQLQ) that are 
specific for asthma, however in a study or comparison between the two, in
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overall terms, not one of these instruments behaved better than the other166 
and therefore the SGRQ is fit for our purpose. It is in two parts which includes 
16 questions. Part 1 consisting of questions 1 to 8 produces the symptoms 
score, and part 2, consisting of questions 9 to 16, the activity and impact 
scores. A total score is also produced.
The first part covers the subject’s recollection of symptoms over a 
preceding period of 1 month to asses the subject’s perception of their recent 
respiratory problems and frequency of respiratory symptoms. The 1 month 
version was used due to the time frame of the study and it is noted that this is 
not designed to be a precise epidemiological tool. The second part addresses 
the subject’s current state (i.e. how they are these days). The activity score 
just measures disturbances to the subject’s daily physical activity. The 
impacts score covers a wide range of disturbances of psycho-social function. 
Validation studies showed that this component in part relates to respiratory 
symptoms, but it also correlates quite strongly with exercise performance (6- 
minute walking test), breathlessness in daily life (MRC breathlessness score) 
and disturbances of mood (anxiety and depression). The impacts score is, 
therefore, the broadest component of the questionnaires, covering the whole 
range of disturbances that respiratory subjects experience in their lives.
The questionnaire is designed for supervised self administration and 
was completed in a quiet area, free from distraction with the patient sitting at a 
desk. The investigator explained to the subject why they were completing it, 
and how important it was to understand how their illness affects them and 
their daily life. They were asked to complete the questionnaire as honestly as 
possible and that there were no right or wrong answers, simply the answer
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that they felt best applied to them. They were advised to answer every 
question and someone was close at hand to answer any queries about how to 
complete the questionnaire.
The subjects completed the questionnaire themselves, but someone 
was available to give advice if required. It is designed to elicit the subject’s 
opinion of his/her health, not someone else’s opinion of it, so family, friends or 
members of staff did not influence the subject’s responses. The questionnaire 
was checked to ensure that there were no missing responses and if found the 
subject was asked to complete them.
A copy of the SGRQ used in this study is included in appendix A. 
Scores obtained from subjects are weighted and calculated as per the scoring 
algorithm suggested by the originators. SGRQ scores in healthy subjects with 
no history of respiratory disease quoted in the SGRQ manual are shown in 
table 4: means (95% confidence intervals).
N Age-years FEV as 
%
predicted
Symptoms
Score
Activity
Score
Impacts
Score
Total
Score
74 46 95 12 9 2 6
Range 17- 
80
(91-99) (9-15) (7-12) (1-3) (5-7)
Table 4. Normal scores the domains of the SGRQ in healthy subjects 
quoted in the SGRQ manual
Scoring of the questionnaires was performed using a computer 
programme designed by a member of the research team at University 
Hospital Aintree based on the scoring algorithm designed and described in 
the St George’s Respiratory Questionnaire Manual. Lower scores indicate 
better quality of life and a meaningful change in SGRQ score is a change of 4.
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2.S.3.3 Impact of Weight on Quality of Life-Lite (IWQOL-Lite)
The iWQOL-Lite is the short form of the IWQOL which was the first 
instrument specifically developed to assess the effects of the obese condition 
on the quality of life of persons who are seeking treatment for this condition. It 
was designed around issues expressed by patients attending an intensive 
treatment programme for obesity at the Duke University Diet and Fitness 
Centre. Patients expressed dissatisfaction with various aspects of their lives 
due to obesity which covered health and physical functioning, 
social/interpersonal life, work, mobility, self-esteem, sexual life, activities of 
daily living, and comfort with food. The Task Force on Developing Obesity 
Outcomes and Learning Tools (TOOLS) was convened by the North 
American Association for the Study of Obesity and this was charged with 
choosing outcome measures to be used by clinicians and researchers. They 
recommended the use of the IWQOL-Lite in clinical practice and in research 
studies on obesity245.
The IWQOL-Lite is a 31 item questionnaire that begins with the phrase, 
“because of my weight...”. They are separated into 5 domains: Physical 
esteem (11 items), self-esteem (7 items), sexual life (4 items), public distress 
(5 items) and work (4 items). There is also a total score. Each item has 5 
response options as follows: (1-’never true”, 2=”rare!y true”, 3=”sometimes 
true”, 4=”usually true”, and 5=”always true.”)
The questionnaire was administered to the subjects to complete by 
themselves and due to the sensitive nature of some of the items respondents 
were allowed to leave a few items blank. This does not affect the scoring and 
it is acceptable for people to omit items, unless it is careless omission of
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items. This was checked in the appropriate manner by the researcher with the 
subject.
A meaningful change in IWQOL-Lite total score is determined using an 
algorithm described by Crosby and Colleagues. Based on this algorithm, 
subjects’ IWQOL-Lite scores are considered to have shown meaningful 
improvement from baseline to one year if they increased between 7 and 12 
points, depending on baseline severity in comparison to the normative mean. 
Normative means for the IWQOL-Lite have been derived from a sample of 
534 non-obese individuals who were not enrolled in any weight loss treatment 
programme shown in table 5.
The scoring system for the IWQOL-Lite questionnaire is described by 
the originators. The scores range from 0 (worst quality of life) to 100 (best 
quality of life).
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IWQOL Sex BMI BMI BMI BMI BMI
scale 18-24.9 25-29.9 30-34.9 35-39.9 40+
Physical
Function
Females 94.8 (7.3) 82.0 (15.0) 71.8 (19.1) 61.9 (22.0) 43.9 (24.6)
Males 93.8(11.0) 88.8(11.0) 78.1 (17.4) 67.6 (20.6) 46.2 (25.7)
Total 94.5 (8.5) 84.4 (14.1) 73.6 (18.8) 63.4 (21.8) 44.5 (24.9)
Self-
Esteem
Females 85.5 (20.1) 65.0 (26.0) 55.4 (26.4) 49.3 (26.7) 40.1 (27.2)
Males 95.0(12.6) 87.9 (16.1) 77.4 (20.7) 68.3 (24.0) 53.1 (27.4)
Total 88.2 (18.8) 73.4 (25.4) 61.8 (26.8) 54.4 (27.3) 43.1 (27.8)
Sexual Life Females 94.5 (14.4) 78.6 (24.8) 71.3 (27.3) 67.3 (28.6) 57.6 (32.6)
Males 97.7 (10.9) 94.3 (13.0) 86.3 (19.3) 80.5 (22.9) 66.1 (29.6)
Total 95.4 (13.5) 84.5 (22.5) 75.7 (26.1) 70.9 (27.8) 59.6 (32.1)
Public
Distress
Females 97.8 (8.1) 94.9(10.2) 89.3 (15.0) 78.2 (21.2) 51.9 (27.9)
Males 97.3 (10.9) 97.3 (6.8) 93.2(11.1) 84.5 (17.5) 55.7 (27.4)
Total 97.7 (9.0) 95.8 (9.2) 90.4(14.1) 79.9 (20.4) 52.8 (27.8)
Work Females 97.6 (8.3) 89.1 (16.3) 84.2(18.8) 77.6 (22.4) 63.7 (28.4)
Males 96.7 (9.9) 93.3(12.6) 88.5(15.1) 83.4 (18.5) 67.7 (26.3)
Total 97.4 (8.7) 90.7 (15.2) 85.4(17.9) 79.1 (21.6) 64.6 (28.0)
IWQOL- 
Lite Total
Females 93.5 (8.8) 80.7 (13.8) 72.5(16.6) 64.4 (19.1) 48.5 (22.3)
Males 95.5 (10.0) 91.3 (9.1) 82.8 (13.4) 74.2 (16.4) 54.6 (22.1)
Total 94.0 (9.2) 84.6 (13.3) 75.4 (16.5) 67.0 (18.9) 49.9 (22.4)
Table 5. Means and standard deviations of normative scores for IWQOL-
Lite Scores by BMI and Gender. (Manual for the impact of weight on 
quality of life IWQOL and IWQOL-lite measure)
Scoring of the IWQOL-Lite was done using an excel spreadsheet 
designed on the scoring system documented in the manual for the impact of 
weight on quality of life (IWQOL and IWQOL-Lite) measure. Lower scores 
indicate better quality of life and a meaningful change in IWQOL-Lite scores 
are determined using an algorithm described by Cosby and colleagues 
suggesting a meaningful improvement from baseline to one year if they 
increased between 7 and 12 points, depending upon baseline severity in 
comparison to the normative mean.
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2.6.4 Peak flow and symptoms diaries
The subject was instructed in the use of a peak flow meter and given a 
mini-Wright™ EN1326 standard peak flow meter (Clement Clarke 
International Ltd) to take home along with a peak flow diary which included 
questions on daily symptoms. Subjects were instructed to complete this with 
twice daily peak flow recording prior to medication for two weeks prior to their 
subsequent visit. Diaries were collected at baseline, 3 months and 6months 
and a new diary provided at 3 months and 6 months.
2.6.5 Skin prick Testing
Atopic status was checked by skin prick testing with a battery of 
commercially available common aeroallergens (including the following: saline 
control, histamine control (Histamine hydrochloride 1.0 mg/ml), cat, dog, 
house dust mite, tree and grass. A positive result being defined as at least 
one response with a wheal diameter >3mm or larger (Dreborg S 1989) than a 
positive control response after 15 minutes. The test was carried out by an 
experienced investigator on the volar aspect of the forearm with a calibrated 
lancet (1mm) held vertically. The reactions were read after 15 minutes and the 
wheal size was measured in two perpendicular directions including the 
longest diameter with the mean recorded as the response. Subjects with at 
least 1 positive result were regarded as atopic.
2.6.6 Exhaled nitric oxide
Exhaled nitric oxide was measured using a NIOX chemiluminescence 
online analyser (Aerocrine, Solna, Sweden) in line with ATS / ERS
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recommendations for standardised procedures for the online measurement of 
exhaled lower respiratory nitric oxide94. Subjects were asked not to eat for 12 
hours prior to their visit and avoid caffeinated drinks.
The analyser was calibrated according to the manufacturer’s 
instructions every 14 days. The analyser has a visual biofeedback mechanism 
to ensure correct technique from the subject and the subject was instructed in 
the correct technique beforehand. Any incorrect measurements are rejected 
automatically by the analyser software to avoid error due to poor expiratory 
flows etc.
Once seated comfortably the subject was asked to inhale through the 
machine mouthpiece / filter for 2 to 3 seconds to total lung capacity which 
provides nitric oxide free air by passing this air through a scrubber. The 
subject then exhaled immediately, because breath holding may affect FeNO. 
TIC is recommended because this is the most constant point in the 
respiratory cycle and patients accustomed to spirometry are familiar with 
inhaling to this volume.
To exclude nasal NO the subject exhaled against an expiratory 
resistance by maintaining a positive mouthpiece pressure initially at a flow 
rate of 50 ml/s for 10 seconds by using the appropriate manufacturers flow 
control supplied with the analyser and the software set to the appropriate rate. 
The screen of the analyser provides visual feedback to the subject to help 
maintain a constant flow rate and pressure for the recommended duration of 
time. If the flow rate or pressure does not meet the manufacturers tolerances 
(+/-10%) then the measurement is not accepted. The plateau nitric oxide 
level (ppb) was recorded.
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To calculate flow independent parameters of exhaled nitric oxide 
concentrations i.e. airway wall NO flux and alveolar nitric oxide 
concentrations, the procedure was repeated using 10ml/s, 30ml/s, 100ml/s 
and 200 ml/s flow rates for 20, 10, 6 and 6 seconds respectively by using 
different resistors supplied by the manufacturer to alter mouth pressure and 
altering software settings as per manufacturers instructions. These settings 
ensure that the total volume of air exhaled at each flow rate accounts for the 
exclusion of dead space. The manufacturer’s information about the NIOX 
analyser states that the accuracy of the FeNO measurement is ± 2.5 ppb of 
measured value <50 ppb, and ± 5% of measured value >50 ppb, and the 
linearity is <2.5 ppb integral linearity.
Three acceptable readings were recorded at each of the five flow rates 
in each sitting. Recalibration was not required after each change of resistors.
Exhaled nitric oxide levels (ppb) were obtained at screening using an 
expiratory flow rate of 50ml/s. At subsequent visits exhaled Nitric Oxide was 
measured at 10ml/s, 30ml/s, 50ml/s, 100ml/s, and 200ml/s to determine flow- 
independent parameters based on the two compartment model of Tsoukias 
and George101. Alveolar NO concentration was determined as the slope of the 
regression line of the 100ml and 200ml flow rates after inspection of the 
trends. Bronchial NO flux was determined as the intercept of this regression 
line263.
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2.6.7 Bronchial challenge testing / reversibility testing for screening visit
Before their visit, subjects withheld medication as per ATS guidelines 
for challenge testing17. Subjects were also asked to refrain from taking 
caffeinated drinks for this period.
Historically, for diagnostic purposes asthma challenge tests target a 
significant change in FEVi with a 20% fall in FEVi being considered a positive 
test and an arbitrary cut off to exclude significant bronchial responsiveness for 
most research studies set at 8mg/ml using increasing doses of methacholine.
Standardised methods have been developed to perform methacholine 
challenge tests (ATS guidelines)17. A doubling concentration of methacholine 
is administered with assessment of the FEVi. The dose of methacholine 
calculated to induce a 20% drop in FEVi is used to define bronchial 
responsiveness and is termed PC2o-
Methacholine inhalation testing was performed using the five breath 
dosimeter method as per ATS guidelines17. Airway responsiveness to 
methacholine was expressed as the provocative concentration of 
methacholine inducing a 20% fall in FEV1 (PC2o)- Bronchial hyper­
responsiveness was defined by > 20% drop in FEV1 with < 8mg/ml 
methacholine
FEVi was determined using a spirometer appropriately calibrated 
beforehand with the subject seated and breathing into the mouthpiece with a 
nose clip in place following a deep inspiration to total lung volume. The 
subject was asked to exhale as hard as they could to residual volume for at 
least 6 seconds. The total volume expired was recorded as the Forced Vital
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Capacity (FVC) and the volume of air expired in the first second recorded as 
the FENA).
The following method was used and adapted from the ATS guidelines.
1. Prepare the following 10 doubling concentrations of methacholine in 
sterile vials, place them in a holder, and store them in a refrigerator:
Diluent: 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32 mg/ml
2. Remove the vials from the refrigerator 30 min before testing, so that 
the mixture warms to room temperature before use. Insert 3 ml of the 
first concentration into the nebuliser, using a sterile syringe.
3. Perform baseline spirometry and calculate a target FEVi that indicates 
a 20% fall in FEVi (baseline FEVi x 0.80)
4. Ask the subject to hold the nebuliser upright with the mouthpiece in his 
/ her mouth. Watch the subject during the breathing manoeuvres to 
ensure that the inhalation and breathhold are correct and that the 
nebuliser is not tipped. The subject should wear a nose clip while 
inhaling from the nebuliser.
5. At end exhalation during tidal breathing (FRC), instruct the subject to 
inhale slowly and deeply from the nebuliser. The nebuliser is 
automatically triggered soon after inhalation. The subject is 
encouraged to continue to inhale slowly (about 5s to complete the 
inhalation) and to hold the breath (at total lung capacity) for another 5s.
6. Repeat the previous step for a total of five inspiratory capacity 
inhalations. Take no more than a total of 2 min to perform these five 
inhalations.
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7. Measure the FEVi at about 30 and 90s after the fifth inhalation from 
the nebuliser. Obtain an acceptable quality FEVi at each time point. 
This may require repeated attempts. Perform no more than three or 
four manoeuvres after each dose, it should not take more than 3 min to 
perform these manoeuvres. To keep the cumulative effect of 
methacholine relatively constant, the time interval between the 
commencement of two subsequent concentrations should be kept to 5 
min.
8. At each dose report the highest FEVi from acceptable manoeuvres.
9. If the FEVi fails less than 20% replace the nebuliser reservoir and 
move on to the next concentration.
10. If the FEVi falls more than 20% from baseline (or the highest 
concentration has been given) give no further methacholine, note signs 
and symptoms, administer inhaled salbutamol, wait 10 min and repeat 
the spirometry.
2.6.8 Reversibility testing
Prior to testing subjects were asked to withhold inhaled medication for 
12 hours prior to testing in all cases. Patients were also asked to refrain from 
taking caffeinated drinks also for this period.
Subjects unable to undergo methacholine testing due to an FEV1 
<50% predicted underwent spirometry with bronchodilator response to 
nebulised salbutamol.
FEVi was performed at baseline. 5mg of nebulised salbutamol was 
given to the subject and the FEV-i was repeated after 15-20 minutes.
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Bronchial hyper-responsiveness was defined by an increase > 15% and 
200ml in FEV1 from baseline following nebulised salbutamol.
2.6.9 Bronchial challenge testing for study visits
Before their visit, subjects withheld medication as per ATS guidelines 
for challenge testing17. Subjects were also asked to refrain from taking 
caffeinated drinks for this period.
Bronchial challenge testing was carried out using a tidal breathing 
method to avoid the bronchoprotective effect of deep inspiratory manoeuvres 
which may affect the bronchial responsiveness in obese subjects. 
Methacholine was used and we followed the American Thoracic Society 
Guidelines for Methacholine and Exercise Challenge Testing - 1999. 
Bronchial obstruction was measured using body plethysmography, again to 
avoid deep inspiratory manoeuvres a change in specific airway conductance 
(sGaw) of >45 % was used to terminate the test and calculate PC45-
All procedures were carried out by the author following instruction by 
laboratory staff at University Hospital Aintree pulmonary function unit.
Prior to performing the challenge test the equipment was assessed to 
ensure that it was able to deliver an aerosol with a particle mass median 
diameter (MMD) between 1.0 and 3.6 pm. We used a Respironics disposable 
sidestream nebuliser (Phillips) which is able to produce these requirements 
according to manufacturer’s information. The nebuliser output was checked 
with the following method to ensure an output within 10% of 0.13 ml/min:
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2.6.9.1 Nebuliser calibration method.
1. Put 3 ml of room temperature saline into the nebuliser.
2. Weight the nebuliser, using a balance accurate to 1.0 mg (preweight).
3. Adjust the flow meter to 7.0 L/min and nebulise for exactly 2 min.
4. Reweigh the nebuliser (postweight). Empty the nebuliser.
5. Repeat steps 1-4 three times for each of the following air flows: 4.0,
5.0, and 6.0 L/min
6. Calculate and plot the average nebuliser output at each airflow.
• The nebuliser output in millilitres per minute, assuming 1 ml of 
saline equals 1,000 mg, is calculated as
Output (ml/min) =[(preweight (mg) - postweight 
(mg))/time (min)]/1000.
• By interpolation, determine the airflow that will generate an 
output of 0.26ml over 2 min (0.13 ml/min). Record the airflow for 
the nebuliser and the date of the calibration check.
7. Subsequent checks of nebuliser output need only test the nebuliser 
output at the flow that generates the correct output. If the output is 
within specification (0.13 ml/min, ± 10%) testing at other flows is not 
necessary.
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2.6.9.2 Two-minute tidal breathing dosing protocol for methacholine
administration.
The following method was used and adapted from the ATS guidelines.
1. Prepare the following 10 doubling concentrations of methacholine in 
sterile vials, place them in a holder, and store them in a refrigerator:
Diluent: 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32 mg/ml
2. Remove the vials from the refrigerator 30 min before testing, so that the 
mixture warms to room temperature before use. Insert 3 ml of the first 
concentration into the nebuliser, using a sterile syringe.
3. Perform baseline plethysmography and calculate a target sGaw that 
indicates a 45% fall in sGaw (baseline sGaw x 0.55)
4. A nebuliser and mask was used. Medical air was used to drive the 
nebuliser at a flow rate of 6 L/min to give the correct nebuliser output as 
described above.
5. Instruct the patient to relax and breathe quietly (tidal breathing) for 2 
min. Set the timer for 2 minutes.
6. Ask the patient to hold the nebuliser upright start the timer and begin 
nebulisation.
7. Watch the patient to ensure that he / she is breathing comfortably and 
quietly, and not tipping the nebuliser. After exactly 2 min, turn off the air 
and take the nebuliser from the patient.
8. Measure the sGaw 90 seconds after the nebulisation is completed. 
Obtain an acceptable quality sGaw. This may require repeated attempts. It 
should take no more than 3 min to perform these manoeuvres. To keep 
the cumulative effect of methacholine relatively constant, the time interval
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between the commencements of two subsequent concentrations should 
be kept to 5 min.
9. At each dose, report the highest sGaw from the acceptable 
manoeuvres.
10. If the sGaw falls less than 45%, empty the nebuliser, add 3ml of the 
next highest concentration and repeat steps 5-8 above.
11. If the sGaw falls more than 45% from baseline (or the highest 
concentration has been given), give no further methacholine, note 
signs and symptoms, administer 5mg nebulised salbutamol, wait 10 
min, and check spirometry.
2.6.9.3 Measuring sGaw: Body plethysmography
Prior to the procedure the equipment was calibrated as per 
manufacturer’s instructions. A Medgraphics™ Elite Plethysmograph was used 
which is capable of accommodating patients up to 180 Kg. Data was 
interpreted using Breeze Suite software. As we wished to avoid deep 
inspiratory manoeuvres so as to avoid the bronchoprotective effect on 
bronchial reactivity, we measured airway resistance only but not full lung 
volumes of the subjects.
The subjects were instructed in the correct technique before starting 
the measurement. Subjects were asked not to take deep breaths and to 
breathe at tidal volume throughout the procedure.
The subject was asked to enter the body box, a nose clip was applied 
and the box sealed. Time for equilibration of pressure and temperature was 
allowed (90 seconds) and then the subject was asked to place their mouth on
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the mouthpiece and make a good seal. The patient was asked to breathe 
normally through a pneumotachograph whilst the operator observed the trace 
of volume over time on the manufacturer’s software to ensure no leak in the 
system and correct technique. At FRC the mouth shutter was closed and the 
patient was asked to pant at 1Hz against the closed shutter. In the body box, 
respiratory efforts against the closed shutter produce changes in alveolar 
pressure, which are closely similar to changes of pressure at the mouth, and 
are associated with reciprocal changes in TGV: TGV is decompressed and 
compressed, causing corresponding changes in box pressure, which are 
recorded in terms of the change in TGV, denoted as “shift volume”.
With the shutter closed the computer displays flow versus shift volume 
and the slope of this line is used by the software to calculate airway 
resistance and therefore the reciprocal sGaw (specific airway conductance). 
Computer displays and manufacturers software were used to accept three 
reproducible manoeuvres and the average of these three results was obtained 
for the purpose of the challenge; if a drop of > 45% of baseline was met the 
procedure was discontinued and the subject received nebulised salbutamol as 
described above otherwise the procedure was repeated after the next 
nebulisation of methacholine.
Between tests the patient moved outside the body box for the next 
nebulisation of methacholine.
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2.S.9.4 Determination of PC^
The concentration of methacholine required to cause a drop in sGaw of 
45% or PC45 was calculated using a logarithmic method as follows:
PC45 = antilog [ log Cl + (log C2-log C1)(45-R1)l
R2-R1
Where
C1 = second-to-last methacholine concentration (concentration 
preceding C2)
C2 = final concentration of methacholine (concentration resulting in a 
45% or greater fall in sGaw)
R1 = percent fall in sGaw after C1
R2 = percent fall in sGaw after C2
2.6.9.5 Determination of bronchial hyperreactivity: Dose response slope
& Bronchial Reactivity Index
To calculate dose response slope and bronchial reactivity index the 
method described by Burrows et al264 was used and adapted to PC45. The 
dose response data were summarised by the expression: percent decline in 
sGaw / dose, where percent decline sGaw was defined as the decline in 
sGaw (from the post saline value) after the final methacholine dose 
administered, and the dose was defined as the final cumulative dose 
administered. This can be graphically represented as the slope of a line 
connecting the origin of a dose response curve with the final point of the curve 
referred to as the dose-response slope.
The slope was calculated by dividing the percent decline in baseline 
sGaw after the last methacholine challenge by the log of the last methacholine 
concentration given to account for skewed data. To avoid negative or zero
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logarithms in the denominator, all concentrations were expressed as 
milligrams per decilitre.
The expression used therefore to obtain the dose response slope is as 
follows:
DRS = percent decline in sGaw 
Logi0C2
C2 = Final concentration of methacholine (mg/dl)
Where percent decline in sGaw = Baseline sGaw - Final sGaw * 100
Baseline sGaw
Bronchial response index was used to provide a continuous and 
relatively normally distributed variable for use in statistical analysis151:
BRI = Logio DRS
2.6.10 Sputum induction, processing and cell counting
2.6.10.1 Sputum induction
Sputum induction was carried out in a secluded area of the laboratory 
to minimise embarrassment for the subject with infection control procedures to 
protect personnel and subjects. A DeVilbiss® large volume ultrasonic 
nebuliser (DeVilbiss® Ultra-Neb) with an output of approximately 1ml/min was 
used for the procedure using fresh 6-9ml sterile saline solutions of 3%, 4% 
and 5% hypertonic saline.
Prior to the procedure the subjects were given a bronchodilator in the 
form of nebulised salbutamol which had been given following the 
methacholine challenge test. The subjects then underwent spirometry to 
obtain a baseline FEVi before proceeding. Subjects were instructed prior to 
the procedure that if they produce sputum felt to arise from the airways to
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expectorate into a sterile container. They were instructed to blow their nose 
and rinse their mouth with water and swallow it prior to their attempt to 
expectorate to minimise the possibility of contamination from the upper 
airways and oral cavity. Following this subjects were asked to breathe 3% 
nebulised hypertonic saline for 7 minutes following which the subject was then 
asked to cough and spit as previously instructed. Spirometry was then 
repeated. If the subject stated that they wished to cough at any point during 
any 7 minute inhalation period the nebuliser was turned off, the specimen 
obtained and the nebuliser was restarted to complete the inhalation period. If 
the subject was unsuccessful in producing sputum then the process was 
repeated with 4% and 5% hypertonic saline solutions. The procedure was 
discontinued if there was a drop in FEVi > 20%, the patient was unable to 
tolerate the procedure or all concentrations of hypertonic saline were 
completed.
2.6.10.2 Sputum processing & slide preparation
Sputum was processed within two hours of expectoration as per the 
following protocol kindly supplied by the department of respiratory medicine 
Glenfield Hospital. Procedures 1-6 below were performed on ice. Centrifuge 
was set at 4°C.
1. Empty whole sample into a petri dish. Select sputum plugs, using fine 
forceps, from saliva and transfer onto the petri dish lid (if necessary 
using inverted microscope). Using blunt forceps gather the sputum 
plugs into one mass then condense it by moving the entire mass 
around the lid with small circular motions. The aim is to spread the
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saliva across the lid but to keep the sputum in one mass. The selection 
procedure and condensation / removal of saliva are important in 
reducing squamous ceil contamination.
2. Transfer the concentrated sputum with blunt ended forceps to an 
empty (pre-weighed) polypropylene centrifuge tube with screw top.
3. Subtract the weight of the empty centrifuge tube from the weight of the 
centrifuge tube plus selected sputum to obtain the weight of sputum 
portion to be processed = W
4. Add dithiothreitol (DTT, Sigma, Poole, UK) freshly diluted from a stock 
solution of 1% (i.e. 200mg in 20ml of water at 4°C for up to 30 days) to 
0.1% using Dulbecco’s phosphate buffered saline (D-PBS, Sigma, 
Poole, UK, cat no: D-8662). Use 4x weight / volume (e.g. 4ml DTT per 
gram of selected sputum).
5. Disperse sputum by repeated gentle aspiration into a plastic Pasteur 
pipette, vortex for 15 seconds and 15 minutes rocking on a bench 
spiromix.
6. Add an equal volume of D-PBS (i.e. If 2ml of 0.1% DTT was added to 
sputum, now add 2ml D-PBS). Vortex for a further 15 seconds, filter 
through 48 pm nylon gauze (Sefar Ltd) placed in a funnel, pre-wet the 
gauze with D-PBS and shake off the excess. Filter into a clean 15ml 
centrifuge tube and note the volume of this cell suspension = X. (This 
can be done by weighing the tube as in step 3)
7. Assess total cell count viability and level of squamous contamination 
using a Neubauer haemocytometer and the Trypan blue exclusion 
method
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• Mix 10 jjI of cell suspension with 10 pi of Trypan blue (dilution 
Z-2)
• Flood haemocytometer with the above mixture a perform a cell 
count within 5 minutes
• Count all cells in 5 or 9 fields of the haemocytometer B (try to 
count 100 cells). If there are 200 cells per field or more dilute an 
aliquot of the cell suspension and recount. Ceils touching the top 
and left lines are counted, cells touching the lower and right 
lines are not. Cells are classified as viable leukocytes, dead 
leukocytes and squamous (whether viable or not). Calculate the 
mean number of cells per square and the percentage of viable 
and squamous cells.
A = Live + Dead Leukocytes (non-squamous cells)
B = Number of fields of Haemocytometer counted
Y = A/B = Mean number of cells in one field of Haemocytometer
% Squamous cells = Squamous cells x 100
[Squamous cells + Viable Leukocytes + Dead
Leukocytes]
(This is the only calculation involving squamous cells)
% Viability = Viable leukocytes x 100
[Viable + Dead leukocytes]
• Calculate the total number of cells and the total cell count 
(cells/g sputum)
Total number of cells (x106) = X x Y x Z
100
[(viable + dead leukocytes) x 2 x volume in ml of filtrate] /100 
5
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Where 5 is the number of fields counted (change this to 9 if p fields
were counted) and 2 is the Trypan blue dilution factor
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Total cell count (106 cells/g sputum) = WxYxZ = Total number of cells x
Wx100 Weight of selected
sputum(g)
8. Centrifuge at 2000 rpm (790g) for 10 minutes, brake off
The purpose of this centrifugation step is to produce a cell and 
debris free supernatent
9. Carefully remove the supernatant without disturbing the cell pellet and 
aliquot into labelled cryotubes either in 0.5ml volumes or into 4 equal 
volumes depending on the amount of supernatant. Supernatent 
aliquots must be stored at -70°C.
10. Label 4 slides as per study subject codes and label a to d respectively 
to distinguish between the four slides.
11. Adjust the cell suspension to 0.5 - 0.75 x 106 cells / ml
12. To calculate the volume required to give 0.5-0.75 x 106 cells/ml
• Total number of cells (106) = Vml 
0.5 x 106
Where V is the final volume the cell suspension must be 
adjusted to, by adding D-PBS to give a cell concentration of 0.5 x 106
cells / ml
• Always resuspend the cell pellet in 0.5-1.0 ml of D-PBS and 
aspirate gently to give a single suspension before topping up to 
the final required volume
13. Use the 50 pi per cytospin to prepare two cytospins (label a and b) and 
the 75 pi per cytospin to prepare two cytospins (label c and d) at 450
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rpm (18.1 g) for 6 minutes using a Shandon III cytogentrifuge (Shandon 
Southern Instruments, Sewickly, PA, USA).
14. Air-dry the four slides for at least 15 minutes at room temperature and 
then stain using a modified rapid Giemsa Romanowski stain (Diff- 
Quik). Slides are dipped into solution A (fixative - Formaldehyde, 
Methanol & Water) for 10 seconds then into solution B (Blue - Azure 
dye (Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride)) for 10 
seconds followed by solution C (red - xanthene dye (Eosin Y)) for 10 
seconds before rinsing in deionized water. The slides are then left to 
air-dry and coverslips applied.
2.6.10.3 Differential cell count
Differential cell counts were carried out on slides that were found to be 
adequately prepared to allow the procedure. Slides containing too few cells, 
spoiled or containing too much squamous contamination were discounted. 
Cells were then counted using a microscope and a differential count of 
neutrophils, eosinophils, macrophages, lymphocytes and bronchial cells was 
performed on at least 300 cells with the aid of a manual differential cell 
counter.
2.7 Study protocol
Subjects were recruited from clinics at University Hospital Aintree or 
poster advertisement with a self-reported BMI >30 kg/m2, aged 18-65 years, 
either non-smokers or ex-smokers of >2 years and taking asthma medication. 
Individuals taking long-term oral corticosteroid therapy, those with other
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significant co-morbidities or those reporting an exacerbation within the 
previous two weeks were excluded. Subjects that fulfilled the entry criteria 
underwent procedures as per the following protocol:
2.7.1 Screening visit
• Inclusion and exclusion criteria checked
• Check subject has read and understood patient information
• Patient consent obtained
• Weight, Height checked plus body fat % by bioimpedence
• History and physical examination Completion of SGRQ, SF-36 & IWQOL- 
Lite questionnaires
• Exhaled nitric oxide measurements at 50ml/s flow rate
• Methacholine challenge testing using 5 breath dosimeter method with
FEVi
• Skin prick testing.
• Venesection for full blood count, urea & electrolytes, liver function tests, 
thyroid function testing and glucose to exclude significant anaemia, 
hypo/hyperthyroidism, diabetes or other biochemical abnormalities which 
might adversely affect health status.
2.7.2 Baseline and subsequent visits
(14-28 days from screening visit)
• Weight, Height, collection of PEFR and symptom diaries
• Body fat % by bioimpedence
• Completion of SGRQ, SF-36 & IWQOL-Lite questionnaires
113
• Exhaled nitric oxide measurements at 10ml/s, 30ml/s, 50ml/s, 100ml/s and 
200mI/s flow rates
• Methacholine challenge testing
• Induced sputum using hypertonic saline
• Further PEFR and symptom diaries given
• Randomisation envelope opened
3 months
Repeat of baseline visit as outlined above.
6 months
Repeat of baseline visit as outlined above.
2.7.3 Subjects without bronchial responsiveness at screening
Subjects’ general practitioners were informed when the subject 
volunteered for the study. If subjects did not show bronchial hyper­
responsiveness this was explained to them and it was recommended but left 
to their discretion on whether to inform their general practitioner. If they 
requested, information was sent with their permission although due to patient 
confidentiality general practitioners were not informed routinely of the test 
results. Medication was not withdrawn by the investigator.
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Chapter 3: Information gained from the screening visit
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Subjects were asked to contact University Hospital Aintree lung 
function department if they were overweight, had a physician diagnosis of 
asthma and were taking inhaled medication. Following a pre-screening 
telephone call subjects were asked to attend the department for a screening 
visit to check inclusion and exclusion criteria for the study. During the course 
of this visit various measures were taken and this chapter explains my 
findings from this visit in which 36.3% did not demonstrate bronchial hyper­
responsiveness and were therefore excluded. 1 wished to explore the 
differences between those that were and were not excluded to understand 
why subjects may have been given the diagnosis of asthma without objective 
measures of bronchial responsiveness. This data has been published in a 
peer reviewed journal: Scott S, Currie J, Albert P, Calverley P, Wilding JP.
Risk of misdiagnosis, health related quality of life and BMI in patients who are 
overweight with doctor diagnosed asthma. Chest. 2012 Mar;141(3):616-24265 
The prevalence of physician-diagnosed asthma is increasing, in part 
because of a link between asthma and obesity266. Several mechanisms lead 
to asthma-like symptoms in obese patients1,247 including the mechanical 
effects of increased BMI on lung volumes, increased work of breathing and 
increased release of adipokines from adipose tissue, although whether these 
mechanisms are associated with objectively demonstrated bronchial hyper­
responsiveness is less certain213. As breathlessness is a common symptom of 
both asthma and obesity there is a risk of diagnostic misclassification of 
asthma, a view supported by a Canadian study which found a third of subjects 
with a prior physician diagnosis of asthma had no evidence of asthma judged 
by symptoms, lung function and bronchial challenge testing249.
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Obesity, like asthma, affects health related quality of life (HRQoL)267,268 
and increased BMI has been related to increased GP attendance rates269. 
Since HRQoL and asthma control are related270 it is easy to see how health 
impairments arising from obesity could be attributed to asthma, further 
increasing the likelihood of a mis-diagnosis.
I hypothesised that physician diagnosed obese asthmatics are at risk of 
mis-diagnosis and would have a significantly impaired HRQoL. I also 
proposed that BMI may correlate more strongly with HRQoL than traditional 
markers of asthma severity. At the screening visit I collected data about 
bronchial hyper-responsiveness and health status both generic and disease 
specific to establish which aspects of their baseline condition related best to 
their health problems. Additionally the relationship of exhaled nitric oxide (a 
marker of airways inflammation in asthma271) and bronchial responsiveness to 
HRQoL were secondary outcome measures.
3.1 Methods
The methods and protocol for the screening visit have been 
outlined in chapter 2 and will be briefly covered here.
3.1.1 Patient Selection
Subjects were recruited from clinics at University Hospital Aintree or 
poster advertisement with a self-reported BMI >30 kg/m2, aged 18-65 years, 
either non-smokers or ex-smokers of >2 years and taking asthma medication. 
Individuals taking long-term oral corticosteroid therapy, those with other 
significant co-morbidities or those reporting an exacerbation within the
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previous two weeks were excluded. Four subjects were found to have a BMI 
<30 kg/m2. In these the BMI was > 28 kg/m2 and inclusion did not significantly 
affect the outcome so were included in the intention to recruit analysis.
3.1.2 Questionnaires
Participants completed the St Georges Respiratory Questionnaire 
(SGRQ)163, Short Form 36 (SF36)158 and Impact of Weight on Quality of Life- 
Lite (IWQOL-Lite)244 questionnaires validated to assess the effect of 
respiratory disease, generic factors and weight on quality of life respectively.
3.1.3 Atopy
Atopic status was determined using skin prick testing with a battery of 
common aeroallergens. A positive result being defined as at least one 
response with a wheal diameter > 3mm or larger than a control response after 
15 min.
3.1.4 Exhaled markers of inflammation
Participants abstained from caffeinated drinks and food for 12 hours 
before testing. The fraction of exhaled nitric oxide (FeNO) measured in ppb 
was measured using a chemiluminescence analyser (NIOX®, AEROCRINE, 
Solna, Sweden) at a flow rate of 50ml/sec as per ERS/ATS guidelines94
3.1.5 Bronchial responsiveness
Methacholine inhalation testing was performed using the five breath 
dosimeter method as per ATS guidelines17. Airway responsiveness to
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methacholine was expressed as the provocative concentration of 
methacholine inducing a 20% fall in FEV1 (PC20).
Subjects unable to undergo methacholine testing due to an FEV1 
<50% predicted underwent spirometry with bronchodilator response to 
nebulised salbutamol.
Bronchial hyper-responsiveness was defined by > 20% drop in FEV1 
with < 8mg/ml methacholine or an increase > 15% and 200ml in FEV1 from 
baseline following nebulised salbutamol.
3.1,6 Statistical Methods
This was an observational study with sample size determined by 
numbers of subjects recruited for an interventional trial powered for obese 
asthmatics with bronchial hyper-responsiveness.
Categorical variables are expressed as percentages of total subjects 
and compared using Chi squared test. Continuous variables are expressed 
using mean ± SD and compared using the Students unpaired f test if normally 
distributed. Non-normal distributions determined by Shapiro-Wilk testing are 
expressed using median and interquartile range. Correlations were performed 
between normally distributed variables using Pearson correlations two-tailed 
test and non-normally distributed variables using Spearman’s. PC20 and 
FeNO were log transformed to provide normal distributions before correlations 
calculated with Pearson’s. A weak correlation was defined as r = 0.2-0.4, 
moderate correlation as r = 0.4-0.7 and a strong correlation as r = 0.7-1.0. 
SPSS version 16 for windows was used for calculation.
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Significance was determined if p<0.05. Significance of comparisons of
multiple variables was adjusted using the Bonferroni correction.
3.2 Results
3.2.1 Subject recruitment
397 subjects underwent telephone screening as outlined in figure 1. 91 
subjects were retained in the analysis.
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Fig 5. Consort diagram for screening patients
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3.2.2 Subject Characteristics: all subjects.
Demographic characteristics, pulmonary function and exhaled nitric 
oxide of the study participants are summarised in Table 6.
Variables
Age, yr 49.2 (9.6) yr
Female Gender 60/91 (65.9%)
Ex-Smokers 32/91 (35.2%)
Pack yr (ex smokers) 17.2(19.3)
BMI Kg/m* 38 (7) Kg/m11
Weight Kg 105.6 (22.6) Kg
Subjects with atopy 61/90 (67.8%)
Dose of inhaled steroids
pg/d
1273.5 (937.1) pg/d
FEV1 % predicted 85.8(19.8)%
FVC % predicted 103.1 (17.2) %
FEV1/FVC 70(10.6)%
PC20 mg/ml 5.087 (6.71) mg/ml
FeNO ppb 25.1 (21.5) ppb
Definition of abbreviations: BMl = Body mass index; F EV1 = forced expiratory 
volume in 1 second; FVC = forced vital capacity; PC2o= concentration in 
mg/ml methacholine to produce a 20% decrease in FEV1; FeNO = fraction of 
exhaled nitric oxide at 50ml/s flow rate.
Numbers expressed as mean (sd) or number of cases / number in group 
(percent)
Table 6. Demographics, medical characteristics, pulmonary function, 
bronchial responsiveness to methacholine and level of exhaled nitric 
oxide for all subjects
Subjects were obese with relatively well preserved lung function. Five 
subjects were taking inhaled steroid medication but did not know their inhaled 
dose while 4 were not using inhaled steroid. Short acting beta agonists were 
prescribed in all. 55 (60.4%) used long acting beta agonists. 1 subject refused 
skin prick testing.
Dose of inhaled steroid (BDP equivalent) weakly related to FEV1 % predicted 
(r= -0.29, p=0.007) and FEV1/FVC (r=-0.26, p=0.017), but not PCso- There 
was no significant difference in PC2o(p=0.630), presence of bronchial hyper­
responsiveness (p=0.673), FEV1 % predicted (p=0.055) or FEV1/FVC ratio
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(p=0.179) between those taking and those not taking long acting beta 
agonists.
BMl weakly correlated with PC2o (r=0.29, p=0,033) and FeNO (r—0.32,
p=0.025).
3.2.3 Questionnaires
SF36 data were not available in 1 subject due to a completion error. 
Questionnaire scores for the whole group are shown in Table 7.
IWQOL Lite Domain Mean (SD)
Physical Function 57.2 (25.5)
Self Esteem 49.4 (28.0)
Sexual Life * 68.7 (56.2)
Public Distress * 75.0 (30.0)
Work* 81.2 (37.5)
Total 60.9 (21.6)
SF36 Domain Mean (SD)
Role physical 53.3 (43.3)
Body pain 62.5 (25.8)
General Flealth 50.0 (22.3)
Vitality 43.5 (23.3)
Social Functioning 65.3 (26.2)
Role Emotional 61.1 (42.6)
Mental Health 64.4(19.3)
Mental Health Total 56.9 (21.2)
Physical Health
Total
52.0 (22.9)
SGRQ Domain Mean (SD)
Symptoms 61.1 (18.4)
Activity 54.7 (22.2)
impacts 33.2 (17.6)
Total 44.3 (17.0)
*= distribution non-normal
Table 7. Questionnaire scores for all subjects for SGRQ, SF-36 and 
IWQOL-Lite
Mean (SD) total scores for SGRQ = 44.4 (17.0), SF36 (Mental Health 
subtotal) = 56.9 (21.2), SF36 (Physical Health subtotal) = 52.0 (22.9) and 
IWQOL-Lite = 60.9 (21.6) with good correlations between them (p<0.001) Fig 
6.
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Fig 6. Scatterplots showing correlation of Total scores of SGRQ, IWQOL- 
Lite and subtotals for mental health and physical health of SF 36
3.2.4 HRQoL, pulmonary function, bronchial responsiveness. BMI and
airway inflammation
The influence of pulmonary function, airway responsiveness, BMI and 
airway inflammation on HRQoL are shown in table 8.
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FEV1 % 
predicts 
d
FVC%
predicts
d
Loglu
PC20
BMI Log lu FeNO
SGRQ
Symptoms -0.14 -0.07 -0.10 0.09 0.20
Activity -0.06 -0.24 -0.20 0.42* -0.15
Impacts -0.17 -0.09 -0.12 0.24 -0.04
Total -0.14 -0.16 -0.00 0.33* -0.05
SF36
Physical Function 0.01 0.23 -0.10 -0.43* 0.07
Role Physical -0.13 -0.00 -0.08 -0.26* 0.28*
Body Pain -0.26* 0.27 -0.00 -0.34* 0.19
General Health 0.19 0.02 0.06 -0.29* 0.21
Vitality 0.03 -0.05 -0.11 -0.29* 0.06
Social Functioning 0.01 -0.06 -0.01 -0.26* 0.13
Role Emotional 0.01 0.01 0.04 -0.30* 0.15
Mental Health -0.06 0.03 -0.07 -0.22* 0.22*
Physical Health 
subtotal
0.01 0.13 -0.11 -0.42* 0.25*
Mental Health 
subtotal
0.04 -0.02 -0.07 -0.35* 0.19
IWQOL-Lite
Physical Function 0.05 0.14 -0.23 -0.56* 0.30*
Self Esteem 0.07 0.15 0.02 -0.22* 0.14
Sexual Life 0.02 0.14 0.15 -0.19* 0.19
Public Distress 0.12 0.00 0.18 -0.62* 0.28*
Work 0.02 0.7 0.01 -0.39* 0.26
Total 0.07 0.14 -0.11 -0.51* 0.31*
* P<0.05 Bonferroni adjusted
Table 8, Correlations (rvalues shown) between measures of pulmonary 
function, airway responsiveness, BMI and airway inflammation
3.2.4.1 Airway inflammation & HRQoL
There were no significant correlations with FeNO and SGRQ domains 
or SF36 domains following Bonferroni correction. There were statistically 
significant weak correlations found with FeNO and IWQOL-Lite Physical 
functioning (r=0.30, p=0.004), Public Distress (r=0.28, p=0.008), and Total 
(r=0.31, p=0.003) domains.
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3.2A2 BMI & HRQoL
SGRQ
BMI correlated moderately with the activity domain of the SGRQ 
(r=0.42, p<0.001) and weakly with Total SGRQ (r=0.33, p<0.001) but not 
symptoms.
SF36
There were moderate negative correlations between BMI, Physical 
function (r=-0.43, p<0.001) and Physical Health subtotal (r = - 0.42, p<0.001) 
and weak negative correlations with Body Pain (r = - 0.34, p<0.001), Genera! 
Health (r = - 0.30, p=0.005), Role Emotional (r = -0.30, p=0.004), Mental 
Health (r = - 0.22, p=0.033)and Mental Health subtotal (r=-0.35, p<0.001). 
(Note that a lower score indicates worse HRQoL for SF36).
IWQOL-Llte
There were moderate correlations between BMI, Physical Function (r=- 
0.56, p<0.001), Public Distress (r=-0.62, p<0.001), and Total (r=-0.51, 
p<0.001) with a weak correlation between BMI and Work (r=-0.39, p<0.001).
3.2.4.3 FEV1% predicted. FVC% predicted & HRQoL
There were no significant correlations between any measures of quality 
of life and FEV1% or FVC% predicted.
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3.2.5 Bronchial hyper-responsiveness as an explanatory variable
Subjects with bronchial hyper-responsiveness n=58 (63.7%) were 
compared to those without n=33 (36.3%) and subject characteristics for each 
group are summarized in table 9.
With bronchial hyper­
responsiveness n=58
Without bronchial hyper­
responsiveness n=33
Variables P
Age Years 47.7 (9.7) 52.0 (9.0) <0.05
Female Gender 38/58 (65.5%) 22/33 (66.7%) 0.911
Ex-Smokers 25/58 (43.1%) 7/33 (21.2%) <0.05
Pack yr (ex smokers) 17.4 (20.7) 16.1 (14.1) 0.882
BMI Kq/nY 37.6 (6.5) 38.5 (7.9) 0.560
Weight Kg 105.4 (21.6) 106.0(22.1) 0.895
Subjects with atopy 45/57 (78.9%) 16/33 (48.5%) <0.05
Dose of inhaled steroids
MQ/d
(BDP equivalent)
1370.9(1033.5) 1082.1 (688.0) 0.186
FEV1 % predicted 81.3(21.3)% 93.7 (13.7)% <0.05
FVC % predicted 102.2(19)% 104.8(13.5)% 0.498
FEV1/FVC 67(11.3)% 75.3 (6.3)% <0.05
FeNO ppb ¥ 19.1 (22.8) 15.0(16.2) <0.05
Taking SABA 57/58 (98.3%) 32/33 (97%) 0.683
Taking LABA 36/58 (62.1%) 19/33 (57.6%) 0.673
¥ non-normal distribution therefore median ./ IQR quoted
Definition of abbreviations: BMI = Body mass index; FEV1 = forced expiratory volume in 1 
second; FVC = forced vital capacity; FeNO = fraction of exhaled nitric oxide at 50ml/s flow rate. 
Numbers expressed as mean (sd) or number of cases / number in group (percent)
Table 9. Demographics, medical characteristics, pulmonary function, 
bronchial responsiveness to methacholine and level of exhaled nitric 
oxide between subjects with bronchial hyper-responsiveness, defined 
as PC2o methacholine <8mg/ml and those without
Those with bronchial hyper-responsiveness (median PC201 -64 (IQR 
3.48)mg/ml) were younger: 47.6 (9.7) yrs vs 52.0 (9.0) yrs (p<0.05), had lower 
FEV1% predicted: 81.3 (21.3) % vs 93.7 (13.7) % (p<0.05), and lower 
FEV1/FVC: 67 (11.3) % vs 75 (6.3) % (p<0.05). There was no significant 
difference in FVC%. Predicted. FeNO (median (IQR)) was significantly 
greater: 19.1 (22.8)ppb vs 15 (16.2)ppb (p=<0.05) and the percentage with 
atopy was greater in the bronchial hyper-responsive group 78.9% vs 48.5% 
(p<0.05) as were ex-smokers 43.1% vs 21.2% (p=<0.05).
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Between groups there was no significant difference in female gender, 
BMI, dose of inhaled steroids or those taking beta agonists.
There were no significant differences in any domain or total scores for 
the SGRQ, SF36 subtotals or IWQOL Lite (Table 10) between those with and 
without bronchial hyper-responsiveness. There were no significant 
correlations between PC20 and any HRQoL domains.
With bronchial hyper­
responsiveness n=58
Without bronchial hyper­
responsiveness n=33
Domain Mean (SD) Mean (SD) P
SGRQ
Symptoms 63.0 (19.5) 57.7 (16.) 0.194
Activity 53.0(21.4) 57.7 (23.7) 0.332
Impacts 32.7 (15.8) 34.2 (26.6) 0.710
Total 43.9(15.7) 45.2(19.3) 0.721
SF36
Physical Functioning 51.5 (25.8) 57.2 (23.5) 0.297
Role-Physical 41.7 (42.7) 59.9 (42.7) 0.054
Bodily Pain 55.4 (28.2) 66.5 (23.6) 0.060
General Health 50.5(24.1) 49.7(21.3) 0.870
Vitality 45.6(23.1) 42.3 (23.5) 0.521
Social Functioning 60.5 (27.3) 68.1 (25.4) 0.194
Role-Emotional 56.5(42.1) 63.8 (43.0) 0.435
Mental Health 63.2 (21.5) 65.0(18.1) 0.673
Physical Health 
subtotal
48.9 (24.0) 53.7 (22.2) 0.349
Mental Health subtotal 55.2 (22.8) 57.8 (20.4) 0.585
IWQOL-Lite
Physical Function 52.7 (27.9) 59.8 (23.8) 0.223
Self Esteem 48.2 (29.5) 50.1 (27.3) 0.773
Sexual Life * 62.5 (65.6) 78.1 (50.0) 0.080
Public Distress * 75.0 (42.5) 77.5(30.0) 0.304
Work* 75.0 (46.9) 84.4 (37.5) 0.123
Total 56.7 (23.8) 63.3 (20.1) 0.182
* Not normally distributed therefore median and IQR quoted. Mann Whitney U 
as test of significance
Table 10. Comparison of questionnaire scores for SGRQ, SF-36 and 
IWQOL-Lite between those with and without bronchial hyper­
responsiveness
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3.3 Discussion
in a group of obese subjects (mean BMI 38.0 Kg/m2) with a prior 
diagnosis of asthma using inhaled medication, 36.3% did not demonstrate 
bronchial hyper-responsiveness. Although this does not exclude asthma it has 
a high negative predictive value17 and suggests a mis-classification of 
diagnosis supported by lower FeNO271, higher FEV1/FVC% and less atopy in 
the unreactive patients.
These patients had significant health impairment despite relatively well 
preserved lung function, the disease and weight specific quality of life being 
worse than previous published healthy populations160,165-272-273i There was 
good correlation between total scores of all questionnaires suggesting they 
were measuring similar outcomes. The variable that correlated strongest with 
degree of health impairment was BMI rather than other traditional markers of 
asthma severity i.e. airway responsiveness (PC20), lung function (FEV1 % and 
FVC% predicted) or airway inflammation (FeNO). There was no significant 
difference in HRQoL between those with and without bronchial hyper­
responsiveness again suggesting less influence than BMI.
This study supports the results of Aaron et al who showed that a third 
of subjects with a prior physician diagnosis of asthma had no evidence of 
asthma judged by symptoms, lung function and bronchial challenge testing249 
and extend these observations to a more rigidly pre-specified population 
where it might be expected that the incidence of hyper-responsiveness in 
obese patients would be higher154.
I have shown a consistent negative correlation of increasing BMI with 
HRQOL measured by both generic and disease specific instruments. This
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effect was much greater than any associations with degree of airway 
inflammation as assessed by FeNO which might have been expected to track 
asthma severity271,274. The presence of bronchial hyper-responsiveness itself 
was not a good discriminator of impaired health status whilst medication use, 
specifically long-acting bronchodilators in addition to inhaled corticosteroids 
was neither different in the reactive and non-reactive groups nor predictive of 
differences in health status. As might be expected reactive individuals tended 
to have marginally worse lung function, more obstruction and more atopy but 
none of these factors would be a reliable discriminator.
A reduced quality of life associated with obesity is related to increased 
attendance rates to primary care269 where patients have the opportunity to 
report respiratory symptoms204,275,276 and each visit can potentially lead to 
mis-classification of asthma diagnosis. Increased physician interaction may 
explain some of the association of asthma with obesity and care must be 
taken when interpreting studies of asthma and obesity based on self reporting 
of asthma diagnosis.
It is likely that the negative correlation of body mass with HRQoL is due 
to a generic effect267 as there were correlations across all questionnaires and 
we did not find a significant correlation between BMI and the symptoms 
domain of the SGRQ which includes questions on frequency of cough, 
sputum, breathlessness, wheeze and exacerbations.
This study has some limitations due to its observational nature using 
data from screening subjects for an interventional study. Subject numbers 
were not equally matched between groups, but groups were well-matched for 
age, weight and BMI. Although there were more ex-smokers in the bronchial
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hyper-responsiveness group, excluding ex smokers from analysis did not alter 
outcomes. The study entry criteria precluded the inclusion of patients with 
normal BMI and so our data are confined to obese patients.
There is no universally accepted definition of asthma15 and patients 
can have asthma without demonstrable bronchial hyper-responsiveness.
Many studies require the presence of bronchial responsiveness defined as a 
PC20 calculated by linear interpolation of the log concentration to 
methacholine to cause a 20% fall in FEV1 of <8 mg/m! or reversibility of 
FEV1 to inhaled bronchodilators of 15%17. I therefore used these criteria 
towards making a diagnosis of asthma which is supported by the evidence of 
less airway inflammation, less airway obstruction and less atopy in those that 
did not show bronchial hyper-responsiveness.
It is possible that the use of inhaled steroids resulted in improvement in 
bronchial responsiveness270. However, there was no difference in mean dose 
of inhaled steroid between those with and without increased bronchial 
responsiveness.
The screening protocol was not designed to measure static lung 
volumes and therefore I was unable to show a relationship between HRQoL 
and functional residual capacity or expiratory reserve volume which are 
reduced in obesity176,199 possibly linked to bronchial hyper-responsiveness154. 
I did however measure FVC which can give an idea of lung volume and there 
was no difference in FVC between those with and without bronchial hyper­
responsiveness and no correlation between FVC and PC20 or HRQoL.
The SGRQ is not specific for asthma but is validated as a tool for 
asthma research277 with a similar ability to discriminate among groups of
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patients based on asthma severity and control compared to the asthma 
quality of life questionnaire166.
Obesity increases the risk of other comorbidities which may influence 
HRQol278. I excluded these through screening.
Previous studies of the impact of asthma on HRQol exist279 and the 
effect is multifactorial including disease severity, pulmonary function, 
symptoms and other measures, little is known about the impact of weight on 
this complex relationship268. There are similar relationships between the effect 
of BMI on HRQol267 and further work is required to explore these complex 
relationships.
I found a significant number of patients with a potential mis-classification of a 
diagnosis of asthma in an obese population. The strongest correlations with 
either generic or disease specific HRQol were found with BMI. This has some 
clinical implications. Much of modern asthma management is focussed on 
symptom reduction either by increasing the intensity of maintenance 
treatment (GOAL Bateman280) or adjusting the daily treatment regime 
(SMART Rabe281). Applying such approaches to patients who remain as 
symptomatic as my non-reactive obese patients might be harmful. The 
reactive and non-reactive groups reported similar degrees of symptom 
intensity and used similar amounts of asthma treatment. Future studies 
should consider whether therapy can be withdrawn effectively in these obese 
patients receiving more therapy. Certainly a more robust initial diagnostic 
approach might save time and money over the long term by identifying 
patients whose asthma corresponds to more conventional diagnostic criteria.
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These data emphasise the complex problems of identifying respiratory 
disease accurately in obese subjects. Future work is needed to study the 
impact of weight loss in this patient group and its impact on HRQoL.
133
Chapter 4: Weight loss in obese asthmatics
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4.1 Introduction
Most previous studies investigating possible links between asthma and 
obesity have relied on cross sectional data247. Although this may suggest a 
possible relationship it is difficult to determine cause and effect. As previously 
noted, some studies have relied on subjects’ self reported history of 
symptoms of wheeze and a doctor diagnosis of asthma, however, as I have 
shown in the previous chapter this may not be a reliable indicator for the 
presence of asthma when objective measures are not included249. Other 
studies investigating a possible relationship between body mass index and 
asthma have relied on data from large cohort studies to determine body mass 
index and relate this to the onset of asthma. These studies have suggested a 
relationship between obesity and asthma and suggest that the risk of 
developing asthma is greater in individuals with a higher body mass index. 
Although more robust in terms of determining a temporal relationship between 
the onset of asthma and the presence of obesity, many of these studies were 
not designed with this question in mind3.
Other studies have sought to investigate the relationship between 
asthma and obesity through interventions inducing weight loss. Some of these 
studies have involved patients that have undergone bariatric surgery, however 
the effect of the surgery itself may act as a confounding factor when 
investigating the effects of weight loss in terms of measuring lung volumes 
and inflammatory markers. The effect of abdominal surgery may affect 
diaphragmatic function and wound healing may affect systemic inflammatory 
markers and therefore introduce possible confounders282'284.
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Non surgical weight loss interventions are available in a number of 
forms including low or very low calorie diets, meal replacements and 
pharmacological intervention which should generally be given together with 
behavioural intervention and support for increased physical activity. (NICE 
clinical guidelines 43)285. Using weight loss techniques that do not involve 
surgery eliminates the possible confounding factor of the surgery itself, and is 
applicable to a much wider group of people with obesity. Although there is still 
the possibility of a change in diet or behavioural intervention affecting asthma 
outcomes such as symptoms, asthma control and quality of life rather than the 
effect of weight loss itself, these are less likely to be significant compared to a 
surgical intervention.
A clinically significant weight loss has been determined by a consensus 
of obesity experts to be >5% of body weight in terms of improving lipid, 
glucose and blood pressure levels with potential reductions in cardiovascular 
disease and diabetes risk286,287. We therefore wished to choose a method 
shown to achieve this target and chose a meal replacement strategy and 
behavioural intervention. Stenius-Aarniala et al managed to achieve a mean 
weight reduction of 14.5% using a weight reduction programme including 12 
group sessions lasting 14 weeks including 8 weeks taking a very low energy 
dietary preparation giving a daily energy intake of 1.76MJ246.
We chose the method outlined in chapter 2 which had previously been 
used by the clinical research department for endocrinology and diabetes at 
University Hospital Aintree for weight loss studies, designed to produce an 
energy deficit of at least 0-.5 MJ per day which has been shown to predict a 
weight loss in itself of 0.45Kg per week288 and can be enhanced with
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behaviour modification289 and meal replacement strategies290. Low calorie diet 
strategies with partial meal replacement plan, when administered with 
behaviour modification have been shown to result in a significant amount of 
weight loss of up to 7% in 3 months and 7-8% at 1 year290. It has also been 
shown to achieve >5% weight loss in 72% at 3 months and 74% at 1 year.
The meal replacement strategy using meal replacement shakes, soups, hot 
chocolate and nutrition snack bars (Slim-Fast; Slim-Fast Foods Company, 
West Palm Beach, FL) has been shown to be effective at producing weight 
loss of £5% and is well tolerated291 and was therefore used in this study.
I hypothesised that an intervention arm of randomised subjects in a 1:1 
fashion would lose clinically significant percentage i.e. >5% of their starting 
weight at 3 and 6 months. I also hypothesised that this would be significantly 
greater than the control or non-intervention group and this difference could 
therefore be used to determine differences in asthma control.
4.2 Methods
The methods used during this study have been outlined in the chapter 
2 but I will recap briefly here.
4.2.1 Randomisation
Subjects were randomised into one of two groups (an intervention 
group referred to as the dietician group and control arm) in a 1:1 ratio based 
on codes generated by the University of Liverpool Statistics Department 
stratified to ensure equal numbers of males and females in each group The
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investigators were blinded to this process. The subjects underwent the 
following interventions as per their group:
4.2.1.1 Group A - Dietician group
The study investigators were not involved in the intervention at any 
point to ensure that they could not influence the study and therefore avoid 
bias. The dietician group entered into a meal replacement strategy low calorie 
diet by a study dietician following the baseline visit as per the protocol 
explained previously. Meal replacement products (Slim-Fast; Slim-Fast Foods 
Company, West Palm Beach, FL) were used
4.2.1.2 Group B - Control arm
At the end of the baseline visit those subjects that were randomised 
into the control group were given a standard leaflet on weight loss (British 
Heart Foundation “so you want to lose weight”) and were not given any further 
dietary advice or support during the study.
4.2.2 Measures of weight and weight change
At each study visit measures of body mass index (kg/m2) calculated 
from weight (Kg) and height (m) were taken using calibrated scales and a 
stadiometer. Bioimpedence using a Bodystat Quadscan (Tanita) was used to 
estimate total body fat%.
4.2.3 Statistical analysis
Sample size was determined based on the study by Stenius- 
Aarniarla246 to have 80% power to detect a 12% change in morning peak flow
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rate. This was felt to reflect a change in asthma severity and therefore would 
allow comparison of other markers of asthma severity used in this study. This 
was felt to be 80 patients randomised on a 1:1 basis into an intervention and 
control group. Allowing for a dropout rate of 5 patients per group it was felt 
that 25 subjects per group would be required to demonstrate significant 
changes in body weight and 30 subjects per group to show a change in lung 
function. A previous study has shown clear differences in body weight and 
measures of asthma severity with 19 subjects per group and it was felt that 
this sample size should be adequate for the primary outcome of improvement 
in bronchial hyper-responsiveness.
Categorical variables are expressed as percentages of total subjects 
and compared using Chi squared test. Continuous variables are expressed 
using mean ±SD and compared between groups with the Students unpaired t 
test if normally distributed. Non-normal distributions determined by Shapiro- 
Wilk testing are expressed using median and interquartile range. Variables 
compared between visits were compared using paired-samples f testing. 
Correlations were performed between normally distributed variables using 
Pearson correlations two-tailed test and non-normally distributed variables 
using using Spearman’s.
Significance was determined if p<0.05.
4.3 Results
As noted in the previous chapter, from 91 subjects who underwent 
screening, 58 met the inclusion criteria to be included in the trial and were 
asked to attend for their first visit (baseline). 7 subjects were lost to follow up
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and did not wish to continue. 51 subjects attended the baseline visit and were 
randomised according to the described protocol stratified by gender. 26 were 
randomised to the dietician group and 25 to the control group.
Control group 
n=25
Attended
n=16
3 month 
visit
Baseline
visit
Attended
n=14
6 month 
visit
Attended
n=22
Attended
n=21
Missed
visits
n=4
Missed
visits
n=3
Lost to 
follow up
n=2
Lost to 
follow up
n=2
Lost to 
follow up 
n=2
Lost to 
follow up 
n=7
58 Subjects eligible
Lost to 
follow up 
n=7
Diet intervention
group
n=26
Visitl
51 subjects randomised to study
Fig 7. Consort diagram for trial
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4.3.1 Subject Characteristics
Demographic characteristics, pulmonary function and exhaled nitric 
oxide of the study participants are summarised below.
4.3.2 Demographics
Dietician Group 
n=25
Control Group 
n=26
P
Age Years 45.6 (8.9) 49(10.9) 0.219
Female Gender 16/25 (64%) 16/26 (61.5%) 0.856
Ex-smokers 13/25 (52%) 3/26 (11.5%) <0.05
Pack yr (ex smokers) 13.2(8.9) 3.7 (1.2) <0.05
BMI Kg/M* 38.2 (5.6) 37.2 (5.5) 0.513
Weight Kg 106.5(21.5) 107.6 (21.4) 0.850
Fat% 43% (8) 41.8%' 0.627
Subjects with atopy 22/25 (88%) 17/26 (65.4%) 0.057
Dose of inhaled steroids
Mg/d (BDP equivalent)
1287.5(858.4) 1054.2 (1010.4) 0.393
FEV1% predicted 78.7% (21.7) 88.6% (17) 0.077
FVC% predicted 100.2% (19.6) 105.5% (14.7) 0.279
FEV1/FVC 66.1% (10.8) 70.6% (0%) 0.117
FeNO ppb 28.5 (26.6) 31.7(25.6) 0.665
Taking SABA 26/26 (100%) 26/26 (100%) Na*
Taking LABA 15/25 (57.7%) 14/26 (56%) 0.903
*unable to perform chi squared but all pts on SABA therefore no significant 
difference noted
Definition of abbreviations: BMI = Body mass index; BDP = Beclomethasone 
dipropionate equivalent; FEV1 = forced expiratory volume in 1 second; FVC = 
forced vital capacity; FeNO = fraction of exhaled nitric oxide at 50ml/s flow 
rate; SABA = Short acting beta agonist; LABA = Long acting beta agonist. 
Numbers expressed as mean (sd) or number of cases / number in group 
(percent)
Table 11. Demographics, medical characteristics, pulmonary function, 
level of exhaled nitric oxide and medication for each study group
Subjects were well matched for lung function, exhaled nitric oxide, 
atopy, age, gender, BMI, weight and medication. There were significantly 
more ex smokers with a higher pack year history in the dietician group vs the 
control group. All subjects were using inhaled short acting beta agonist 
medication. One subject in the dietician group did not know their inhaled
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steroid dose and two subjects in the control arm were not taking inhaled 
steroids. Despite this there was no significant difference in dose of inhaled 
steroid (BDP equivalent) between groups. There were no significant 
correlations between steroid dose and FEV1% predicted, FVC% predicted, 
FEV1/FVC ratio, FeNO or PC20 in either the dietician or control groups:
There was no significant difference in long acting beta agonist use 
between groups. In the dietician group there was no significant difference in 
PC20 (p=0.553), FEV1% predicted <p=0.239), FVC% predicted (p=0.302) or 
FEV1/FVC ratio (p=0.440) between those taking and those not taking long 
acting beta agonists. This was similar in the control group for PC20 (p=0.734), 
FEV1% predicted (p=0.284), FVC% predicted (p=0.082), or FEV1/FVC ratio 
(p=949).
4.3.3 Intention to treat analysis
4.3.3.1 Change in weight between visits
Between groups
Mean (SD) Kg
Visit Dietician group Control group P value
Baseline 106.5(21.5) Kg 107.6 (21.4) Kg p=0.850
3 months 102.2 (20.9) Kq 107.4 (22) Kg p=0.485
6 months 104 (18.9) Kg 105.2(13.2) Kg p=0.824
Table 12. Weight of subjects at each visit in each group mean (sd)
shown
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Fig 8. Mean weight of subjects in dietician and control groups 
comparing differences between baseline to 3 months, 3 months to 6 
months and baseline to 6 months
The results of weight loss in Kg show that those in the dietician group 
achieved significant weight loss between baseline and 3 months and this 
remained significant when comparing weight at 6months with their original 
weight although there was no significant weight loss between 3 and 6 months 
suggesting that most weight loss occurred in the first 3 months of the 
intervention and was maintained at 6 months. In the control group there was a 
trend towards weight loss which did not reach significance at either 3 months 
or 6 months.
The following graph and accompanying data shows weight loss in each 
group as expressed as percentage of original weight. Numbers of subjects in 
the table denotes number of subjects that had paired samples (i.e. attended 
visits at 3 & 6 months, this is different from the total numbers randomised due 
to drop out or non attendance for the 3 month visit. See consort diagram.)
143
Percentage weight change from baseline
p=0.24 :: 0=0.23
Baseline 3 months 6 months
Dietician Group 
Control group
Fig 9. Change in weight as % of baseline at 3 and 6 months for each 
group, p values indicate differences between groups at each visit
Despite significant weight loss in the dietician group, when 
percentage weight loss in Kg at 3 and 6 months was compared between 
groups there was a trend towards increased loss of weight in the dietician 
group but this did not reach significance. This is also true for BMI and Fat %.
Time from 
baseline
Dietician group Contro group
No of 
subjects
% weight 
loss (SD)
No of 
subjects
% weight 
loss (SD)
p value
3 months 21 -5 (3.5)% 14 -3 (6.4)% p=0.24
6 months 22 -4.9 (4.3)% 16 -2.7 (6.6)% p=0.23
Table 13. Percentage weight loss from baseline for each group. Number 
of subjects in each group at 3 and 6 months and mean percentage 
change in weight from baseline, p value indicates comparison between 
dietician and control groups
4.3.4 Last observation carried forward
Due to the number of patient drop outs or non-attendance we have 
also investigated the above using last observation carried forward, as this 
methodology is commonly used in weight loss studies as a means of
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assessing response to interventions where dropouts occur and is currently 
recommended for such studies by regulators such as the US FDA.
4.3.4.1 Change in weight between visits
Between groups
Mean (SD) Kg
Visit Dietician group Control group P value
Baseline 106.5(21.5) Kg 107.6(21.4) Kg p=0.850
3 months 102.2(20.9) Kg 107.4 (22) Kg p=0.512
6 months 101.9(19.4) Kg 108.1 (19.3) Kg p=0.422
Table 14 Weight of subjects at each visit in each group mean (sd) shown
Weight change Dietician group
Baseline 3 months 6 months
Visit
Weight change Control Group
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Fig 10. Mean weight of subjects in dietician and control groups 
comparing differences between baseline to 3 months, 3 months to 6 
months and baseline to 6 months
As for the intention to treat analysis there was a significant weight loss 
in the first three months which is sustained at six months. There was no 
significant weight loss seen in the control group at either three or six months 
although there was a trend towards weight loss. When analysing for 
percentage of weight lost as a percentage of the starting weight there was a 
trend towards a greater percentage weight lost in the dietician group 
compared with the control group, however this did not reach significance. The 
mean percentage weight loss did however reach > 5% in the dietician group
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which is thought to be clinically significant in terms of health improvement. 
This is also true for BMI and Fat %.
The graph and table is similar to the intention to treat analysis.
Percentage weight change from baseline
p=0.24 1 p=0.09
Baseline 3 months 6 months
—Dietician Group 
-ft— Control group
Fig 11. Change in weight as % of baseline at 3 and 6 months for each 
group, p values indicate differences between groups at each visit
Time from 
baseline
Dietician group Contro group
No of 
subjects
% weight 
loss (SD)
No of 
subjects
% weight 
loss (SD)
p value
3 months 21 -5 (3.5)% 14 -3 (6.4)% p=0.24
6 months 24 -5.1 (4.5)% 18 -2.3 (6.3)% p=0.2
Table 15. Percentage weight loss from baseline for each group. Number 
of subjects in each group at 3 and 6 months and mean percentage 
change in weight from baseline, p value indicates comparison between 
dietician and control groups
4.3.5 Using 5% weight loss as groups
As noted previously clinically significant weight loss is accepted by 
expert opinion to be > 5%. I therefore examined the groups for any significant 
differences in the numbers of subjects that achieved this amount of weight 
loss. The following table shows numbers of subjects in each group at 3 and 6 
months that achieved 5% weight loss.
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Intention to treat analysis
Control group n 
(%)
Dietician group n 
(%)
P value
3 months 6 (42.9%) 8 (38.1%) 0=0.778
6 months 5(31.3%) 11 (50%) p=0.248
Table 16. Number (percentage) of subjects in each group at 3 months 
and 6 months that lost > 5% of baseline weight, p value represents 
comparison of means for each group
Control group n 
(%)
Dietician group n 
(%)
P value
3 months 6 (42.9%) 8(38.1%) p=0.778
6 months 5 (27.8%) 12 (50%) p=0.248
Table 17. Number (percentage) of subjects in each group at 3 months 
and 6 months that lost > 5% of baseline weight, p value represents 
comparison of means for each group
There was no significant difference between the control and dietician 
groups for the numbers of subjects achieving 5% weight loss.
4.3.6 Influence of age and gender on weight loss
There was no significant difference in absolute weight loss or 
percentage weight loss in either the control or dietician groups between male 
or female subjects. There was no significant correlation with age of subject 
and absolute amount of weight loss or percentage weight lost.
4.3.7 Fat % as a variable
When using fat % as measured by bioimpedence as a measure of 
obesity there was no significant differences in outcomes compared to BMI or 
changes in weight.
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4.4 Discussion and Conclusions
I was able to show significant weight loss in the intervention arm of the 
study at 3 months which was sustained at 6 months. Although there was a 
trend towards weight loss n the control group this was not significant at any 
time point. When comparing between groups at 3 and 6 months there was a 
greater weight loss in the dietician group, however this did not reach 
significance. This was true in the intention to treat analysis and also the last 
observation carried forward analysis.
One reason for this is that in both groups there were individual subjects 
that gained weight as well as lost weight and with both groups achieving an 
overall mean weight loss the difference between the two was not great 
enough to achieve significance. There was no difference between the groups 
for the number of subjects that achieved the clinically significant weight loss of 
>5% although the mean weight loss for the dietician group as a whole did 
reach this level at 3 and 6 months but was not reached in the control group. 
One of the reasons for weight loss in both groups may be due to the so called 
Hawthorne effect in that subjects in a control group of a study experience an 
effect due to the very fact that they are taking part in the study itself292.
I can therefore suggest that further analysis of markers of asthma 
severity can continue using the two groups of subjects although as there were 
individuals that lost significant amounts in both groups we can include 
analysis of the group as a whole between those that achieved clinically 
significant weight loss vs those that did not. Interestingly Fat% measured by 
bioimpedence did not add any further information and therefore will not be 
included in further analysis in this thesis.
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The choice of weight loss intervention may not have been sufficiently 
effective: different methods of weight loss include reduced calorie diet, very 
low calorie diet with meal replacement, pharmacological and weight loss with 
surgical intervention. I used a partial meal replacement plan and a 
comprehensive behavioural approach which has previously been reported to 
induce a 10% to 12% initial weight loss in the first 12 to 16 weeks293 and had 
been used in a similar published trial on the effects of weight loss on 
asthmatic subjects. Most studies have found that patients who completed a 
comprehensive VLCD program (that includes lifestyle modification) generally 
lost 15% to 25% of initial weight in 3 to 4 months. A metanalysis of weight 
management using a meal replacement strategy VLCD vs LCD293 showed a 
weight loss between 13.4% and 19.9% at 26 weeks. Another metanalysis of 
studies of partial meal replacement vs conventional reduced calorie diet 
showed a 7% weight loss in the PMR group at 3 months and 7-8% at 1 year. 
There was significant different between the two groups at 3 months (4% vs 
7%) and 1 year (3-7% vs 7-8%).
The weight loss seen in this study is similar to what might be expected 
using a multicomponent approach as recommended by NICE. In the meta­
analysis reported in the NICE Obesity Guideline285 (CG43), mean weight loss 
at 1 year was 3.82Kg compared to information alone, which is consistent with 
the weight loss seen here. Cultural differences between our UK study 
population and those studied by others (in Sweden and the USA) may also 
explain the difference in response to that previously reported.
it is felt by obesity experts that >5% weight loss is clinically significant 
to improve lipid, glucose and blood pressure levels with potential reductions in
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cardiovascular disease286 and in the Heymsfield metanalysis290 it was shown 
that at 3 months, 34 and 72% of RCD and PMR groups lost >5% of initial 
body weight, respectively (p<0.001) with 33% vs 74% at 1 year. Again the 
intervention was designed on a method that was shown to achieve this 
amount of weight loss.
Partial meal replacement strategies redirect meal/food selections, 
potentially replacing self selected calorie dense foods with well-defined 
reduced calorie alternative of known nutritional value. VLCDs replace all 
meals and represent an extreme in structured diets for weight control. PMRs 
may function in a similar way while additionally permitting subjects to develop 
learning skills in portion sizes as well as maintain an acceptable lifestyle. The 
higher calorie level of PMRs and slower rate of weight loss compared to 
VLCDs is less likely to promote complications such as cholecystitis and 
therefore my method was chosen to be safe.
There are some potential limitations to these analyses including the 
drop out rate. Weight loss studies are known to have high drop out rates of up 
to 66% in a systematic review of 44 long-term weight loss studies in obese 
adults286. I was able to achieve follow up at six months in 71% of the subjects 
with a drop out rate of 29% which is comparable to many interventional 
studies of weight loss also supported in a metanalysis of six VLCD weight loss 
studies that showed an attrition rate of 22.3% and a metanalysis of partial 
meal replacement studies290 with a dropout rate of 19% at 3 months and 47% 
at 1 year. I have analysed my results with intention to treat analysis which is 
sometimes criticised as it is felt that this may bias the weight loss arm of the 
trial as more subjects are likely to continue in the trial if the weight loss is
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successful and subjects are more likely to discontinue if they do not lose 
weight. To overcome this, last observation carried forward analysis is often 
used and I have also employed this method, however this also has its critics. 
Despite this the conclusions drawn do not differ between either method of 
analysis of the data.
4.5 Summary
The weight loss intervention, although not achieving a significant 
difference between groups at 3 and 6 months, appears to have been effective 
at achieving significant weight loss at 3 and 6 months. Therefore further 
analysis of data in this study can use ‘between groups’ comparisons and also 
compare between visits at 3 and 6 months. Further analysis can also be 
carried out between those that achieved clinically significant weight loss of 
£5% and those that did not in both groups for the whole cohort and also using 
all subjects by weight change.
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Chapter 5: Health Related Quality of Life and weight loss
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5.1 Introduction
As noted previously in Chapter 3 both weight and asthma can affect 
health related quality of life (HRQoL) or the “physical, psychological, and 
social domains of health, seen as distinct areas that are influenced by a 
person’s experiences, beliefs, expectations, and perceptions”156. HRQoL 
reflects an individual’s subjective evaluation and reaction to health or illness294 
rather than a medical professional’s evaluation and measuring the effects of 
weight change on HRQoL therefore measures the impact of weight change on 
aspects of disease that are important to the patient and compliments other 
objective measures of asthma severity such as bronchial reactivity or 
measurable airway inflammation. HRQoL is recognised to be 
multidimensional and tools generally measure the functional ability, physical, 
emotional and social wellbeing of individuals. I have explored the relationship 
between weight loss, asthma control and HRQoL with two specific 
questionnaires and a generic questionnaire, these being the St George’s 
Respiratory Questionnaire (SGRQ)163 for asthma, the Impact of Weight on 
Quality of Life-Lite (IWQOL-Lite)244 questionnaire for weight and the Short- 
Form 36 (SF36)160 for generic quality of life. Disease specific questionnaires 
are more sensitive to change in the particular condition they are designed for 
and this is why they have been used here alongside the generic questionnaire 
from which they are derived.
Previous studies have shown that obesity is associated with worse 
quality of life that improves with weight loss interventions243. Studies have 
also shown the effect of asthma on quality of life which improves with 
improvement in asthma control161. I have already demonstrated how HRQoL
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may be related to BMI in obese subjects with a prior diagnosis of asthma with 
or without bronchial hyper responsiveness and explore this further in this 
chapter longitudinally with change in weight.
5.1.1 Exploring changes in weight / BMI and health related quality of life
I have explored the different health related quality of life questionnaires 
and compared changes between the two groups within the study as the 
primary outcome. Correlations with changes in HRQol and changes in weight 
and relationships between change in HRQol between subjects that achieved 
clinically significant weight loss (£ 5% of original weight) and those that did not 
were secondary outcomes. I have also explored the relationship with 
bronchial responsiveness, exhaled nitric oxide and the possible effect of 
gender.
5.2 Methods
The methods, order of investigations and study protocol are outlined in 
chapter 2 and I will recap the use of the questionnaires here in brief.
All questionnaires were administered to each subject at each visit i.e. 
baseline, 3 and 6 months. All were self completed as per the designer’s 
recommendations.
On arrival to the department the questionnaires were completed before 
any procedures were undertaken. The subjects were asked to complete the 
questionnaires by themselves in a quiet area, free from distraction, although 
the investigators were on hand to answer any questions if required. They 
were asked to complete the questionnaires as honestly as possible and were 
told that there were no right or wrong answers. After completion the
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questionnaires were checked to ensure that there were no answers missed in 
error and the questionnaires were collected.
Questionnaires were scored as per the designer’s instructions as 
described in Chapter 2.
5.2.1 Statistical analysis
Categorical variables are expressed as percentages of total subjects 
and compared using Chi squared test. Continuous variables are expressed 
using mean ±SD and compared between groups with the Students unpaired t 
test if normally distributed. Non-normal distributions determined by Shapiro- 
Wilk testing are expressed using median and interquartile range. Variables 
compared between visits were compared using paired-samples f testing. 
Correlations were performed between normally distributed variables using 
Pearson correlations two-tailed test and non-normally distributed variables 
using Spearman’s. Any correlations were checked visually for 
homoscedasticity to confirm any relationship. Significance for multiple 
comparisons were adjusted by Bonferroni correction. Significance was 
determined if p<0.05 and alpha level adjusted by Bonferroni for number of 
observations studied.
5.3 Results
58 subjects completed screening and were randomised into the trial as 
per the consort diagram Fig 7 (p140). Of 26 subjects in the dietician group, 21 
attended at 3 months and 22 attended at 6 months. Of 25 subjects enrolled 
into the control group 14 attended at 3 months and 16 at 6 months. Due to
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errors in completing questionnaires data was missing for 1 subject for SF36 at 
3 months and 1 subject at 3 months and 6 months for the IWQOL-Lite.
5.3.1 HRQoL scores for all subjects for all visits
The HRQoL scores for all subjects are shown below for all visits and 
for each questionnaire. The mean scores for all questionnaires showed worse 
HRQoL in our population when compared to normative scores previously 
published (see chapter 2).
SF-36 (mean (sd))
Baseline (n=51) 3 months (n=34) 6 months (n=38)
Rhys Functioning 60.1 (20.9) 64.7 (20.7)* 71.8 (20,5)¥
Role Physical 57.4(41.9) 75.7 (37.2)* 73.7 (37.2)¥
Bodily Pain 65.5 (25.4) 68.0 (22.4) 70 (24.8)
General Health 51 (21) 51 (21.5) 55.8 (21.4)¥
Vitality 47.2(21.5) 51.6 (21.5)* 52.9 (20.2)¥
Social functioning 70.3 (23) 76.6 (25.5)* 77.1 (26.1)
Role Emotional 69.3 (38.8) 76.5 (37.2) 73.7(41.2)
Mental Health 68.8 (15.8) 67.2 (19.7) 67.4 (20.5)
Physical Health 
summary
56.2 (20.3) 62.2 (18.3)* 64.8 (19.1)¥
Mental Health 
Summary
61.4 (18) 64.5(19)* 65.3 (20.9)¥
Total 61.2(19) 66.4(18.8*) 66.7 (20.7)¥
* = Significant change (p<0.05) between baseline and 3 months 
¥ = Significant change (p<0.05) between baseline and 6 months 
For SF36 higher score = better HRQoL
Table 18. Mean (SD) scores for each domain of the SF36 HRQoL 
questionnaire at each visit for all subjects
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SGRQ (mean fsd))
Baseline (n=51) 3 months (n=35) 6 months (38)
Symptoms 62.7(19.5) 58.2 (19.9)* 54.2 (19.3)¥
Activity 50.8(19.6) 47.2(21.1)* 41.8 (21.4)¥
Impacts 29.7(15.4) 25.2 (14.8)* 26.6(18.7)
Total 41.6(14.9) 37.4(15.1)* 35.8 (17.4)¥
* = Significant change (p<0.05) between baseline and 3 months 
¥ = Significant change (p<0.05) between baseline and 6 months 
For SGRQ lower score = better HRQoL
Table 19. Mean (SD) scores for each domain of the SGRQ HRQoL 
questionnaire at each visit for all subjects
IWQOL Lite (mean (sd))
Baseline (n=51) 3 months (n=34) 6 months (n=37)
Physical Function 65.4 (19.9) 66.7 (19.7)* 69.3 (20.2)¥
Self Esteem 52.7 (30.1) 53.4 (24.9) 57.8 (27.6)¥
Sexual Life 39.1 (28.1) 71.3(27.1)* 72.1 (29.2)¥
Public Distress 75.4 (25.4) 74.5 (25) 80.8 (23.8)¥
Work 79.2 (20.5) 80.8(17.6)* 84.3 (20)¥
Total 66 (19.8) 67.5(18.1)* 70.5 (20.6)¥
* = Significant change (p<0.05) between baseline and 3 months 
¥ = Significant change (p<0.05) between baseline and 6 months 
For IWQOL-Lite higher score = better HRQoL
Table 20. Mean (SD) scores for each domain of the IWQOL-Lite HRQoL 
questionnaire at each visit for all subjects
There was a trend for improvements in all HRQoL total scores in the
three questionnaires from baseline to 3 months and baseline to 6 months but
no significant change between 3 and 6 months for any domains in any of the
questionnaires used.
5.3.2 Comparing HRQoL scores between groups: Dietician group vs
Control group
Questionnaire scores for all domains were compared between the 
dietician and control group at each visit and for each questionnaire. 
Differences in mean scores were compared between groups for each score
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using independent-samples t-test and ANOVA with Bonferroni correction for 
multiple comparisons.
SF-36
Dietician
group
Baseline
(n=26)
Control
group
Baseline
(n=25)
Dietician
group
3 months 
(n=20)
Control
group
3 months 
(n=14)
Dietician
group
6 months 
(n=22)
Control
group
6 months 
(n=16)
Phys
Functioning
55.2
(20.9)
65.2
(20.1)
63.8 (20.3) 66.1 (21.9) 70.5 (18.4) 73.8 (23.7)
Role Physical 43.3
(41.6)
72 (37.7) 78.8 (34.7) 71.4 (41.4) 76.1 (36.6) 70.3 (39)
Bodily Pain 60.8
(26.1)
70.4
(24.3)
65.2 (23.5) 72.1 (20.9) 68.3 (21.8) 72.3 (28.9)
General
Health
46.2 (21) 56 (20.2) 44.3 (24.2) 60.5 (12.3) 51.6 (25.1) 61.6 (13.5)
Vitality 40.2
(21.8)
54.4
(19.1)
50.3 (23) 53.6 (19.9) 51.1 (19.1) 55.3 (21.9)
Social
functioning
62.2 (24) 78.7
(18.9)
77.6 (27.1) 75.1 (24) 73.5 (28.3) 82.1 (22.8)
Role
Emotional
66.7
(38.9)
72 (39.3) 75 (38.8) 78.6 (36) 69.6 (42.4) 79.2 (40.1)
Mental Health 65.4
(16.5)
72.3
(14.5)
60.8 (20.6) 76.3 (14.6) 63.6 (19.5) 72.5 (21.4)
Physical
Health
summary
49.1
(19.6)
63.5
(18.7)
60.4(18.2) 64.8 (18.9) 63.5(17.2) 66.6 (22)
Mental Health 
Summary
56.2
(18.6)
66.8
(16.1)
61.5(20.1) 68.8 (17.3) 61.8 (20.2) 70.2 (21.4)
Total 54.9
(18.3)
67.7
(17.7)
64.5 (18.7) 69.1 (19.2) 63.6 (19.1) 70.9 (22.7)
For SF36 hia ier score = better HRQoL
Table 21. Mean (sd) scores for each domain for dietician and control 
groups at each visit for the SF-36 HRQoL questionnaire, n = number of 
subjects in each group that attended each visit
There were no significant differences (ANOVA) between dietician and control 
group scores for any domain for the SF36 at any time point following 
Bonferroni correction for multiple comparisons (adjustment of alpha level: 
p<0.00625).
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SGRQ
Dietician
group
Baseline
(n=26)
Control
group
Baseline
(n=25)
Dietician
group
3 months 
(n=21)
Control group
3 months 
(n=14)
Dietician
group
6 months 
(n=22)
Control group
6 months 
(n=16)
Symptoms 66.8 (17.8) 58.5 (20.6) 61.9 (18.6) 52.7 (21.1) 56 (17.4) 51.9 (22)
Activity 55.6 (17.3) 45.8 (20.8) 48.8(18.4) 44.9 (25.3) 46.3 (20) 35.7 (22.4)
Impacts 32.8 (17) 26.5 (13.2) 28.3(15.7) 20.5 (12.6) 28.8 (19.2) 23.6 (18.2)
Total 45.4 (14.9) 37.7 (14.1) 40.1 (14.3) 33.3 (15.9 38.6 (17.1) 32 (17.7)
For SG RQ lower score = better HRQoL
Table 22. Mean (sd) scores for each domain for dietician and control 
groups at each visit for the SGRQ HRQoL questionnaire, n = number of 
subjects in each group that attended each visit
There were no significant differences (ANOVA) between dietician and
control group scores for any domain for the SGRQ at any time point following 
Bonferroni correction for multiple comparisons (adjustment of alpha level: 
p<0.0125).
IWQOL-Lite
Dietician
group
Baseline
(n=26)
Control
group
Baseline
(n=25)
Dietician
group
3 months 
(n=20)
Control
group
3 months 
(n=14)
Dietician
group
6 months 
(n=22)
Control
group
6 months 
(n=15)
Physical
Function
59.4 (20.4) 71.6
(17.7)
64.8
(18.7)
69.3 (21.4) 68.6 (17.3) 70.5 (24.4)
Self Esteem 46.5 (30.2) 59.1
(29.3)
52 (26.3) 55.4 (23.6) 56.5 (25.4) 59.8 (31.3)
Sexual Life 69 (26.7) 69.3 (30) 73.1
(27.7)
68.8 (27.2) 76.1 (24.2) 66.3 (35.3)
Public
Distress
72.3 (24.9) 78.6
(25.9)
74.3
(21.9)
74.6 (29.8) 78.6 (24.2) 84 (23.7)
Work 73.7 (20.1) 85(19.8) 80(14.7) 82.1 (21.6) 83.2(17.1) 85.8 (24.1)
Total 61.2 (19.3) 70.9
(19.4)
66.7
(17.5)
68.6(19.5) 70.3 (17.4) 70.8 (25.2)
For IWQOL-Lite higher score = better HRQoL
Table 23. Mean (sd) scores for each domain for dietician and control 
groups at each visit for the IWQOL-Lite HRQoL questionnaire, n = 
number of subjects in each group that attended each visit
There were no significant differences (ANOVA) between dietician and 
control group scores for any domain for the IWQOL-Lite at any time point 
following Bonferroni correction for multiple comparisons (adjustment of alpha 
level: p<0.00833).
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5.3.3 HRQoL scores: Change from baseline
Changes in summary or total scores for each questionnaire and for 
each group at 3 and 6 months from baseline are shown below.
3 months
Dietician
group
3 months 
Control group
6 months
Dietician
group
6 months 
Control group
SF36
Physical
Health
summary
12.5(13.3) -0.2(14.1) 12.9(16.8) 3(11.7)
Mental Health 
Summary
8(13) 3.5(17.5) 6.9(14.3) 4.6(16.4)
Total 11.3(13.2) 1.6 (16.7) 8.2(19.2) 4.1 (13.9)
SGRQ
Total -7.5 (8.7) -3 (8.2) -6.1 (9.5) -4.9 (12)
IWQOL-Lite
Total 7.3 (8.2) 3.4 (14.6) 8.7(11.2) 2.3(11.9)
Significant correlation p<0.05
Table 24. Mean (SD) change in scores for each HRQoL questionnaire 
between baseline to 3 months and baseline to 6 months. Subtotal scores 
for SF-36 and total scores for SGRQ and IWQOL-Lite shown
Comparing changes in HRQoL scores from baseline there were no 
significant differences after Bonferroni correction for multiple comparisons 
between the dietician and control groups for total scores for the SF36, SGRQ 
or IWQOL-Lite from baseline to 3 or 6 months.
Although there was a trend for an increased improvement in HRQoL 
scores as can be seen from the graphs below this did not reach significance.
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Change in SF36 Mental Health Summary score from baseline for dietician 
and control groups
1=0.851 p=0.658
Baseline 3 months 6 months
—Dietician Group 
Control group
Change in SF36 Physical Health Summary score from baseline for 
dietician and control groups
Baseline 3 months 6 months
Visit
Change in baseline in SGRQ Total Score for Dietician and 
Control groups.
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Change in baseline in IWQOL-Lite Total Score for Dietician and 
Control groups.
Fig 12. Graphs to show change in change in scores for SF-36 Subtotals, 
SGRQ and IWQOL-Lite total scores for each group from baseline to 3 
months plus 6 months, p values represent comparison of means at 3 
and 6 months between study groups
5.3.4 Relationship between weight and HRQoL scores.
5.3.4.1 Correlations between BMI and HRQoL
SF36
There were no significant correlations (appendix B) between BMI and 
any domain of the SF36 or subtotals after Bonferroni correction for all subjects 
or either group except the role physical domain at 6 months in the control 
group (r=-0.693, p=0.003)..
SGRQ
There were no significant correlations after Bonferroni correction 
(Appendix B) for any visits between BMI and HRQoL domain or total scores 
for the SGRQ questionnaire for all subjects or either group except the 
symptoms domain in the control group at 6 months (r=-0.640, p=0.008).
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iWQOL-Lite
There were significant correlations after Bonferroni correction with BMI 
and multiple domains of the IWQOL-Lite questionnaire for all subjects at 
baseline for physical function (r=-0.437, p=0.001), public distress (r=-0.715, 
p=0.000) and total score (r=-0.460, p=0.001). This was also seen in the 
control group at baseline for public distress (r=-0.826, p=0.000) and total 
scores (r=-0.586, p=0.002). At 3 months there were correlations between BMI 
and public distress in all subjects (r=-0.704, p=0.000) and the control group 
(r=-0.752, p-0.003) plus total score for all subjects (r=-0.705, p=0.007) and 
control group (r=-0.705, p=0.007). Although at 6 months the correlation in all 
subjects between BMI and public distress (r=-0.581, p=0.000) and total scores 
(r=-0.471, p=0.003) remained there were no correlations in the control group. 
In addition there were correlations at 6 months between BMI in all subjects 
and physical function (r=-0.482, p=0.002) and public distress in the dietician 
group (r=-0.606, p=0.003).
5.3.4.2 Correlations between change in weight and change in scores
Changes in weight as a percentage of baseline at 3 and 6 months were 
compared with changes in questionnaire scores at the same time points for ail 
subjects and for each group to investigate the possibility of a relationship 
between weight change and change in HRQoL. Data is shown in appendix B.
SF36
There was no significant correlation after Bonferroni correction 
between change in any questionnaire domains for the SF36 with percentage
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weight change between baseline to 3 months, 3 months to 6 months or 
baseline to 6 months.
SGRQ
There was no significant correlation after Bonferroni correction 
between change in any questionnaire domains for the SGRQ with percentage 
weight change between baseline to 3 months, 3 months to 6 months or 
baseline to 6 months.
iWQOL-Ute
There was no significant correlation after Bonferroni correction 
between change in any questionnaire domains for the IWQOL-Lite with 
percentage weight change between baseline to 3 months, 3 months to 6 
months or baseline to 6 months except at baseline to 3 months for self 
esteem (r—0.511, p=0.02) and total score (r=-0.551, p=0.001) for the whole 
group plus selfesteem (r=-0.704, p=0.007) and total score (r=-0.621, 
p=0.024) for the control group.
5.3.5 Comparing groups that achieved >5% weight loss at 6 months with
those that did not
I have explored the relationship between HRQoL and weight change 
between the study groups. As noted previously there were subjects that lost 
significant weight in the control group and also those that did not loose weight 
in the dietician group. Therefore I have also explored possible differences in
164
change in HRQoL between those that did and did not lose significant weight 
suggested at >5% of original weight by expert opinion.
SF36 Scores
There was a trend towards improvement in generic HRQoL measured 
by SF36 in those that lost £5%weight between baseline and 6 months 
although this was not significant after Bonferroni adjustment for any SF36 
domain at 3 or 6 months.
Using paired samples T test change in scores was compared between 
baseline to 3 months and baseline to 6 months for the group with significant 
weight loss and those without. Between baseline and 3 months there were no 
significant differences in scores for any domain in the group that showed no 
significant weight loss. In the weight loss group there were significant 
improvements after Bonferroni adjustment in Role Physical (65 vs 91.7), Role 
Emotional (64.5 vs 91.1), Physical Health summary score (60.7 vs 69.3), 
Mental Health summary score (62.1 vs 72.1) and Total score (64.1 vs 74.3).
Between baseline and 6 months there were no significant 
improvements after Bonferroni adjustment in the non weight loss group. In the 
weight loss group there was significant changes in Physical Functioning (61.9 
vs 73.4).
When comparing the overall change in SF36 domain scores from 
baseline to 3 and 6 months between groups there were no significant 
differences at 3 or 6 months between those that lost significant weight and 
those that did not.
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Change in SF-36 Mental Health Summary Score from baseline for 
significant weight loss vs. non significant weight loss groups
p=0.977
p=0.681
ra o .E
(O °
U. CO
Baseline 3 months 6 months
Visit
—>5% weight loss 
<5% weight loss
Change in SF-36 Physical Health Summary Score from baseline for 
significant weight loss vs. non significant weight loss groups
Fig 13. Graphs showing mean change in summary scores of SF-36 for 
mental health and physical health subtotals for those that lost > 5% of 
baseline weight from baseline at 3 and 6 months and those that did not 
p value represents comparison between groups at 3 and 6 months
SGRQ scores
There was a trend towards improvement in respiratory specific HRQoL 
measured by SGRQ in those that lost >5%weight between baseline and 6 
months although this was not significant after Bonferroni adjustment for any 
domain at 3 or 6 months.
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Using paired samples T test change in scores was compared between 
baseline to 3 months and baseline to 6 months for the group with significant 
weight loss and those without. Between baseline to 3 months there were no 
significant improvements after Bonferroni adjustment in quality of life in the 
non weight loss group, however in the weight loss group there were significant 
improvements in Activities domain (48.9 vs 39.8), and Total score (38.2 vs 
31.3).
Between baseline to 6 months there were significant improvements 
after Bonferroni correction in scores in the no weight loss group for Activities 
score (51.6 vs 43.7). This was also true for the weight loss group, Activities 
score (48.4 vs 39.2).
When comparing the overall change in SGRQ domain scores from 
baseline to 3 and 6 months between groups there were no significant 
differences at 3 or 6 months between those that lost significant weight and 
those that did not.
Change in baseline in SGRQ Total score for significant weight loss vs 
non significant weight loss groups
Fig 14. Graph showing mean change in total score of SGRQ for those 
that lost > 5% of baseline weight from baseline at 3 and 6 months and 
those that did not. p value represents comparison between groups at 3 
and 6 months
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IWQOL-Lite
There was a trend towards improvement in weight specific HRQoL 
measured by IWQOL-Lite in those that lost >5%weight between baseline and 
6 months although this was not significant after Bonferroni adjustment for any 
domain at 3 or 6 months.
Using paired samples T test change in scores was compared between 
baseline to 3 months and baseline to 6 months for the group with significant 
weight loss and those without. Between baseline to 3 months there were no 
significant differences after Bonferroni adjustment in scores in the non weight 
loss group, however in the weight loss group there was significant 
improvement in scores for Physical function domain (66.1 vs 71.7) and Total 
score (68.8 vs 74.8).
Between baseline and 6 months there were no significant changes 
after Bonferroni correction for any domain in the non weight loss group. In the 
weight loss group there were significant deteriorations in quality of life scores 
for the Total score (66.8 vs 75.7).
When comparing the overall change in IWQOL-Lite domain scores 
from baseline to 3 and 6 months between groups there were no significant 
differences at 3 or 6 months between those that lost significant weight and 
those that did not.
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Change in baseline in IWQOL-Lite Total score for significant weight 
loss vs non significant weight loss groups
Fig 15. Graph showing mean change in total score of IWQOL-Lite for 
those that lost ^ 5% of baseline weight from baseline at 3 and 6 months 
and those that did not. p value represents comparison between groups 
at 3 and 6 months
5.3.6 Effect of gender on HRQoL scores
SF36
When comparing males with female subjects there was a consistent 
trend for HRQoL scores to be higher for males compared to females. These 
were significant in the following cases. At baseline there were significant 
differences in questionnaire scores between males and females for the 
Physical Function score (male 68.4 vs female 55.2).At 3 months, there were 
significant differences for Physical function (male 75.4 : female 57.3), Role 
Emotional (male 95.2 : female 63.4), Mental Health summary (male 72.1 : 
female 59.1) and total score (male 74.2 : female 61). At 6 months, there were 
significant differences in Physical Function (male 79.1 : female 66), Vitality 
(male 60.9 : female 46.4), Social Functioning (male 87.6 : female 68.7), 
Mental Health (male 75.3 : female 61 ), Mental Health summary (male 72.8 : 
female 59.3) and Total score (male 72.9 : female 61.6)
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SGRQ
When comparing males with female subjects there was a consistent 
trend for SGRQ scores to be lower for males compared to females. This was 
significant at baseline for the activities domain (male 40: female 57.2). Again 
at 3 months there was a significant difference for the activities domain (male 
36.6: female 54.3) and at visit 4 the same was true (male 33.6 : female 48.5)
IWQOL-Lite
For the IWQOL-Lite there were consistently lower scores again in the 
female group compared to males. All were significant at baseline except 
Public Distress: Physical Function (male 73 : female 60.9), Self Esteem (male 
69.9 : female 42.5), Sexual Life (male 83.9 : female 60.4), Work (male 88.8 : 
female 73.6) and Total (male 76.2 : female 59.9). At 3 months only Sexual life 
was significant (male 87.5 : 61.3) which remained so at 6 months (male 90.2 : 
female 58.3) with Total score (male 79 : female 64.1).
5.3.7 Effect of gender on change in questionnaire scores between visits
SF36
There was no significant difference between males and females 
between each visit for all questionnaire scores for SF36.
There were no significant correlations after Bonferroni adjustment 
between percentage change in weight between baseline to 3 months, 3 
months to 6 months and baseline to 6 months and SF36 questionnaire scores 
for either males or females.
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SGRQ
There was no significant difference after Bonferroni adjustment 
between males and females between each visit for all questionnaire scores 
for SGRQ. There were also no significant correlations between percentage 
change in weight between all visits and SGRQ questionnaire scores for either 
males or females.
IWQOL-Lite
There was no significant difference after Bonferroni adjustment 
between males and females between each visit for all questionnaire scores 
for IWQOL-Lite.
For changes of IWQOL-Lite scores between baseline and 3 months 
and change in percentage weight there were no significant correlations in 
males however in females there were significant correlations after Bonferroni 
adjustment in Self Esteem (r= -0.710, p=0.000) and Total score (r= -0.603, p= 
0.005). There were no correlations for males or females between 3 and 6 
months or baseline to 6 months.
5.3.8 Comparing dietician and control groups: Effect of gender
SF36
At baseline there were no significant differences after Bonferroni 
adjustment in questionnaire scores in either the dietician or control groups for 
all domains of the SF36 between males and females. At 3 months in the 
dietician group there was no significant difference after Bonferroni adjustment 
although in the control group there was a significant difference between males
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and females for the Vitality domain (male 69.2 : female 41.9). At 6 months 
there were no significant differences after Bonferroni adjustment in scores 
between males and females in either group
SGRQ
For baseline, 3 and 6 month visits there was no significant difference 
after Bonferroni adjustment between males and females in either group for 
any score for SGRQ.
IWQOL-Lite
In the dietician group there were no significant differences after 
Bonferroni adjustment in any questionnaire score for ail domains at any visit. 
In the control group there were significant differences at baseline for Self 
Esteem (male 78.3: female 46.4), Sexual Life (male 88.7: female 56.2), Work 
(male 98.1 : female 76.2) and Total scores (male 84.2: female 62.1). At 3 
months there were significant differences for Sexual Life (male 97.5: female 
52.8) in the control group which remained significant at 6 months (male 92.9: 
female 43).
5.3.9 Relationships between Questionnaire scores and markers of
asthma severity
5.3.9.1 Exhaled nitric oxide
There were no significant correlations after Bonferroni adjustment for 
the SF36 or IWQOL-lite scores at any visit 2 with FeNOso, alveolar or 
bronchial exhaled nitric oxide.
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There were no significant correlations after Bonferroni adjustment for SGRQ 
domains at any visit except for Impacts and FeNOso (r=0.395, p=0.005) and 
bronchial nitric oxide (r=0.419, p=0.008) at baseline plus Impacts and 
bronchial nitric oxide (r=0.505, p=0.005) at 3 months.
There were no significant correlations after Bonferroni adjustment 
between change in questionnaire scores between baseline and 6months and 
changes in exhaled nitric oxide at 50ml flow rate, alveolar nitric oxide or 
bronchial wall flux.
5.3.9.2 Bronchial responsiveness and specific airway conductance
There were no significant correlations after Bonferroni adjustment
between airway responsiveness or specific airway conductance and 
questionnaire scores for any visit for SF36, SGRQ or IWQOL-Lite.
There were no significant correlations after Bonferroni adjustment 
between change in any of the domains for any questionnaire and change in 
bronchial responsiveness or specific airway conductance between baseline 
and 6 months
5.3.10 Peak flow and symptoms diaries
The completion and return rate of self completed patient peak flow and 
symptoms diaries was too low to allow further analysis of these results and 
are therefore not included.
Additional material for this chapter can be found in appendix B
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5.4 Conclusions and discussion
Both obesity and asthma can significantly affect HRQoL in an adverse 
way164,267. We showed that quality of life score means for all subjects and in 
each group were worse than published means for the questionnaires SF36160 
and SGRQ273 and the total scores of all the questionnaires correlated 
significantly with each other suggesting that they are recording similar effects 
on health related quality of life. The IWQOL-Lite published normal scores are 
stratified for BMI, with mean BMI in our subjects being 38 Kg/m2 our subjects 
showed scores similar or slightly worse than means published272 in the 
IWQOL manual for the BMI range 35-39.9 Kg/m2.
For all subjects there were significant improvements in generic HRQoL 
measured by the SF36 physical health summary score, mental health 
summary score and total scores between baseline and 3 months and also 
between baseline and 6 months. This was also seen in the specific 
questionnaires SGRQ total score and the IWQOL-Lite total score. There were 
no significant differences between the dietician and control groups. Therefore 
there was no significant effect seen on HRQoL in those that had intervention 
from a dietician compared to those that did not. Although there was 
improvement in HRQoL scores at 3 and 6 months, the improvement was not 
significantly better in either group as the two groups did not diverge 
significantly despite a trend to greater improvement in scores in the dietician 
group compared with the control group. Our study may have been 
underpowered to detect a difference in the two groups as the trend seen did 
not reach significance. We have also shown previously that not all subjects in 
the dietician group lost weight and some lost weight in the control group which
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may be another reason for the lack of significant differences in HRQoL 
between these groups. Weight loss achieved was relatively modest in our 
study of-5% and - 4.9% at 3 and 6 months in the dietician group and -3 and - 
2.7% in the control group and although there is a linear relationship reported 
regarding weight loss and improvement in HRQoL, below 10% this may be 
unreliable295. Finally we may have been seeing an improvement in the HRQoL 
simply as a result of subjects taking part in a study (the so-called Hawthorne 
effect) rather than the results of interventions or weight loss292.
There were no significant correlations in the dietician group between 
BMI and HRQoL scores but there were significant correlations in the control 
group at 3 and 6 months for the generic and respiratory specific 
questionnaires, although the total scores showed no significant correlation. 
There were greater correlations with BMI in the weight specific questionnaire 
as would be expected which became less clear at 3 and 6 months. There 
were correlations for total IWQOL-Lite score and BMI for all subjects and the 
control group at baseline and 3 months but not at 6 months when there was 
no correlation for total score for any group. The trend again was a possible 
relationship towards a worse HRQoL with increasing BMI as the correlation 
coefficients between questionnaire total scores and BMI for each correlation 
were in the correct direction even if they did not reach significance in most 
cases. The lack of correlations in the dietician group could be due to the effect 
of behavioural intervention causing a global improvement in HRQoL which 
may have masked any effect from BMI itself. However, there were no 
significant differences in scores between the control and dietician group in 
those that did not lose clinically significant weight which does not support this
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hypothesis as we would expect to see an improvement in HRQoL in the 
dietician group.
It is known that there is a bidirectional or reciprocal relationship 
between some aspects of HRQoL such as those associated with 
psychological well being and weight loss295. Therefore it may be that those 
who had improvements in HRQoL due to the effects of intervention may have 
achieved greater weight loss because of changes in HRQoL rather than 
change in weight leading to improvements in HRQoL although some subjects 
in our study improved HRQoL but did not lose weight.. We are unable to 
investigate this further as changes coexist during treatment phases of studies. 
The changes in psychological well-being that take place during weight 
management programs might independently contribute to their success and 
causal paths between psychosocial and behavioural / weight changes are 
most likely closely intertwined. This reciprocal determinism should be 
explored further in future studies.
Our results therefore suggest that there may be a relationship between 
HRQoL and BMI. Improvements in HRQoL in these subjects that were seen 
mostly in the first three months may be related to the period when most 
weight loss occurred (see chapter 4) which was also over this period. We are 
unable to comment further on whether this is due to the effect of weight 
reduction or other improvements in asthma control because there were no 
relationships between HRQoL scores and FeNO or PC20 suggesting that the 
effect of weight loss is the dominant factor.
Correlations appeared to be stronger for the IWQOL-lite questionnaire 
vs BMI compared to the other questionnaires. As this is a specific
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questionnaire for the impact of weight on quality of life244 and therefore more 
sensitive to changes in weight, this would further suggest that the strongest 
influence on HRQoL in our study is BMI rather than the effect of asthma as 
there are a lack of significant correlations between BMI and SGRQ which is a 
specific respiratory based questionnaire163.
Despite these individual effects there was no significant relationship 
between change in weight and change in questionnaire scores for either 
specific or generic questionnaires for all subjects or for individual groups. It 
may be that the questionnaires are not measuring the right thing and as we 
showed in the screening data in chapter 3, quality of life in asthmatic obese 
subjects is likely to be more complicated, multi-factorial and therefore difficult 
to measure. HRQoL can be influenced by many factors and obesity is 
associated with many comorbidities162 that we did not measure in this study.
Some studies have suggested a difference in the effects of obesity on 
asthma between males and females215. We explored the effect of gender on 
HRQoL in our study and found a trend towards a worse quality of life in 
females compared with males. Although there were no significant differences 
in change in HRQoL with percentage change in weight, females tended to 
have greater improvements in some domain scores compared to males. Other 
studies have found that HRQoL appears to affect females more than males257.
We showed significant effects on role physical, vitality and social 
functioning in the generic questionnaire SF36 between baseline to 3 months 
and baseline to 6 months. Other studies have varied in which domains are 
affected by weight loss243 but Kolotkin et al in their review of quality of life and 
obesity267 state that quality of life, as measured by the SF-36 improves after
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smaii to moderate amounts of weight loss in physical aspect domains as 
physical function, vitality and mental health in one study296, vitality, general 
health perception and role limitations in another294 and also physical function 
and bodily pain in one more297, more than psychosocial aspects of HRQoL.
Studies on the effect of obesity on HRQoL show that the effects of 
weight loss generally improve HRQoL. In a ten-year follow up study of the 
trends in health-related quality of life after surgical and conventional treatment 
for severe obesity, Karlsson et al295 showed that measures of HRQoL tracked 
changes in weight and improvement in quality of life was associated with the 
magnitude of weight loss. Anxiety however was not a useful measure in the 
long term although anxiety was reduced in the first four years following weight 
loss surgery. They showed also that for subjects with <10% weight loss the 
effects on HRQoL were trivial. As we used a cut off of 5% weight loss this 
may explain why our results did not reach significance although there was a 
trend for improvement with weight loss. This study however used different 
measures of HRQoL to mine and the authors note this as a limitation of the 
study as they do not measure physical function for example. They also do not 
state the existence of any co-morbidities which may have contributed to 
quality of life.
Kolotkin et al298 studied the effect of weight loss in a group of subjects 
using pharmacological intervention with the IWQOL-Lite questionnaire. They 
also found an improvement in quality of life with weight loss which improved in 
a linear fashion with amount of weight lost although there was considerable 
variability among different facets of HRQoL in terms of response to weight 
loss. Among those dimensions measured by the IWQOL-Lite, Physical
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Function showed the most improvement with weight loss, followed by Self- 
Esteem. Again they used 10% weight loss as a clinically meaningful change, 
below this weight loss they did show improvement in HRQoL however. They 
also showed as in my study a worse quality of life in females compared to 
males with an improvement in more domains in females compared to males. 
They did not use another generic quality of life score and acknowledge this in 
their discussion.
Interestingly there were improvements seen in the respiratory specific 
questionnaire SGRQ between visits from 3 months to 6 months when 
compared to baseline. This could mean that the questionnaire is measuring a 
global effect on HRQoL which is improving with weight loss or that there are 
particular aspects of respiratory function or symptoms that have improved with 
weight loss. There was a lack of correlation between HRQoL scores and 
bronchial responsiveness or airway inflammation which suggests that 
improvement in HRQoL is not due to an improvement in asthma severity 
measured by these markers but is likely due to the reduction in weight itself. 
Previous studies have shown that associations between HRQoL measures 
and reference measures of asthma diseases status are generally greater for 
symptom measures than for lung function161,163 i.e. patients symptoms 
correlated with HRQoL better than FEV1. However I was unable to explore 
this effect further as a measure of dyspnoea was not part of the protocol and I 
wished to avoid deep inspiratory manoeuvres. Changes in resting lung 
volumes, in particular ERV and FRV may improve symptoms with weight loss 
which in turn may affect HRQoL. Further studies are required measuring full 
lung volumes to explore this further. In the previous chapter I showed that
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those subjects with and without bronchial responsiveness had similar impacts 
on HRQoL which would support this suggestion that weight has a greater 
impact on HRQoL than other objective markers of “asthma” such as lung 
volumes or bronchial responsiveness.
The SF36 questionnaire has been shown to be highly significantly 
correlated with the severity of asthma assessed by both a validated clinical 
score and the pulmonary function of the patients299. Again I showed significant 
change from baseline at 3 and 6 months in the group as a whole but did not 
find significant correlations between markers of asthma severity and SF36 
questionnaire scores. This would support the suggestion that the greater 
impact on quality of life in our subjects was from BMI rather than asthma 
severity and that improvements in scores were more likely to be due to 
improvements in weight and the effect of being in a study than any 
improvement in asthma severity. Again caution must be applied as others 
have suggested that the SF-36 has only a poor or moderate response 
involving those with milder asthma164.
The specific respiratory questionnaire validated in CORD and asthma 
was the St Georges Respiratory Questionnaire (SGRQ) which has good 
discriminative capacity and responsiveness for group comparisons although 
the symptoms domain may show a lack of longitudinal validity and 
responsiveness if a long recall period version is used166. The use of this 
questionnaire addresses the uncertainty about responsiveness of a generic 
questionnaire on changes in asthma severity and also in detecting the effect 
of HRQoL from milder asthmatics. I used a 1 month recall period and 
hopefully eliminated this problem but we should use caution when using the
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symptom domain of the SGRQ to equate to the subjects symptoms in relation 
to other markers of asthma severity such as specific airway conductance or 
PC2o. Again I found no relationship between severity of asthma and domain 
scores using the SGRQ questionnaire, confirming the results obtained using 
the generic questionnaire. Others have found a limited correlation between 
traditional measures of asthma control such as bronchial obstruction and 
HRQoL and therefore there may be a clinical-functional dissociation due to a 
lack of precision in determining HRQoL and asthma symptoms300. One 
study151 has shown that my interpretation of bronchial responsiveness using 
the dose threshold of methacholine to trigger bronchoconstriction may not 
have been the best measure to use and may explain a lack of relationship 
between HRQoL and PC45. They found that bronchial reactivity index as a 
measure of the intensity of bronchoconstriction was a better correlator with 
poorer HRQoL than PC20 in patients with stable asthma. The presence of 
bronchial responsiveness by PD2ois associated with poorer HRQoL in 
moderate to severe asthmatics compared to those with a negative PD2o151'
301. I excluded those subjects with a negative methacholine challenge and 
therefore may have excluded a proportion of subjects that may have been 
defined as having asthma by other criteria which may have explained our 
results.
The interplay between HRQoL with obesity can affect asthma, the 
effect on psychological well being can affect asthma quality of life and asthma 
control161 and vice versa. Adams showed that psychological distress is more 
frequent in subjects with asthma compared to those without. However, in 
those with psychological distress the mental health component summary
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score of the SF12 did not differ between asthmatics and non-asthmatics. 
Therefore, in an obese population that are more likely to have psychological 
distress than a normal weight group we may lose the discriminatory power of 
these HRQoL measures in asthmatic patients. This is clearly a complex 
relationship and one that is difficult to tease apart and we are only beginning 
to understand.
Along with psychosocial issues, many other conditions can affect 
HRQoL. I attempted to reduce these to a minimum by excluding those 
subjects with significant comorbidities, however we could not completely 
exclude these and were unable to screen for commonly associated conditions 
with asthma and obesity such as gastroesophageal reflux and sleep apnoea 
which may influence HRQoL in obese asthmatics. This is another limitation of 
the study. Asthmatics have been shown to have more comorbidity as reflected 
in hospitalisations, emergency department visits and ambulatory care than 
non-asthmatics and comorbidity has been associated with decreased quality 
of life and poor asthma control162.
The questionnaires themselves may cause limitations due to the period 
of recall involved in the questions, I used questionnaires with recall periods 
that should have been adequate for the length of the study, however the 
length of the study itself may cause problems as a patient may adopt an 
avoidant coping strategy or distress caused by asthma may still occur for a 
period after it has become better controlled302. The issue of recall periods may 
be addressed by the use of symptom diaries rather than questionnaires, 
however these are more likely to suffer from ceiling and floor effects. I have 
used symptom diaries also in this study, however, response rate in returning
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and completing these diaries was poor. Diaries are however more useful for 
assessing longitudinal correlations with pulmonary function.
The influence of weight on the relationship between asthma and 
HRQol needs to be taken into account in future studies exploring the 
relationship between clinical aspects of asthma and HRQol questionnaires 
Previous studies have used BMI categories amongst others to explore effects 
on determinants of quality of life. Ford et al303 used a simplified four item set 
of health related quality of life questions in a population of asthmatics using a 
telephone survey and found a U-shaped relation with poor or fair health, 
increased numbers of physically unhealthy days, mentally unhealthy days and 
days with activity limitations. I have explored this in a longitudinal study and 
although we have shown similar findings cross sectionally have failed to show 
significant improvements with weight loss.
Another limitation to my study which may explain some of the lack of 
effects of weight loss may come from selection bias. It is known that obese 
subjects seeking treatment tend to have worse quality of life than those not 
seeking treatment and we may therefore have selected subjects through 
recruitment with a worse quality of life than the general obese population304.
Lastly it is difficult to assess the effect purely of BMI and obesity on 
HRQol in this study without the inclusion of a group of subjects with a normal 
BMI. As this was a weight loss study this was not practical and the study was 
not designed to include a normal weight group but those that lost weight could 
be expected to act as a surrogate group with lower BMI to compare with the 
obese group.
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The strengths of this study are the longitudinal nature of the study and 
the inclusion of a dietician group and a control group. Also the use of generic 
and specific questionnaires allowed us to compare a generic HRQoL with the 
SF36 which could possibly compare the HRQoL of our subjects with other 
diseases and also the more sensitive nature of the specific questionnaires for 
their respective diseases which would be more sensitive to change than the 
generic questionnaire. Although we were comparing multiple variables we 
accounted for this by using correction for multiple variable analysis with 
Bonferroni correction.
5.5 Summary
In summary my subjects had significantly impaired HRQoL as 
measured by a generic questionnaire and specific questionnaires for weight 
and asthma. There was an improvement in questionnaire score at 3 and 6 
months into the study compared to the baseline visit. There was a trend 
towards, but no significant correlation between BMI and HRQoL however 
there was also a trend towards a relationship between percentage of weight 
loss and change in HRQoL with a non-significant difference between dietician 
and control groups. There were no significant relationships between 
measures of asthma severity i.e. bronchial responsiveness as measured by 
PC45, airway narrowing measured by specific airway conductance or exhaled 
nitric oxide. I can therefore tentatively suggest that the greatest impact on 
HRQoL in obese asthmatics comes from the obesity element of their health 
impairment rather than severity of asthma and improvements in HRQoL as
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weight decreases mainly comes from the direct result of weight reduction 
rather than any improvement in asthma severity.
The interplay between asthma severity, obesity and HRQoL is 
complicated and each can influence the other. Further specific studies on 
HRQoL in this group of patients are therefore required to explore this further.
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Chapter 6: Induced sputum differential cell counts and weight loss
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6.1 Introduction
Asthma is an inflammatory condition with a type 2 inflammatory 
response involving mainly eosinophils20. It has previously been demonstrated 
that asthma severity and control can be related to airway eosinophil counts125, 
128 which can be measured non-invasively by collecting sputum induced with 
hypertonic saline. The methodology has been described in chapter 3. Adipose 
tissue has been found to produce adipokines221,222 which are able to regulate 
systemic inflammation305. Leptin, IL-6, CRP and TNF-a have been shown to 
be increased in obesity which may modulate Th2 immunity. Conversely IL-10 
which inhibits the production of IL-6 and TNF-a is decreased in obesity. It is 
suggested that the inflammation in asthma may be influenced in obesity by 
these changes in the production of adipokines in the increased fat mass of the 
patient and therefore produce a specific phenotype of asthma306 in obese 
asthmatics or amplify the usual inflammation related to asthma which could be 
measured non-invasively by measuring the differential cell count in induced 
sputum113.
The results of differential cell counts obtained from induced sputum is 
one method of determining asthma ‘phenotypes’ along with patterns of 
bronchial responsiveness and exacerbations23. Haidar et al suggested a 
model of asthma phenotypes in a population of asthmatics and suggested that 
obese patients were more likely to have a symptom predominant non- 
eosinophilic phenotype25. Lessard et al compared a group of obese versus 
non-obese asthmatics to try to determine a specific obese asthma phenotype, 
part of this involved the use of induced sputum differential cell counts307. They 
found no difference in differential cell counts between obese and non-obese
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subjects. In their whole population there was an inverse relationship between 
eosinophils and waist circumference and a similar trend for BMI. Others have 
also failed to identify an obese asthma phenotype by investigating the induced 
sputum differential cell counts in obese and non-obese subjects although not 
all found the same relationship between eosinophils and BMI236,240,241.
I wished to explore the cell counts of an obese asthmatic population to 
see whether there was evidence of a relationship between weight or BMI and 
a specific differential cell phenotype. I also explored the presence of bronchial 
responsiveness with these cel! counts and its relationship to exhaled nitric 
oxide. Furthermore I wished to explore the effect of a change in weight on 
these cell counts.
It has been hypothesised that an increase in BMI leads to an increase 
in airway inflammation due to the increase in the pro-inflammatory substance 
leptin and a reduction in the anti-inflammatory product adiponectin. The IL-6 
like effects of leptin have been linked to an upregulation in TH2 type 
inflammation and has therefore been linked with the possible relationship 
between asthma and obesity305. I investigated the relationship between 
individual cell lines from the differential cell count and BMI for the group as a 
whole, for intervention groups and also in relation 
to changes in BMI between visits.
6.2 Methods
Detailed methods are outlined in Chapter 2. Sputum was obtained from 
subjects at baseline, 3 months and 6 months using hypertonic saline by the 
investigator with standardised techniques. The investigator received training
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from centres established in developing and using the technique. Sputum was 
processed within two hours of obtaining the sample with a sputum selection 
method and cytospins prepared and stained with Diff-Quik Giemasa 
Romanowski stain.
Differential cell counts were obtained manually by the investigator who 
had previously been trained by established sites performing this technique 
using 300 cells. Counts were performed twice to assess repeatability and 
reliability of the procedure.
6.2.1 Statistical analysis
Categorical variables are expressed as percentages of total subjects 
and compared using Chi squared test. Continuous variables are expressed 
using mean ±SD and compared between groups with the Students unpaired t 
test if normally distributed. Non-normal distributions determined by Shapiro- 
Wilk testing are expressed using median and interquartile range. Variables 
compared between visits were compared using paired-samples f testing. 
Correlations were performed between normally distributed variables using 
Pearson correlations two-tailed test and non-normally distributed variables 
using Spearman’s. Any correlations were checked visually for 
homoscedasticity to confirm any relationship. Significance for multiple 
comparisons were adjusted by Bonferroni correction. Significance was 
determined if p<0.05 and alpha level adjusted by Bonferroni for number of 
observations studied.
Reproducibility of counting technique was assessed using Bland 
Altman plots.
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6.3 Results
6.3.1 Sputum collection technique, reproducibility, viability etc.
The following data shows the results of the subjects’ ability to produce 
adequate sputum samples during the technique, the proportion processed 
and numbers of slides produced including those whose quality meant that it 
was not possible to count the cells required for a result i.e. acceptability
Baseline
Attended: 51
Sputum induction attempted: 51 (100%)
Adequate sputum produced: 36 (71%)
Sputum processed: 36 (71%)
Slides produced: 36 (100%)
Slides unreadable: 8 (22%)
3months
Attended: 35
Sputum induction attempted: 33 (94%)
Adequate sputum produced: 27 (77%)
Sputum processed: 27 (77%)
Slides produced: 25 (93%)
Slides unreadable: 5 (20%)
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6 months
Attended: 38
Sputum induction attempted: 36 (95%) 
Adequate sputum produced: 26 (72%) 
Sputum processed: 26 (72%)
Slides produced: 25 (96%)
Slides unreadable: 5 (20%)
6.3.1.1 Slide quality data
Squamous contamination and cell viability were assessed in each case 
and good results were obtained for these as outlined below suggesting that 
good quality slides were obtained from induced sputum samples.
N Minimum Maximum Mean SD
Squamous 78 0 50 8.4 10
Viability 78 0.66 100 85.1 20.4
Table 25. Quality data of slides prepared from induced sputum for all 
samples prepared for squamous contamination and cell viability 
obtained from haemocytometer sample
6.3.1.2 Reproducibility
The investigator received training in performing the technique in 
centres with experience in the procedure prior to starting the study. I would 
like to acknowledge the Institute for Lung Health Leicester and Montreal 
General Hospital for their generous support in this. To check reproducibility of 
the results slides were counted more than once and the outcomes of those 
counts were compared. There were no significant differences between the two 
counts suggesting that technique was sound. This is also reflected in the
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results between visits which show good correlations between visits for 
differential cell counts for individual subjects.
There were good correlations for cell counts for Neutrophils, 
Macrophages, and Eosinophils at all visits and also for epithelial cells at 
baseline and 3 months. Correlations were not significant for lymphocytes and 
metachromatic cells or epithelial cells at 6 months, however counts were very 
low which may explain this discrepancy. As phenotype is mainly determined 
by neutrophilic and eosinophilic inflammation this was felt to be adequate to 
continue with analysis.
Bland Altman plots for each cell count at each visit are shown in the 
appendix along with correlations between visits and between two successive 
differential cell counts for a particular visit.
6.3.2 Differential cell counts for each visit
Differential counts for baseline, 3 month and 6 month visits are 
represented here for all subjects and also for each group. Results are 
presented as total cells counted for each cell type from a total of 300 cells 
rather than as percentages of the total count.
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6.3.2.1 All subjects
Baseline n=28 3 months n=20 6 months n=20
Neutrophils 159 (60) 176 (73) 182 (56)
Macrophages 103 (55) 102 (63) 90 (49)
Eosinophils 24 (37) 15(26) 22 (25)
Epithelial 12 (11) 5(6) 4(4)
Lymphocytes 2(2) 1 (1) 2(1)
Metachromatic 0(0) KD 0(0)
Cell counts presenlted as number of ce Is counted from a to tal of 300. Data
presented as mean (SD)
Table 26. Mean (SD) total cell counts for each visit from a total of 300 
cells counted for each cell line for all subjects
For the whole group of all subjects there were no significant differences
between baseline to 3 months, 3 months to 6 months or baseline to 6 months
for any cell type in the differential cell count.
6.3.2,2 Comparing dietician and control groups
Differential cell counts for each study group are presented here as per 
those for all subjects.
Baseline 3 months 6 months
Cell type Dietician
group
n=15
Control
group
n=13
Dietician
group
n=13
Control
group
n=7
Dietician
group
n=13
Control
group
N=7
Neutrophils 172 (49) 144 (69) 184 (73) 161
(75)
187 (65) 174
(35)
Macrophages 97 (46) 111 (65) 90 (58) 122
(71)
88 (59) 93 (28)
Eosinophils 18 (19) 30 (51) 18(31) 10(11) 20 (26) 27 (24)
Epithelial 11 (11) 12(12) 6(6) 3(3) 3(5) 5(3)
Lymphocytes 2(2) 3(2) 3(1) 2(1) 2(1) 2(1)
Metachromatic 0(0)____ 0(0)___ 2(0)___ 1(1)___ 0(1)____ 0(0)___
Cell counts presented as number of cells counted from a total of 300. Data 
presented as mean (SD)
Table 27. Mean (SD) total cell counts for each visit from a total of 
300 cells counted for each cell line for dietician and control groups.
When comparing mean cell counts between the dietician and control
groups there were no significant differences at any visit. There were also no
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significant differences in cell counts in either group between baseline to 3 
months, 3 months to 6 months and baseline to 6 months.
6.3.3 Relationship between BMI and differential cell counts
The relationship between individual cell lines from the differential cell 
count and BMI for the group as a whole, for intervention groups and also in 
relation to changes in BMI between visits is presented here.
6.3.3.1 All subjects
Baseline 3 months 6 months
Neutrophils -0.4(0.841) 0.206 (0.385) 0.044 (0.852)
Macrophages 0.098 (0.620) -0.304 (0.193) -0.130 (0.586)
Eosinophils -0.081 (0.682) 0.200 (0.399) 0.208 (0.380)
Epithelial -0.048 (0.807) -0.100 (0.676) -0.422 (0.064)
Lymphocytes 0.262 (0.177) -0.188 (0.428) 0.404 (0.077)
Metachromatic 0.126 (0.523) -0.446 (0.049) -0.057 (0.812)
Data presented as r value (p)
Table 28. Correlations coefficients comparing total cell count for each 
cell line with BMI for all subjects, r (p)
There were no significant correlations with any of the cell counts and 
BMI for all subjects at any study visit.
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6.3.3.2 Comparing dietician and control groups
Baseline 3 months 6 months
Cell type Dietician
group
Control
group
Dietician
group
Control
group
Dietician
group
Control
group
Neutrophils 0.262
(0.345)
-0.339
(0.257)
0.206
(0.385)
0.779
(0.039)
0.075
(0.808)
-0.440
(0.323)
Macrophages -0.221
(0.428)
0.401
(0.174)
-0.304
(0.193)
-0.849
(0.016)
-0.116
(0.706)
-0.159
(0.734)
Eosinophils 0.002
(0.993)
-0.119
(0.698)
0.200
(0.399)
0.316
(0.490)
0.132
(0.666)
0.828
(0.021)
Epithelial -0.290
(0.294)
0.240
(0.429)
-0.100
(0.676)
-0.030
(0.949)
-0.432
(0.140)
-0.207
(0.656)
Lymphocytes 0.191
(0.496)
0.420
(0.153)
-0.188
(0.428)
-0.668
(0.101)
0.373
(0.209)
0.558
(0.193)
Metachromatic -0.004
(0.989)
0.261
(0.390)
-0.446
(0.049)
-0.732
(0.061)
-0.008
(0.980)
-0.421
(0.347)
Data presented as r value (P)
Table 29. Correlations coefficients comparing total cell count for each 
cell line with BME for dietician and control groups, r (p)
There were no significant correlations between BMI and any cell type in 
either the intervention or the control group at any visit.
6.3.4 Correlation between change in differential cell count between visits
and change in weight %
On investigating the percentage change in weight between visits and 
change in cell count there was no significant correlation after Bonferroni 
correction between percentage change in weight from baseline and changes 
in differential cell count.
6.3.5 >5% weight loss Group vs <5% weight loss group - between group
comparisons
As previously discussed, some subjects in the control group lost weight 
and some subjects in the dietician group gained weight To explore any
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possible relationship with weight loss further I have compared those that lost 
clinically significant weight, generally accepted as >5% with those that did not, 
Again there were no significant differences in each type of cell in the 
differential cell count between those subjects that achieved >5% weight loss 
and those that did not at any visit. I am therefore unable to find a relationship 
between BMI and the inflammatory phenotype in obese asthmatic patients. 
Although there was a possible trend towards an increase in neutrophil count 
in the dietician group with weight loss this is not reproducible in any of the 
other analyses.
6.3.6 Exploration of Eosinophilic or Neutrophilic predominant sputum
It is suggested that sputum differential cell counts can be separated in 
terms of phenotypes into eosinophilic predominant if there is >3% eosinophils 
or neutrophilic predominant if neutrophils £60% I therefore investigated 
whether BMI was significantly different when separated by this definition.
BMI Kg/rrf
Visit >3%
Eosinophils
<3%
Eosinophils
>60%
Neutrophils
<60%
Neutrophils
Baseline 37.7 39.8 39.1 38.1
3 months 37.5 36.7 38.4 35.4
6 months 36.8 37.8 37.6 36.4
*=p<0.05
Table 30. Mean BMI for each visit when comparing eosinophilic vs. non 
eosinophilic predominant phenotypes and neutrophilic vs. non 
neutrophilic phenotypes
There was no significant difference in BMI between eosinophilic vs non 
eosinophilic or neutrophilic vs non-neutrophilic groups at any visit.
196
6.3.7 Secondary outcome measures: Relationship of differential cell
counts with exhaled nitric oxide and bronchial responsiveness
There were no significant correlations between any of the cell lines in 
the differential cell count and exhaled nitric oxide using either FeNO at 50 ml 
flow rate, alveolar nitric oxide or bronchial nitric oxide for all visits.
There were no significant correlations between any of the cell lines in 
the differential cell count and bronchial responsiveness measured by PC45 for 
all visits.
6.3.8 Medication and differential cell counts
There were no significant correlations with any cell lines in the 
differential cell count and inhaled steroid dose.
Additional material for this chapter can be found in appendix C
6.4 Conclusions and discussion
Despite theoretical evidence which would suggest that the possible link 
between asthma and obesity may be due to an increase in airway 
inflammation or the development of a specific inflammatory phenotype232,234, 
3051 have been unable to reproduce this with my own data. I did not find a 
significant correlation between BMI and differential cell count in these obese 
asthmatics nor been able to demonstrate a significant change in differential 
cell count with a change in weight. I am therefore unable to find a relationship 
between BMI and the inflammatory phenotype in obese asthmatic patients. 
Although there was a possible trend towards an increase in neutrophil count 
in the dietician group with weight loss this is not reproducible in any of the
197
other analyses. This reflects the cross sectional studies by Lessard et a307l 
and Todd et al236 who found no difference in differential cell counts between 
obese and non-obese groups. Also more recently Dixon showed no change in 
differential cell counts with weight loss before and after bariatric surgery for 
weight loss2.
I did not find a trend or relationship between BMI and eosinophils in my 
group which was shown by Lessard. I also did not find a correlation between 
change in eosinophil count and change in weight or a relationship between 
eosinophil or neutrophil predominant phenotypes and weight change in either 
the control or dietician groups. Previous data from Todd et al also supports 
this. They retrospectively analysed a database of 727 sputum differential cell 
counts stratified into increasing BMI groups and showed that there was no 
difference in differential cell counts between groups. They also showed an 
increase in eosinophils in those with asthma in both the obese and non-obese 
categories but there were no differences between these groups. Unlike 
Lessard et al they did not find any correlation between BMI and any measure 
of cellular airway inflammation which reflects my own data.
Other cross sectional studies that have investigated airway 
inflammation and obesity include van Veen et a240l and Sutherland et al241. 
van Veen showed a lower percentage of sputum eosinophils in an obese 
group of patients compared with normal BMI and linear regression analysis 
showed a negative association between BMI and sputum eosinophils. 
Sutherland showed similar results to Todd et al and showed that asthmatic 
patients had higher levels of sputum eosinophils than non asthmatics but 
there were no differences in either group between obese and non-obese
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individuals. To summarise this, it appears that asthmatics have higher 
eosinophils than non asthmatics but BMI does not influence the number of 
eosinophils in an asthmatic population.
I was able to perform differential cell counting in this group with good 
quality specimens in most cases and the results were reproducible on 
repeated differential cell counting. My overall differential cell counts for each 
visit are similar to other reported studies as outlined in table 31 and most 
closely mirror the study by Sutherland.
Study Eosinophil
s
Neutrophil
s
Lymphocyte
s
Macrophage
s
Metachromat 
ic cells
TodcP0 0.7% 59.2% 6.7% 0.3% NA
Lessard*™' 5.1% 41.5% 1.5% 48.7% 3.2%
Van
Veen**240
0.5% 54.6% NA NA NA
Sutherland2
41
11.3% 28.9% 1.2% 4.25% NA
Scott Visit2 8% 53% 0.7% 34% 0%
Scott Visits 5% 59% 0.3% 34% 0.3%
Scott Visit4 7.3% 61% 0.7% 30% 0%
*Group reported using SABA & ICS
** Do not report values for Lymphocytes, Macrophages or metachromatic
cells
Table 31. Comparison of reported mean differential cell counts in 
published studies of obese subjects and mean differential cell counts at 
each visit in this study
This is the first study to report longitudinal data of sputum differential 
cell counts in a group of subjects with non-surgical weight loss and adds to 
the evidence from cross-sectional and surgical weight loss studies that 
obesity does not appear to influence the differential cell counts in asthma.
Many of the studies suggesting a link between inflammatory cytokines 
related to leptin and adiponectin in obesity and asthma involve animal models 
using leptin deficient mice247. Administration of exogenous leptin in leptin-
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deficient mice augments airway hyperreactivity following allergen challenge, 
as well as lung inflammation following ozone exposure232,308 and exogenous 
administration of adiponectin prevents the development of allergen-induced 
airway hyperreactivity plus also inhibits vascular smooth muscle proliferation 
but not airway smooth muscle proliferation309. Studies in humans are less 
conclusive and this study reflects this in that although I have tried to control 
for most factors I still have a heterogenous group of subjects on a variety of 
medications and different severities of asthma. This may therefore account for 
my results not showing a predominant cell type, however I would expect to 
find a signal in the analysis of the longitudinal data from the study but this was 
not the case.
I was unable to find a relationship with sputum differential cell type or 
phenotype and other non-invasive markers of airway inflammation i.e. exhaled 
nitric oxide and also there was no relationship between any sputum cell 
predominance and bronchial responsiveness in my population.
The relationship between exhaled nitric oxide and BMI is more complex 
as measurement of nitric oxide is affected by the flow of air through the 
airways101 and may reflect areas of gas trapping due to low lung volumes in 
obesity which may explain the possible negative correlation between exhaled 
nitric oxide and BMI. This may be one reason why I did not find a correlation 
between exhaled nitric oxide and differential cell counts. It would be important 
to include measures of lung volumes and in particular to measure the closing 
volume of these subjects which l was unable to do due to the nature of the 
design and is an area for future research.
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The effect of BMI on lung volumes may also explain the lack of a 
correlation between bronchial responsiveness and differentia! cell counts. A 
link between sputum eosinophil counts and bronchial responsiveness has 
been shown previously310, however it is also known that breathing at low 
volumes can reduce the bronchoprotective effect of deep inspiration and 
increase bronchial reactivity154. It has also been shown however that in 
obesity this effect may not occur311,312. There is a possibility that ERV may be 
important to factor into the relationship between bronchial reactivity and 
sputum cell counts and again I was unable to measure this in these subjects 
due to the design of the study to avoid manoeuvres involving deep inspiration. 
However the lack of a significant correlation between change in BMI and 
changes in bronchial reactivity, FeNO and differential sputum cell counts 
would help to take into account the lung volumes and therefore suggest that 
our conclusion would be correct.
The link between asthma and obesity is complex and is not due to one 
particular mechanism but likely to be due to a combination of mechanical, 
psychological and immunological processes. The very fact that asthma can 
present as many different phenotypes23 makes it difficult to find a specific 
phenotype linked with obesity. I propose that rather than a specific phenotype 
of asthma, obese patients with asthma can reflect the same overall mixture of 
phenotypes of all asthmatics but may be recognised earlier due to the other 
effects of obesity which cause them to amplify their symptoms, seek medical 
help earlier and mimic the symptoms of asthma. I was unable to examine 
adipokines and other inflammatory markers in the blood but a recent study
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has shown that there may still be a link between inflammation and asthma in 
obesity which does not involve the differential cell type2.
This study has some weaknesses. Although similar to other published 
studies using sputum induction for differential cell counts I obtained sputum in 
71-77% of patients at each visit and was able to perform differential cell 
counts on 78-80% of these. Also not all subjects attended every visit. Despite 
this I was able to analyse significant numbers of subjects similar or larger in 
number to other published weight loss studies. Another limitation would be the 
expertise of the observer performing the differential cell counts which were 
performed by hand. I tried to exclude error by counting slides twice and 
comparing reproducibility of counts which correlated well, had reasonable 
bland-Altman plots and there were also good correlations between visits. 
Another limitation of the study has previously been mentioned in another 
chapter in that not all subjects in the dietician group lost weight, however 
when comparing those that lost significant weight with those that did not I 
found no significant difference. Lastly, my group of subjects were not all taking 
the same amounts of medication and represented a heterogenous group of 
subjects in respect to prior smoking status and atopy, although this may have 
implications on the cross sectional analysis of data the strength of this 
investigation was its longitudinal nature so any changes in differential cell 
count in each individual would be related to a change in BMI as long as other 
variables remained the same. I also found no relationship between the dose 
of inhaled steroids taken by the subjects and the differential cell counts.
202
6.5 Summary
My results reflect previously published cross-sectional studies236,240,241 
that suggest there is no particular inflammatory ‘obese phenotype’ as 
determined by differential sputum cell counts and this is the first reported 
interventional study using dietary intervention. Asthmatic subjects may have 
higher sputum eosinophil counts than non asthmatic subjects but there are no 
differences between obese and non obese asthmatics. Weight loss does not 
alter the inflammatory profile of the airways measured non-invasively by 
differential ceil counts of induced sputum.
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Chapter?: Exhaled nitric oxide and BMI
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7.1 Introduction
The diagnosis of asthma is a clinical one and features that increase the 
probability of a diagnosis of asthma include symptoms, the presence of 
variable airflow obstruction and airway inflammation15.
Airway inflammation is typically described as a type II inflammatory 
response with an eosinophilic predominance313, although different phenotypes 
have been described. Airway inflammation can be monitored non-invasively 
by measuring exhaled nitric oxide using standardised techniques using a 
chemiluminescence analyser94. Levels of exhaled nitric oxide have been 
shown to correlate with asthma control or asthma severity105,106 and can be 
used to monitor treatment90.
Asthma has been associated with obesity and it is not clear whether 
this relationship is due to the mechanical effects of increased BMI on airway 
physiology or an inflammatory effect of adipose tissue on airway 
inflammation247. As noted above measuring exhaled nitric oxide is a non- 
invasive way of measuring this airway inflammation in subjects with asthma. 
Exhaled nitric oxide has been shown to be increased in obesity239 in some 
studies but has also been found to decrease with increasing BMI240. The 
fraction of exhaled nitric oxide measured at the mouth is made up of nitric 
oxide originating in the alveolus and also in the bronchial wall101 and this can 
be affected by airway inflammation, airway physiology with reductions in nitric 
oxide with bronchoconstriction and the effects of back diffusion of nitric oxide 
in the airways during gas trapping314,315. Measuring the alveolar and bronchial 
wall nitric oxide may mitigate the effects of airway narrowing and gas trapping 
that occurs in obesity and its effects on exhaled levels of nitric oxide.
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The aim of this chapter is to investigate the effect of BM1 and weight 
loss on levels of fraction of exhaled nitric oxide through a single flow 
exhalation rate but also to investigate the effect of BMI and weight loss on the 
flow independent parameters of alveolar nitric oxide and bronchial wail flux.
7,2 Methods
Details of the measurement of exhaled nitric oxide have been 
described in Chapter 2 but will be briefly reviewed here.
I monitored exhaled nitric oxide using a NIOX chemiluminescence 
analyser using a standard technique (ATS/ERS guidelines316) after 
withholding medication, and fasting for 12 hours. Exhaled nitric oxide levels 
(ppb) were obtained at baseline, 3 and 6 months exhaled Nitric Oxide was 
measured at 10ml/s, 30ml/s, 50ml/s, 100ml/s, and 200ml/s to determine flow- 
independent parameters based on the two compartment model of Tsoukias 
and George101. Alveolar NO concentration was determined as the slope of the 
regression line of the 100ml and 200ml flow rates after inspection of the 
trends. Bronchial NO flux was determined as the intercept of this regression 
line263.
Measurements were taken before any other respiratory measurements 
took place at each visit so as not to be influenced by anything involved such 
as methacholine.
I compared fraction of exhaled Nitric Oxide at 50ml flow rate (FeN05o), 
Alveolar NO and NO flux in Obese subjects between visits for the whole 
group. I also explored differences between groups (dietician vs control) and
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also between those that had significant weight loss vs those that did not and 
explored possible correlations.
7.2.1 Statistical analysis
Categorical variables are expressed as percentages of total subjects 
and compared using Chi squared test. Continuous variables are expressed 
using mean ±SD and compared between groups with the Students unpaired t 
test if normally distributed. Non-normal distributions determined by Shapiro- 
Wilk testing are expressed using median and interquartile range. Variables 
compared between visits were compared using paired-samples f testing. 
Correlations were performed between normally distributed variables using 
Pearson correlations two-tailed test and non-normally distributed variables 
using Spearman’s. Any correlations were checked visually for 
homoscedasticity to confirm any relationship. Significance for multiple 
comparisons were adjusted by Bonferroni correction. Significance was 
determined if p<0.05 and alpha level adjusted by Bonferroni for number of 
observations studied.
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7.3 Results
For consort diagram see Fig 7, (p140).
Missing data occurred in each study visit for the following reasons:
Dietician group
Baseline: Exhaled Nitric Oxide available in 24 missing in 2 subjects
Flow independent parameters available in 19 missing in 7
subjects 
3 months:
subjects 
6 months:
subjects
Exhaled Nitric Oxide available in 21 missing in 0 subjects 
Flow independent parameters available in 19 missing in 2
Exhaled Nitric Oxide available in 21 missing in 1 subjects 
Flow independent parameters available in 17 missing in 5
Control group
Baseline: Exhaled Nitric Oxide available
Flow independent parameters
subjects 
3 months:
subjects 
6 months:
subjects
Exhaled Nitric Oxide available 
Flow independent parameters
Exhaled Nitric Oxide available 
Flow independent parameters
in 24 missing in 1 subject 
available in 20 missing in 5
in 12 missing in 2 subjects 
available in 11 missing in 3
in 15 missing in 1 subject 
available in 13 missing in 3
7.3.1 Exhaled nitric oxide measures for all subjects, dietician and control
groups
Measurements of fraction of exhaled nitric oxide at 50ml flow rate and 
flow independent parameters are show here for the baseline visit, 3 and 6 
months. Data is presented as median (interquartile range) due its the skewed 
nature.
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Fraction of exhaled nitric oxide measured at SOmlfiow rate for each visit
Baseline
FeNO (50ml/s)
3 months
FeNO (50ml/s)
6 months
FeNO (50ml/s)
All subjects 18.3(26.2) 24 (40.1) 24.7 (26.3)
Dietician group 16.4(26.9) 25.3 (40.6) 31 (24.6)
Control group 18.9(24.6) 17.2(39.1) 15.8(36.6)
All measures expressed as median (IQR)
Table 32. Mean (SD) exhaled nitric oxide measured at 50mI/s flow rate 
from the mouth for all subjects and each group for each visit
Alveolar nitric oxide measured at each visit.
Baseline
Alveolar
NO
3 months
Alveolar
NO
6 months
Alveolar
NO
All subjects 2.3 (1.9) 1.9 (3.13) 2.3 (3.1)
Dietician group 2.3(19) 2.5(2.8) 2.9 (2.9)
Control group 2.1 (2) 1 (2.1) 1.4 (2.7)
All measures expressed as median (IQR)
Table 33. Mean (SD) calculated alveolar nitric oxide from exhaled air the 
mouth for all subjects and each group for each visit
Bronchial flux nitric oxide measured at each visit.
Baseline
Bronchial
NO flux
3 months
Bronchial
NO flux
6 months
Bronchial
NO flux
All subjects 1000 (1300) 880 (2225) 1080(1445)
Dietician group 940(1000) 1040 (2460) 1460(1440)
Control group 1030 (1365) 840(1620) 960 (1610)
All measures expressed as median (IQ R)
Table 34. Mean (SD) calculated bronchial flux nitric oxide from exhaled 
air the mouth for all subjects and each group for each visit
There were no significant differences for all subjects or either group for 
any measure of nitric oxide between visits, baseline to 3 months, 3 to 6 
months or baseline to 6 months. Also there were no significant differences for 
all measures of nitric oxide between the dietician and control groups at any 
visit.
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7.3.2 Correlations between measures of nitric oxide and BMI
There were no significant correlations between any measure of nitric 
oxide and BMI at any visit.
7.3.3 Correlations between change in measures of nitric oxide and
change in weight from baseline
Change in FeNOso, Alveolar NO and bronchial NO flux between 
baseline, 3 and 6 months were analysed with change in weight for all 
subjects, dietician and control groups. There were no significant correlations 
found between baseline and 3 months, 3 to 6 months or baseline to 6 months 
for any group.
7.3.4 >5% weight loss group vs <5% weight loss group - between group
comparisons
As in previous chapters it is noted that some subjects lost weight in the 
control group just as some subjects in the dietician group gained weight. 
Further analysis was performed using groups that lost clinically significant 
weight determined as >5% of baseline weight vs those that did not.
Fraction of exhaled nitric oxide measured at SOmlflow rate for each visit
Baseline
FeNO (50ml/s)
3 months
FeNO (50ml/s)
6 months
FeNO (50ml/s)
>5% weight loss 
group
16.4 (14.8) 29.8 (58.6) 31 (25.2)
<5% weight loss 
group
18.5(41.2) 24.7 (39.7) 19.2 (29.3)
All measures expressed as median (IQR)
Table 35. Mean (SD) exhaled nitric oxide measured at 50ml/s flow rate 
from the mouth for significant weight loss group vs. non significant 
weight loss group for each visit
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Alveolar nitric oxide measured at each visit
Baseline
Alveolar
NO
3 months
Alveolar
NO
6 months
Alveolar
NO
>5% weight loss 
group
1.8 (2.1) 2.5 (2.9) 2.9 (3.5)
<5% weight loss 
group
2.2 (1.1) 1.4 (3.8) 2.9 (3.5)
All measures expressed as median (IQR)
Table 36. Mean (SD) calculated alveolar nitric oxide from exhaled air the 
mouth for significant weight loss group vs. non significant weight loss 
group for each visit
Bronchial flux nitric oxide measured at each visit
Baseline
Bronchial
NO flux
3 months
Bronchial
NO flux
6 months
Bronchial
NO flux
>5% weight loss 
group
1040 (940) 740 (2460) 1000(1435)
<5% weight loss 
group
960(1150) 970 (2090) 1220 (1560)
All measures expressed as median (IQR)
Table 37. Mean (SD) calculated bronchial flux nitric oxide from exhaled 
air the mouth for significant weight loss group vs. non significant weight 
loss group for each visit
There was no significant difference for any measure of nitric oxide 
between those that lost >5% of total body weight compared to those that did 
not. There was also no significant difference for either group for any measure 
of nitric oxide between baseline and 3 or 6 months and from 3 to 6 months.
7.3.5 Medication and exhaled nitric oxide
There were no significant correlations with any markers of exhaled 
nitric oxide and inhaled steroid dose.
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7.3.6 Other measures
Relationships between exhaled nitric oxide and quality of life and 
bronchial responsiveness have been explored elsewhere in the relevant 
chapters and no relationship between exhaled nitric oxide was found with 
these other variables.
Additional material for this chapter can be found in appendix C
7.4 Conclusions and discussion
There was no correlation between BMI and levels of exhaled Nitric 
Oxide (a measure of eosinophilic airway inflammation317) either at a standard 
flow rate or using the computed flow independent parameters of alveolar and 
bronchial wall flux of nitric oxide. There was no significant correlation between 
weight change and change in levels of all nitric oxide parameters. There was 
also no significant difference in all nitric oxide variables when comparing the 
dietician group vs the control group and those that lost over 5% of their body 
weight in 6 months vs those that did not.
Nitric oxide in the lung can be detected in the exhaled air of subjects 
and is produced by the enzyme nitric oxide synthase which exists in inducible 
and constitutive isoforms71"75. Only the expression of inducible nitric oxide 
correlates with levels of exhaled nitric oxide and this enzyme is expressed in 
increased amounts in asthma. Increased levels of exhaled nitric oxide are 
related to eosinophilic airway inflammation which theoretically may be 
increased by IL-6 like proinflammatory substances such as leptin associated 
with adipose tissue239. Adipose tissue associated with obesity also produces
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increases in IL-4 and IL-5 which theoretically could increase airway 
inflammation along with reduced levels of the anti-inflammatory adipokine 
adiponectin221,222. My findings do not support this and suggest that any 
change in the health status of obese asthmatics is not as a result of a change 
in eosinophilic airway inflammation but due to other possible reasons such as 
the mechanical effects of obesity on lung physiology176 or non-eosinophilic 
airway inflammation such as a neutrophil predominant phenotype24. Kim et al 
investigated non asthmatic subjects and also found no relationship between 
adiposity, serum levels of leptin, adiponectin, tumour necrosis factor alpha or 
interleukin-6 and exhaled nitric oxide. They also suggest that inflammation 
due to adiposity may not have an influence on nitric oxide production in the 
lungs detectable by exhaled nitric oxide318.
Maniscalco et al showed that non-asthmatic obese subjects had lower 
levels of exhaled nitric oxide than healthy controls which increased following 
weight loss induced by bariatric surgery and this was also related to FRC4. 
This suggests that I may be seeing an effect of airway calibre and breathing 
near to closing volume resulting in an altered characteristic of nitric oxide 
diffusion through the airways masking a signal from an inflammatory 
component in these asthmatic subjects314,315. Any increased NO due to 
airway inflammation could be offset by the effects of airway calibre resulting in 
a net effect to cancel out the effect of each mechanism240. This could be why I 
did not find a significant correlation in this group of subjects and therefore did 
not reproduce the findings of Maniscalco who excluded asthmatic and atopic 
subjects. Both of these studies described have in fact excluded asthmatics 
which may explain why my findings differ.
213
Obesity causes reductions in FRC and ERV bringing the lungs close to 
closing volume176 which could be involved in changes in measured levels of 
exhaled nitric oxide, especially alveolar levels of nitric oxide which would be 
‘trapped’ in areas of lung which are affected by low lung volumes. Reduced 
airway calibre may result in decreased residence time for NO gas in the 
airways due to increased airflow velocity and also there may be effects of 
back diffusion of NO from the bronchial compartment to the alveoli. Although 
the protocol did not allow measures of static lung volumes to be performed 
and I did not measure closing volume the reproducibility of all measures of 
exhaled nitric oxide suggests that this is not an issue as one would expect to 
see changes in alveolar NO with weight loss as FRC would be expected to 
increase. This is reinforced by the evidence that there was no correlation 
between nitric oxide levels and airway specific conductance which is a marker 
of airway calibre and therefore a surrogate for lung volume. Another reason 
for a reduction in exhaled NO could be the increased blood flow to the lungs 
that occurs in obesity which may be acting as a sump for NO which is a highly 
reactive molecule203,205,319.
There was no relationship between PC45 and exhaled nitric oxide and 
no relationship between change in PC45 and change in exhaled nitric oxide. 
This may again reflect the effect of obesity on lung volumes and other 
influences on bronchial responsiveness rather than the influence of 
inflammation; it may also suggest that inflammation other than eosinophilic 
inflammation may play a part in the obese subjects. Specific airway 
inflammation due to ‘phenotype’ was explored in the previous chapter through
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the ceil counting from induced sputum however and there did not appear to be 
a neutrophilic predominance either.
There are several potential limitations noted that may explain the 
negative outcomes found. The subjects were asthmatic and were taking 
inhaled steroids. The study design was not such that steroid medication could 
be withdrawn or standardised. Steroids are known to improve airway 
inflammation and reduce exhaled nitric oxide107. This may therefore reduce 
levels of exhaled nitric oxide in my subjects and mask the effect of BMI. 
However there was no significant difference in mean dose of inhaled steroids 
between the dietician and control groups therefore any difference would have 
been due to the additional effect of the intervention or weight change. Also 
there was no relationship between dose of inhaled steroids used and the 
levels of exhaled nitric oxide measured. This was the same for the significant 
weight loss vs non significant weight loss groups. Additionally the treatment 
did not change appreciably between visits and therefore change longitudinally 
would likely have been due to change in weight rather than a change in 
medication. As this was a real life study investigating many factors related to 
medical weight loss in obese asthmatics I wished to explore the effect of 
weight loss in a population that would likely be encountered in clinical 
practice.
Exhaled nitric oxide can also be affected by factors such as smoking, 
diet and other respiratory conditions which may have affected the study94,320 I 
attempted to exclude these factors by excluding those with other significant 
comorbidities, subjects were asked to fast and avoid caffeinated drinks prior 
to their visit and all subjects were non smokers or ex-smokers.
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Although this is one of the largest studies of its kind the numbers 
recruited are still low and therefore the power of the study may not have been 
sufficient to show a difference between groups.
Lastly I was unable to measure lung volumes in my patients due to the 
need to avoid deep inspiratory manoeuvres at the time of bronchial challenge 
testing and therefore I am unable to adjust for FRC in my subjects which may 
affect the level of exhaled nitric oxide and is also related to obesity.
7,5 Summary
Despite these limitations my results agree with other studies that have 
failed to show a relationship between BMI, adiposity, adipokines, airway 
inflammation and exhaled nitric oxide. The association between asthma and 
obesity is unlikely to be related to an association with eosinophilic airway 
inflammation linked to inflammatory substances from increased adipose 
tissue. This would not exclude non-eosinophilic airway inflammation however 
and this is explored in chapter 6 with differential cell counts obtained from 
induced sputum.
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Chapter 8: Bronchial responsiveness and reactivity in obese asthmatics
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8.1 Introduction
Obesity and asthma are related, with an increase in BMI associated 
with an increase in the prevalence of asthma3. Asthma is characterised by 
reversible airway obstruction as a result of hyper-responsiveness of bronchial 
wall smooth muscle which can be measured using bronchial provocation 
challenge testing, non-selectively, either directly or indirectly by exposing the 
airways to various stimuli14. The relationship of bronchial responsiveness to 
BMI is controversial with some suggesting that although wheeze and 
breathlessness is associated with obesity, bronchial responsiveness is not213. 
Others suggest otherwise and have shown an increase in bronchial 
responsiveness in obese subjects211,212.
Indirect challenges involve the use of chemical stimuli to initiate one or 
more of the intermediate steps leading to bronchoconstriction and direct 
challenges involve the use of substances such as muscarinic agonists (e.g. 
methacholine) to directly stimulate receptors on airway smooth muscle14,17, 
143. Challenge testing can be used to assist with making a diagnosis and to 
assess asthma control or severity, however airway hyper-responsiveness to 
methacholine is not synonymous with asthma and its severity is not 
synonymous with asthma severity17,149,321. Despite this the measurement of 
bronchial hyper-responsiveness to methacholine is accepted as a way of 
assessing asthma severity in clinical trials and a way of tracking change with 
intervention144.
Historically, for diagnostic purposes, asthma challenge tests target a 
significant change in FEV-i with a 20% fall in FEVi being considered a positive
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test and an arbitrary cut off to exclude significant bronchial responsiveness for 
most research studies set at 8mg/ml using increasing doses of methacholine.
Standardised methods have been developed to perform methacholine 
challenge tests17. And a doubling concentration of methacholine is 
administered with assessment of the FEV-i. The dose of methacholine 
calculated to induce a 20% drop in FEVi is used to define bronchial 
responsiveness and is termed PC2o. Alternatively airway constriction can be 
measured using body plethysmography which can avoid deep inhalations to 
measure increase in airway resistance or its reciprocal, specific airway 
conductance (sGaw) and the cut off of a 45% drop in sGaw is used to 
produce PC45 which equates to PC20. Two standardised methods are also 
described to administer methacholine, one requires deep inhalations and the 
other a tidal breathing method.
There are two theoretical reasons for an increase in bronchial 
responsiveness in obesity, an increase in the underlying airway inflammation 
due to an increase in proinflammatory substances produced by adipose tissue 
leading to an increase in bronchial smooth muscle responsiveness305 and the 
mechanical effect of obesity leading to a reduction in lung volumes, decrease 
in airway diameter and reduced smooth muscle stretch154,176
To investigate bronchial responsiveness in relation to obesity it is 
important to avoid methods that would require deep inhalations which may 
provide a bronchoprotective effect154,200,319,322. Direct challenge with 
methacholine was chosen using a tidal breathing method to administer 
methacholine and body plethysmography to measure changes in sGaw.
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We hypothesised that bronchial responsiveness would be related to 
BMI with increased responsiveness associated with increasing BMI which 
would decrease with weight reduction. To explore whether any change in 
bronchial responsiveness could be related to airway inflammation or a 
reduction in airway calibre we explored the relationship between bronchial 
responsiveness, exhaled nitric oxide and specific airway conductance.
As a secondary outcome measure we explored bronchial hyper­
reactivity and its relationship to BMI and weight loss as the speed or intensity 
of response to a bronchoconstricting agent, which has been shown to have a 
better relationship with HRQoL related to severity of asthma151. The slope of 
the dose-response curve used in this way has been shown to be more useful 
in identifying patients with asthma152 and in maintaining a better relationship 
with the degree of oxidative stress of patients153. For analysis I used the dose- 
response slope and also the bronchial reactivity index.
8.2 Methods
The methods have been described in detail in Chapter 2 and will be 
outlined in brief here.
To avoid the bronchoprotective effect of deep inspiratory manoeuvres, 
bronchial challenge testing was carried out using the tidal breathing method 
and airway responsiveness was measured by specific airway conductance 
(sGaw) using body plethysmography with a change in sGaw of >45 % used to 
terminate the test and calculate PC45.
All procedures were carried out by the author following instruction by 
laboratory staff at University Hospital Aintree pulmonary function unit and the
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procedure was performed on all subjects at baseline, 3 months and 6 months. 
The order of tests has been explained earlier in chapter 2.
Prior to testing subjects were asked to refrain from using their inhaled 
medication for 12 hours and any oral medication for 24 hours, They were also 
asked to refrain for taking caffeinated drinks for 12 hours.
The Two-minute tidal breathing dosing protocol was used adapted from 
the ATS guidelines17 previously mentioned using the following 10 doubling 
concentrations of methacholine: Diluent, 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2, 4,
8, 16, 32 mg/mi. The PC45 was calculated as the concentration of 
methacholine required to produce a 45% fall in sGaw (baseline sGaw x 0.55). 
sGaw was measured using a Medgraphics™ Elite Plethysmograph was used 
which is capable of accommodating patients up to 180 Kg and as I wished to 
avoid deep inspiratory manoeuvres so as not to affect bronchial reactivity I 
measured airway resistance only but not full lung volumes of the subjects by 
asking the subjects to breathe at tidal volume throughout the procedure. 
Between tests the patient moved outside the body box for the next 
nebulisation of methacholine.
Following the procedure 5mg nebulised salbutamol was administered 
and spirometry checked.
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Determination of PC45.
The concentration of methacholine required to cause a drop in sGaw of 
45% or PC45 was calculated using a logarithmic method as follows:
PC45 - antilog [ log C1 + flog C2-log C1)(45-R1)l
R2-R1
Where
C1 = second-to-last methacholine concentration (concentration 
preceding C2)
C2 = final concentration of methacholine (concentration resulting in a 
45% or greater fall in sGaw)
R1 = percent fall in sGaw after C1
R2 = percent fall in sGaw after C2
Determination of bronchial hyperreactivity: Dose response slope & 
Bronchial Reactivity Index.
To calculate dose response slope and bronchial reactivity index the 
method described by Burrows et al264 was used and adapted to PC45. The 
dose response data were summarised by the expression: percent decline in 
sGaw / dose, where percent decline sGaw was defined as the decline in 
sGaw (from the post saline value) after the final methacholine dose 
administered, and the dose was defined as the final cumulative dose 
administered. This can be graphically represented as the slope of a line 
connecting the origin of a dose response curve with the final point of the curve 
referred to as the dose-response slope.
The slope was calculated by dividing the percent decline in baseline 
sGaw after the last methacholine challenge by the log of the last methacholine 
concentration given to account for skewed data. To avoid negative or zero
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logarithms in the denominator, all concentrations were expressed as 
milligrams per decilitre.
The expression used therefore to obtain the dose response slope is as 
follows:
DRS = percent decline in sGaw 
Logi0C2
C2 = Final concentration of methacholine (mg/dl)
Where percent decline in sGaw = Baseline sGaw - Final sGaw * 100
Baseline sGaw
Bronchial response index151 was used to provide a continuous and 
relatively normally distributed variable for use in statistical analysis:
BRI = Logic DRS
8.2.1 Statistical analysis
Categorical variables are expressed as percentages of total subjects 
and compared using Chi squared test. Continuous variables are expressed 
using mean ±SD and compared between groups with the Students unpaired t 
test if normally distributed. Non-normal distributions determined by Shapiro- 
Wilk testing are expressed using median and interquartile range. Variables 
compared between visits were compared using paired-samples f testing. 
Correlations were performed between normally distributed variables using 
Pearson correlations two-tailed test and non-normally distributed variables 
using Spearman’s. Any correlations were checked visually for 
homoscedasticity to confirm any relationship. Significance for multiple 
comparisons were adjusted by Bonferroni correction. Significance was
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determined if p<0.05 and alpha level adjusted by Bonferroni for number of 
observations studied.
8.3 Results
Control group 
n=25 (23)
Attended 
n=16 (15)
Attended 
n=14 (12)
6 month 
visit
3 month 
visit
Baseline
visit
Attended 
n=21 (18)
Attended 
n=22 (18)
Missed
visits
n-4
Missed
visits
n=3
Lost to 
follow up 
n=2
Lost to 
follow up 
n=2
Lost to 
follow up 
n=2
Lost to 
follow up 
n=7
58 Subjects eligible
Lost to 
follow up
Diet intervention
group
n=26 (25)
Visitl
51 subjects randomised to study
Fig 16. Consort diagram for study, (numbers in brackets = subjects with 
available completed questionnaires)
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Missing data was present for the following reasons:
Pt12 6 months FEV1 too low (41%) therefore not done
Pt17 3 months pt refused
Pt17 6 months pt refused
Pt27 6 months Starting sGaw too low
Pt29 6 months Starting sGaw too low
Pt38 3 months Technical error
Pt60 baseline Technical error - equipment failure
Pt67 baseline Starting sGaw too low
Pt78 baseline Used screening visit as first visit
*in brackets = number of subjects with BR data available
8.3.1 Measures of specific airways conductance, bronchial
responsiveness and reactivity at each visit
All subjects. Mean fsd)
Bronchial responsiveness, starting specific airway conductance and 
measures of bronchial reactivity for all subjects are shown below.
Baseline 3 Months 6 Months
sGaw 0.155 (0.05) 0.156 (0.05) 0.155 (0.05)
10
0C
L 0.219 (0.3) 0.271 (0.394) 0.331 (0.619)
LogPC45 -0.900 (0.439) -0.827 (0.447) -0.776 (0.458)
DRS 52.5 (24.5) 48.3 (23.8) 48.8 (22.9)
BRI 1.77 (0.15) 1.74 (0.149) 1.74 (0.149)
sGaw = Specific airway conductance; PC45 = Provocative concentration of 
methacholine to cause a 45% drop in sGaw from baseline; LogPC45 = Log 
base 10 of PC45; DRS = Dose response slope; BRI = Bronchial response 
index.
Table 38. Mean (SD) for all subjects for specific airway conductance, 
bronchial responsiveness and reactivity for each visit
There were no significant differences for all measures of bronchial 
responsiveness and reactivity or airway conductance between baseline to 3 
months, baseline to 6 months and 3 months to 6 months. There was a trend 
towards an improvement in PC45 at 3 months and 6 months.
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Comparing between groups. Mean (sd)
Bronchial responsiveness, starting specific airway conductance and 
measures of bronchial reactivity for all subjects are shown below.
Dietician
group
baseline
Control group 
baseline
Dietician
group
3 months
Control group 
visit
3 months
Dietician
group
6 months
Control group
6 months
sGaw 0.149 (0.054) 0.16 (0.048) 0.151 (0.056) 0.165 (0.061) 0.151 (0.054) 0.161 (0.048)
PC45 0.203 (0.229) 0.236 (0.365) 0.278 (0.401) 0.261 (0.399) 0.375 (0.787) 0.276 (0.319)
LogPC4
5
-0.915
(0.451)
-0.884
(0.435)
-0.799
(0.436)
-0.869 (0.48) -0.785
(0.501)
-0.765
(0.414)
DRS 53.33 (25.77) 51.58 (23.56) 47.23 (24.23) 50.13 (23.87) 52.32 (26.6) 44.29 (14.76)
BRI 1.77 (0.16) 1.76 (0.15) 1.73 (0.15) 1.75 (0.16) 1.76 (0.17) 1.72 (0.12)
sGaw = Specific airway conductance; PC45 = Provocative concentration of 
methacholine to cause a 45% drop in sGaw from baseline; LogPC45 = Log 
base 10 of PC45; DRS = Dose response slope; BRI = Bronchial response 
index.
Table 39. Mean (SD) for dietician and control groups for specific airway 
conductance, bronchial responsiveness and reactivity for each visit
There were no significant differences for either the dietician or the 
control group for all measures of bronchial responsiveness and reactivity or 
airway conductance between baseline to 3 months, baseline to 6 months and 
3 months to 6 months. Again there was a trend towards an improvement in 
PC45 at 3 and 6 months.
There were no significant differences between the control group and 
dietician group for any visit for any measure of bronchial responsiveness and 
reactivity or airway conductance.
Change from baseline per visit for sGaw
0.015 1
0.01 -
0.005 -
—•—Dietician group 
------ Control groupBaseline 3 months
-0.005 -
-0.01 -
-0.015 J
Change from baseline per visit for PC45
0.2 n
0.18 -
0.16 -
0.14 -
0.12 -
0.08
P=0.64 P=0.440.06 -
0.04 -
0.02 -
Baseline 3 months 4 months
—■— Dietician group 
-------Control group
Change from baseline per visit for LoqPC45
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Change from baseline per visit for Bronchial Reactivity Index
Fig 17. Graphs to show change in from baseline at each visit for 
Dietician and Control groups for sGaw, PC45, LogPC45, Dose Response 
Slope and Bronchial Reactivity Index. P values represent differences 
between groups at each visit from paired samples analysis
8.3.2 Correlations between BMI and specific airway conductance plus
measures of bronchial responsiveness and reactivity for all subjects
and each group
There were no significant correlations for all subjects between BMI at 
each visit and specific airway conductance or any measure of bronchial 
responsiveness or reactivity except for LogPC45 at 3 months (r=0.391, 
p=0.025).
There were no significant correlations for either the dietician or control 
group between BMI at each visit and specific airway conductance or any 
measure of bronchial responsiveness or reactivity except for LogPC45 at 3 
months (r=0.659, p=0.014) for the control group.
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8.3.3 Relationship between percentage change 8n weight and change in
specific airway conductance and change in measures of airway 
responsiveness and reactivity. All subjects, dietician and control groups
There were no significant correlations between percentage weight 
change from starting weight and change from baseline in sGaw or change in 
bronchial responsiveness or reactivity except for sGaw between baseline and 
3 months (r=0.528, p=0.020) although when examining the scatterplot for 
heteroscedasticity this did not appear true . This was also true if compared to 
percentage change from baseline for sGaw, bronchial responsiveness and 
reactivity variables.
8.3.4 >5% weight loss group vs <5% weight loss group - between group
comparisons
>5% weight 
loss group 
Baseline
<5% weight 
loss group 
Baseline
>5% weight 
loss group
3 months
<5% weight 
loss group
3 months
>5% weight 
loss group
6 months
<5% weight 
loss group
6 months
sGaw 0.146 (0.051) 0.154 (0.055) 0.150 (0.067) 0.161(0.052) 0.147 (0.056) 0.161 (0.047)
PC45 0.226 (0.276) 0.234 (0.362) 0.206 (0.219) 0.276 (0.425) 0.477 (0.941) 0.241 (0.281)
LogPC4 -0.927 -0.862 -0.864 -0.813 -0.709 -0.818
5 (0.516) (0.405) (0.407) (0.441) (0.545) (0.405)
DRS 52.31 (24.24) 50.47 (24.51) 50.70 (22.03) 48.03 (27.02) 52.05 (30.15) 46.75 (17.56)
BRI 1.764 (0.168) 1.756 (0.145) 1.762 (0.137) 1.732 (0.161) 1.755 (0.179) 1.735 (0.132)
sGaw = Specific airway conductance; PC45 = Provocative concentration of 
methacholine to cause a 45% drop in sGaw from baseline; LogPC45 = Log 
base 10 of PC45; DRS = Dose response slope; BRI = Bronchial response 
index.
Table 40. Mean (SD) for significant weight loss and non-significant 
weight loss groups for specific airway conductance, bronchial 
responsiveness and reactivity for each visit
There were no significant differences between those that lost 
significant weight (>5% of baseline) and those that did not for specific airway 
conductance, bronchial responsiveness or reactivity at any visit.
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8.3.5 Relationship between specific airway conductance, bronchial
responsiveness and bronchial reactivity with exhaled nitric oxide
I have explored the relationship between measures of airway 
conductance and bronchial responsiveness and reactivity with exhaled nitric 
oxide here. Relationships between health related quality of life questionnaire 
scores and induced sputum differential cell counts have been discussed 
elsewhere in the relevant chapters. Correlations are shown below for each 
visit.
FeNOSOml Baseline FeNOSOml 3 months FeNO50ml 6 months
sGaw R= 0.043
P= 0.774
R= 0.199
P= 0.293
R= 0.155
P= 0.375
PC45 R= -0.178
P= 0.241
R= -0.405*
P= 0.027
R= -0.252
P= 0.156
LogPC4s R= -0.203
P= 0.181
R= -0.533*
P= 0.002
R=-0.351*
P= 0.045
DRS R= 0.301*
P= 0.045
R= 0.500*
P= 0.004
R- 0.408*
P= 0.018
BRI R= 0.312*
P= 0.037
R= 0.557*
P= 0.001
R= 0.446*
P= 0.009
* significant correlation p<0.05
sGaw = Specific airway conductance; PC45 = Provocative concentration of 
methacholine to cause a 45% drop in sGaw from baseline; LogPC45 = Log 
base 10 of PC45; DRS = Dose response slope; BRI = Bronchial response 
index.
Table 41. Correlations between exhaled nitric oxide, specific airway 
conductance, bronchial responsiveness and measures of bronchial 
reactivity at each visit for ail subjects
There were significant correlations between measures of bronchial 
reactivity and the fraction of exhaled nitric oxide at baseline, 3 months and 6 
months. There were also correlations between PC45 and FeNOso at 3 months 
and logPC45 and FeN05o at 3 and 6 months. However there were no 
significant correlations between change in FeNOso from baseline and the 
corresponding change in specific airway conductance and measures of
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bronchial responsiveness or reactivity between baseline to 3 months and 
baseline to 6 months.
8.3.6 Inhaled steroids and bronchial responsiveness
There were no significant correlations with any measures of bronchial 
responsiveness and inhaled steroid dose.
Additional material for this chapter can be found in appendix D
8.4 Conclusions and discussion
I investigated the presence of bronchial responsiveness and reactivity 
in a group of obese asthmatic subjects. Although there was a trend towards a 
decrease in bronchial responsiveness at 3 and 6 months for the group as a 
whole this did not reach significance. This was also true when exploring 
individual groups and was seen in both the dietician and control groups. There 
was a larger decrease in responsiveness from baseline in the dietician group 
compared to the control group although the difference between groups at 
each visit did not reach significance. There was no significant change in 
airway specific conductance between visits for all subjects or between groups. 
There was also no significant change for all subjects and in either group at 3 
or 6 months for measures of bronchial reactivity, i.e. the dose response slope 
or bronchial reactivity index. There was a trend towards a decrease in weight 
at 3 and 6 months in the group as a whole and an increased weight loss in the 
dietician group which may explain this change in bronchial responsiveness, 
however when exploring the relationship between BMI and bronchial reactivity
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there was no significant correlation between BMI and bronchial 
responsiveness at any visit for all subjects or for either group. There was also 
no correlation between weight loss as a percentage of original weight at 3 and 
6 months and changes in measures of bronchial responsiveness or reactivity 
over this period which would suggest that BMI is less likely to be linked to any 
changes in reactivity or responsiveness in this population of obese 
asthmatics. This was further reinforced when comparing those subjects that 
lost >5% of their original weight compared to those that did not achieve this 
significant weight loss as no significant differences were found between these 
two groups.
It has been suggested that bronchial responsiveness and reactivity can 
be affected by lung volumes by becoming increased by lower lung volumes154, 
20°. I was unable to measure lung volumes directly as the method required the 
avoidance of deep inspiratory manoeuvres, however I was able to measure 
airway calibre by specific airway conductance (sGaw) and did not find a 
relationship between sGaw and BMI in either group or the group as a whole. I 
did not see changes in sGaw at 3 or 6 months as I did with PC45 and there 
were no correlations between change in weight and change in sGaw or any 
significant differences in sGaw between those that lost significant weight i.e. 
>5% of their original weight compared to those that did not achieve significant 
weight loss.
It is unlikely therefore that any trend towards improvement in bronchial 
responsiveness is related to changes in specific airway conductance or 
changes in baseline airway calibre which may be a surrogate for lung 
volumes.
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There was a possible relationship between airway reactivity and airway 
inflammation as measured by the fraction of exhaled nitric oxide as there were 
significant correlations between the dose response slope and bronchial 
reactivity index at each visit, although there were no correlations with PC45. 
Despite this however there were no correlations between change in FeN05o 
between visits and change in measures of bronchial responsiveness or 
reactivity. This suggests that any change in bronchial responsiveness or 
reactivity in our obese asthmatic population is unlikely to be due to the 
influence of weight through an immunological mechanism. As discussed in 
chapter 7 the possible effect of airway calibre on measured FeNO must be 
bourne in mind however and this may have masked an association with this 
variable240-314’315.
Airway hyper-responsiveness (AFIR) is a characteristic of asthma, and 
histamine and methacholine bronchoprovocation challenges have been widely 
used to document and quantitate AFIR17,143. We assessed bronchial 
responsiveness in our subjects using a direct stimulus acting directly on 
airway smooth muscle; methacholine. Bronchial hyper-responsiveness is 
responsible for recurrent episodes of wheezing, breathlessness, chest 
tightedness, and coughing in asthma14. The methacholine challenge is the 
most commonly performed. I used a commonly used method standardised to 
American Thoracic Society Guidelines to ensure comparability of the data and 
also to ensure comparability between visits for the subjects17. The 2-min tidal 
breathing method was chosen to avoid deep inspiratory manoeuvres and it 
should be noted that this provides maximum diagnostic sensitivity when 
methacholine is inhaled by non-deep inhalation methods322. It was previously
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thought that deep inhalation and breathhold probably resulted in greater 
retention of aerosol, better deposition of aerosol or both but further studies 
have shown this not to be the case. When the methods are performed as per 
the ATS guidelines, the tidal breathing method repeatedly produces a greater 
response due to the greater dose administered in the tidal breathing method, 
and also due to the lack of brochodilatation and bronchoprotective effect of 
deep inhalation323,324 There is a correlation between asthma severity and the 
severity of AHR144,145 that improves with anti-inflammatory therapeutic 
strategies such as inhaled steroids146. There is a modest correlation between 
the severity of direct AHR and airway inflammation with mainly eosinophils or 
metachromatic cells147. There is also an increased response to direct stimuli 
with nonasthmatic airflow obstruction closely related to the severity of chronic 
bronchial obstruction felt to represent a geometric issue with regard to airway 
diameter148. Therefore the method chosen for this study is appropriate for 
investigating obese subjects. Future studies of obese subjects are needed to 
compare methods of performing challenge testing to report on how a raised 
BMI can influence the sensitivity of these different methods including those 
that involve deep inspirations and those that don’t.
There is felt to be two components to AHR, a variable and fixed 
component with the variable component being able to change with 
improvement in airway inflammation and the fixed component being related to 
structural and functional changes in the airway termed airway remodelling143. 
My subjects had fairly well preserved FEVi which would suggest that airway 
remodelling and fixed airflow obstruction was unlikely to be an important
234
factor and I was measuring the variable component which should track airway 
inflammation.
Although AHR is felt to be related to eosinophilic airway inflammation 
some studies have dissociated the relationship between eosinophils and 
AHR. Studies using Mepolizumab an anti-interleukin-5 agent found that 
patients that had a reduction in eosinophils continued to have AHR and 
symptoms134. This helps to explain the lack of a response to weight loss in 
terms of any change in immunological response through measurements of 
exhaled nitric oxide. Dixon et al have also demonstrated a lack of a 
relationship between airway inflammation measured by airway differential cell 
counts and bronchial responsiveness in obese subjects undergoing surgical 
weight loss suggesting that another mechanism is involved2.
One of the difficulties inherent in assessing bronchial responsiveness 
and reactivity is the fact that specificity is low and bronchial responsiveness 
can be present in non-asthmatic conditions such as allergic and nonallergic 
rhinitis325. As there is no gold standard confirmation of the presence of asthma 
it is also difficult to determine whether my population had bronchial 
responsiveness as a consequence of the asthma syndrome, however all the 
subjects had symptoms, had a doctor diagnosis of asthma and were on 
significant amounts of treatment. Changes in bronchial reactivity could be due 
to a number of reasons, including the mechanical effects of obesity. I strived 
to exclude patients with other reasons for AHR although I cannot completely 
exclude gastroesophageal reflux disease which is common in obese persons 
and may be related to AHR326.
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It is important to note limitations to the study in terms of measuring 
bronchial responsiveness. Due to the nature of the subjects’ obesity it is 
difficult to perform measurements in these patients accurately especially using 
body plethysmography as the subjects’ size presents problems with volumes 
in the body box. I used a plethysmograph which is rated to 180Kg and paid 
careful attention to calibration, subject technique and allowed time for the 
equipment to settle before performing measurements. Despite this there may 
have been some errors introduced in measurements due to subjects having to 
move between locations to nebulise methacholine and perform 
measurements.
Another source of potential error may be introduced from the 
requirement to avoid deep inhalations322. During the measurement of specific 
airway conductance the subject is required to pant at a predetermined 
frequency and during the process of doing this subjects may wish to deepen 
their inspiration. I tried to avoid this by carefully explaining to each subject 
what was required from them and providing feedback from the graphical 
representation of the equipment software.
Bronchial responsiveness can be altered by a number of factors and 
there is a natural variability in repeatability of the test. I tried to reduce these 
extra factors to a minimum by avoiding exacerbations, using standardised 
recommendations for avoiding medication, all visits were in the morning and 
at the same time of day. Co-morbidities can also affect bronchial 
responsiveness such as gastroesophageal reflux disease326, however as this 
was a longitudinal study this effect should have less impact.
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Lastly there is some controversy over the best measurement of 
bronchial responsiveness or reactivity. I have used PC45 to methacholine with 
sGaw as this is recommended in international guidelines, is therefore 
standardised and can be compared with other studies17. I have also used the 
slope of the response in the bronchial responsiveness index and dose 
response slope which some suggest is a more sensitive measure151,152,
8.6 Summary
Weight loss in obese asthmatics appears to have no significant effects 
on objective measures of airway obstruction or airway reactivity as a marker 
of severity. There was no correlation between airway responsiveness and BMI 
or change in weight. Measuring airway responsiveness in the obese 
population is difficult and further studies are required to establish the optimal 
method to allow comparison of different studies.
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Chapter 9: Conclusions and Discussion
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9.1 Summary of results
In this thesis I have shown that when recruiting obese asthmatic 
subjects, of 91 subjects tested for bronchial responsiveness, approximately 
one third did not demonstrate increased bronchial responsiveness that would 
be consistent with a diagnosis of asthma by most accepted definitions12,15,327. 
There was no significant difference between those with and those without 
bronchial responsiveness who were well matched for asthma medication, age 
and gender, for health related quality of life as measured by generic, 
respiratory specific and weight specific quality of life questionnaires, There 
was no significant difference between exhaled nitric oxide either. There was a 
significant correlation between BMI and HRQoL but not with other measures 
of asthma severity.
51 subjects were enrolled into the study, 26 were randomised into the 
dietician group and 25 into the control group. Both groups lost weight overall 
with a greater mean weight loss in the dietician group (-5% at 3 months and - 
4.9% at 6 months) than the control group (-3% at Smooths and -2.7% at 6 
months) although the two groups did not differ significantly. In addition there 
was a significant weight loss between baseline and 3 months (p<0.05) and 6 
months (p<0.05) in the dietician group which was not seen in the control 
group. This was seen with intention to treat analysis which did not differ with 
last observation carried forward. Therefore further analysis in the study used 
intention to treat. It is accepted by expert opinion that a clinically important 
weight loss is >5%286,287, there were subjects that achieved this level of 
weight loss in the control group as well as the dietician group, therefore
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further analysis was carried out for each variable by using two further groups, 
significant weight loss vs non significant weight loss.
Health related quality of life measured using the generic SF36160, 
disease specific SGRQ163 and IWQOL-Lite244 showed improvement in quality 
of life scores from baseline to 3 months and 6 months in the dietician group 
but not the control group. There was no significant difference at any visit 
between groups although there was a trend towards a greater improvement in 
the dietician group compared to the control group that did not reach 
significance. In contrast to the screening visit cross sectional analysis, there 
was no relationship between generic and respiratory specific quality of life and 
BMI or change in weight, although as would be expected there were some 
weak correlations between the IWQOL-Lite weight specific questionnaire 
domains, BMI and weight change. When comparing those that lost >5% of 
baseline weight there was a trend towards a greater improvement in HRQoL 
vs those that did not lose weight although this did not reach significance. 
Although the HRQoL scores were better in the >5% weight loss group 
compared to the <5% weight loss group the two did not differ statistically. 
There was no significant effect of gender on the HRQoL scores and no 
significant correlation between other measures of asthma severity (FeNO, 
PC45) and HRQoL.
There were no significant correlations between BMI and differential cell 
counts from induced sputum and no significant differences between dietician 
and control groups or those that lost £5% weight and those that did not. There 
was also no significant correlation with weight change and any cell line and no
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relationship between eosinophil predominant or neutrophil predominant 
inflammation and BMI.
Similarly when using exhaled nitric oxide as a marker of eosinophilic 
airway inflammation, no significant relationships were found with BMI, weight 
change and no significant differences were found between dietician and 
control groups or those that lost >5% baseline weight vs. those that did not.
Lastly there was no significant correlation with bronchial 
responsiveness, reactivity or specific airway conductance vs. BMI or weight 
change and no differences between the dietician vs. control group or >5% 
weight loss vs. <5% weight loss group.
Using fat% measured by bioimpedence technique did not show any 
additional significant results and there were no significant correlations with 
body fat% and any of the markers of asthma severity in addition to those 
already described with BMI. Therefore body fat% has not been explored 
further in the analysis.
Inhaled steroid dose had no effect on any measures of asthma 
severity.
Although I intended to do so I was unable to analyse serum 
inflammatory markers or adipokines due to technical difficulties. Due to poor 
reply rates and poor completion I was unable to include peak flow and 
symptoms diaries in the analysis.
9.2 Interpretation
I have shown that of the subjects that attended and had been given a 
physician diagnosis of asthma on significant amounts of treatment, around
241
one third did not demonstrate bronchial hyper-responsiveness, suggesting a 
mis-classification of diagnosis possibly due to the effects of obesity on 
respiratory mechanics producing similar symptoms to asthma. These subjects 
have a significant health impairment with HRQoL having a greater impact than 
other traditional markers of asthma severity i.e. airway responsiveness (PC2o), 
lung function (FEV1% and FVC% predicted) or airway inflammation (FeN05o). 
As the negative correlation between BMI and HRQoL was found in ail 
questionnaires used it is likely to be a generic effect of the impact of obesity 
on HRQoL rather than an effect on the respiratory system in asthma per se as 
there was no significant correlation between BMI and the symptoms domain 
of the SGRQ which includes questions on the frequency of cough, sputum, 
breathlessness, wheeze and exacerbations. Although patients can have 
asthma without the presence of bronchial hyper-responsiveness many studies 
require the presence of bronchial responsiveness defined as a PC2o of <8% 
mg/ml or reversibility of FEV1 to inhaled bronchodilators of 15%17,143.1 
therefore used this criteria towards making the diagnosis of asthma which was 
supported by the evidence of less airway inflammation, less airway 
obstruction and less atopy in those that did not show bronchial hyper­
responsiveness. It is interesting that one third of subjects did not fulfil these 
criteria despite their diagnosis and this may reflect the possibility that 
symptoms of breathlessness associated with the effects of increased BMI on 
airway physiology may be misinterpreted to be consistent with asthma in an 
obese population. This has important implications for interpreting studies that 
have not included these objective tests to confirm a diagnosis of asthma in a 
population.
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Of those subjects that fulfilled the inclusion criteria for the study I 
demonstrated that it was possible to achieve a significant weight loss with 
dietary intervention and meal replacement strategy over a 6 month period 
albeit mild when compared to surgical weight loss studies. Although there was 
a trend towards greater weight loss in the dietician group vs. the control group 
the two groups did not differ significantly at 3 or 6 months. It is noted that not 
all subjects lost weight in the dietician group and also some of the subjects in 
the control group lost significant weight therefore two further groups were 
created i.e. a significant weight loss vs. no significant weight loss. Although 
the study was powered to show a significant difference with the numbers of 
subjects recruited, and this is one of the largest trials of dietary intervention in 
obese asthmatics, it is likely that the study was underpowered to demonstrate 
a significant difference between groups as we had aimed to recruit 40 
subjects into each group with the hope of retaining 25 per group. There may 
also have been a study effect on the control group, the so called Hawthorne 
effect292, resulting in weight loss occurring due to the fact that the subject was 
involved in a clinical study. Although there were trends to suggest that the 
dietician group differed from the control group this was not shown statistically 
and more numbers are likely to be needed in any future studies of this nature.
There were significant improvements seen in all subjects and the 
dietician group for HRQoL from baseline to 3 and 6 months although the 
dietician and control group did not differ significantly. This may be due to a 
lack of power once again for the study and too few subjects enrolled in each 
group. Again there was a trend for an improvement in HRQoL in the control 
group as well as the dietician group which could be due to the effect of
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enrolment into a clinical trial rather than the effect of diet or weight loss in 
itself. There was not a similar correlation between BMI and measures of 
HRQoL as was seen in the screening visit in the generic and respiratory 
specific questionnaires although there were significant correlations seen for 
the weight specific questionnaire which would be expected to be more 
sensitive to changes in weight244. There was a trend towards an improvement 
in HRQoL with lower BMI. The same was true for change in weight and 
change in HRQoL with significant correlations seen only in the weight specific 
questionnaire. When comparing those that lost significant weight (>5% of 
baseline weight) with those that did not, again there was a trend towards a 
greater improvement in HRQoL in the weight loss group although not 
significant. There were no relationships found between HRQoL and bronchial 
hyper-responsiveness or measures of inflammation. Although non significant 
when taking into account results from the screening patients HRQoL is 
affected in obese asthmatic subjects mainly by BMI and excess weight rather 
than other traditional measures of asthma severity. Weight loss has the 
potential to improve the quality of life of these patients which may account for 
improvements in asthma severity and asthma control161.
When investigating the effect of BMI on inflammation there were no 
relationships found between BMI and any cell type in the differential cell count 
from induced sputum, no significant differences between either dietician or 
control groups or significant vs non significant weight loss groups. This is 
similar to findings of other groups who have failed to show a relationship 
between BMI and airway inflammation as measured by induced sputum2,236, 
241. This does not support the theory that obesity alters the inflammatory
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profile of the lung or that increase in BMI is associated with an increase in 
airway inflammation. There did not appear to be a specific sputum phenotype 
associated with obesity in this group of subjects either. This was also 
supported by the lack of a relationship between exhaled nitric oxide and BMI, 
changes in weight or when comparing between dietician vs. control groups or 
significant weight loss vs. no weight loss groups. It is important to note that 
many of the subjects were taking significant amounts of inhaled steroid 
medication which may have an effect on reducing exhaled nitric oxide 
levels108 and reducing eosinophil counts116, however, longitudinally there was 
no apparent change in markers of inflammation with change in weight. As 
medication was not altered this helps to support the suggestion that BMI does 
not affect the inflammatory milieu of the airways as has been suggested in 
animal studies and in vitro. Kim et al studied the effect of BMI and airway 
inflammation measured by exhaled nitric oxide in healthy adults and failed to 
find a significant relationship but do note that there are significant differences 
in the possible confounding factors that become important in investigating 
these measures in asthmatic individuals such as atopy, ethnicity, medication, 
combined respiratory diseases and other clinical variables318. Although FeNO 
measures eosinophilic airway inflammation and does not reflect 
noneosinophilic airway inflammation, it may be that obesity could affect airway 
inflammation without recruitment of eosinophils. However I failed to show any 
association with neutrophils in sputum differential cell counts and BMI in this 
study. Sutherland et al showed that in asthmatics, no significant interaction 
was observed between systemic and airway inflammation supporting my 
findings241. The theory that systemic inflammation spilling over into the blood
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from adipose tissue can cause local inflammation in distant organs including 
the airways appears unlikely.
Finally there were no correlations between BMl or change in weight 
and measures of bronchial responsiveness, reactivity or airway calibre 
measured as specific airway conductance. There were also no differences 
between groups. This therefore suggests that BMl does not influence 
bronchial responsiveness in obese asthmatics and weight loss does not 
improve this marker of asthma severity in this group of subjects. Obesity may 
affect bronchial responsiveness due to its effect on lung volumes and 
therefore airway calibre154,176. I was careful to avoid deep inspiratory 
manoeuvres prior to challenge testing to avoid the bronchoprotective effect of 
deep inspiration322 but as a result was unable to describe the FRC of the 
subjects which may have a significant relationship with bronchial 
responsiveness or reactivity. I was able to measure specific airway 
conductance which may act as a surrogate for airway calibre and this had no 
effect.
I have shown that asthma severity associated with an increase in BMl 
is unlikely to be due to an effect of obesity on bronchial responsiveness or 
airway inflammation in these patients. There is a possible relationship with 
worsening of health related quality of life which had an inverse correlation with 
BMl with a trend to improve with weight loss but this may be due to a generic 
effect of obesity on HRQoL rather than from improvements in asthma severity. 
The effect of obesity on airway physiology can result in symptoms that are 
similar to those of asthma such as wheeze and shortness of breath249 and
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reduced quality of life can be associated with an increase in asthma 
symptoms that may be due to the generic effects of obesity on quality of life 
that could alter the patients’ perception of their symptoms. This could 
therefore explain the results of some studies of the effects of surgical weight 
loss in obese asthmatics that have reported improvement in symptoms but 
have not included any measures of asthma severity such as bronchial 
responsiveness, spirometry or measures of airway inflammation.
One of the problems in making a diagnosis of asthma is that there is no 
universally accepted definition15. It is generally accepted that asthma consists 
of appropriate symptoms, airway inflammation and reversible airway 
obstruction and I have selected a population of subjects with airway hyper­
reactivity and symptoms although not ail were found to have markers of 
increased airway inflammation. This population differs from some studies that 
have included subjects simply on the basis of symptoms and a physician 
diagnosis of asthma. I have shown that these types of populations may 
possibly include subjects that do not fulfil all the criteria for a diagnosis of 
asthma and no evidence of airway inflammation or bronchial hyper­
responsiveness. Improvements in these subjects with weight loss may have 
been due to the improvement in airway mechanics rather than improvements 
in asthma severity. I have been unable to investigate the relationship of 
airway mechanics to HRQoL, airway inflammation or bronchial hyper­
responsiveness in this study as the protocol was not designed to do so and 
this should be explored further in future studies.
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Another study by Aaron et al249 has found similar results and reported 
in an uncontrolled study of weight loss in 58 obese women with 24 subjects 
having a physician made diagnosis of asthma showed that weight loss 
improved respiratory function independently of the severity of airway 
responsiveness. Others have also found similar findings in measuring induced 
sputum differential cell counts. Todd et al have reported no difference in 
differential cell counts between obese and non-obese subjects and also did 
not find a correlation between cel! counts and BMI236
It is likely that the relationship between asthma and obesity remains 
complex. There are theoretical reasons that the inflammation associated with 
increased adipose tissue in obesity should influence the inflammatory state of 
the lungs in asthma with a resultant increase in bronchial responsiveness 
leading to increased airway obstruction, symptoms and a decline in control1, 
232,234,309,318 j have SftQyNri that although health related quality of life is worse 
in obesity this does not appear to be related to any change in airway 
inflammation or bronchial responsiveness. It is likely that obesity has an 
influence on the mechanics of breathing and this combined with its generic 
effect on quality of life leads to an increase in the perception of asthma in 
obese individuals rather than a worsening of the severity of asthma per se.
Recent studies in asthmatic and non asthmatic subjects undergoing 
surgical weight loss who achieved larger reductions in weight than this study 
have found improvements in bronchial responsiveness with weight loss and 
improvements in serum and adipose markers of inflammation but no change 
in inflammatory cell type2,328. When comparing asthmatics to control subjects
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there was less airway inflammation in the obese group at baseline which 
increased with weight loss. This supports my findings of not showing an 
increase in airway inflammation in this group of subjects who were all 
asthmatic.
Significance
These findings add to the body of evidence of the complexities of the 
relationship between obesity and asthma. I have shown the importance of 
confirming a diagnosis in the obese population with asthma like symptoms by 
obtaining objective evidence of airway inflammation or bronchial 
responsiveness. I have also highlighted that previous studies reporting the 
effects of BMI on asthma and the effect of weight loss based on self reported 
diagnosis of asthma must be interpreted in the light that a third of these 
subjects may not have true asthma with bronchial hyper-responsiveness by 
definition. 1 have demonstrated that there is no particular inflammatory asthma 
“phenotype” associated with obesity as has been suggested previously.
I was unable to report on the importance of alterations in lung volumes 
and further work is required to explore how the relationship, particularly with 
FRC and closing volume affect symptoms, bronchial responsiveness and the 
measurement of exhaled nitric oxide. I was also unable to report on levels of 
serum adipokines, leptin and adiponectin and how they may relate to airway 
inflammation and bronchial reactivity due to problems with measuring these 
markers. Others have failed to show relationships between these markers and 
airway inflammation. Due to the nature of the subject visits it would be 
impractical to include more investigations however these variables could be 
investigated separately. Although there was a lengthy recruitment process
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with an extensive advertisement for subjects I was unable to reach the 
recruitment target and the study has likely lacked the power to produce a 
significant result. As trends towards improvements in some areas were seen it 
would be important to repeat the study with more subjects.
I have shown that significant weight loss can be achieved in obese 
asthmatics and although it is unlikely to improve asthma severity in terms of 
airway inflammation or improvements in bronchial responsiveness, 
improvements in quality of life and respiratory mechanics can be gained which 
have a significant clinical impact in these patients.
More recently it has been shown that with larger improvements in 
weight loss changes in bronchial responsiveness, serum and adipose 
inflammatory markers plus airway inflammatory markers can occur although 
there is no change in airway inflammatory cells2,328. There were some trends 
towards this which did not reach significance likely due to the smaller weight 
loss in this study. There are also important differences in the changes seen in 
obese asthmatics vs non asthmatics.
9.3 Limitations and future recommendations
Limitations have been discussed in detail in each chapter relating to 
individual variables measured and I will discuss limitations which are pertinent 
to the study as a whole here.
There are several limitations to the study which could have potentially 
affected the outcomes. Although I recruited relatively large numbers of 
subjects compared to previously published prospective studies, numbers were 
still relatively low and therefore likely to be underpowered to find significant
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relationships between variables measured or differences between groups. 
There was also a significant drop out rate which was greater in the control 
group which also decreased the power of the study. A longer period of 
recruitment may have helped to increase numbers.
As this was a clinical study investigating the effect of weight loss in the 
real world, asthma medication was not withdrawn prior to screening the 
subjects and this may have excluded some subjects that may have had 
asthma that was well controlled however as one of the outcomes was to 
detect a possible improvement in bronchial responsiveness it was important to 
include only those with detectable bronchial responsiveness. Interestingly 
steroid dose showed no correlations with markers of airway inflammation or 
airway responsiveness.
Full lung volumes were not measured which may have been altered in 
obesity which could have had a significant effect on symptoms and other 
measured variables. As it is possible to induce a bronchoprotective effect by 
deep inspiratory manoeuvres it was decided that the protocol would avoid 
techniques requiring a deep inspiration to total lung capacity prior to 
measuring bronchial responsiveness. After performing methacholine 
challenge testing, lung volumes were likely to be altered and therefore 
measuring these after would not likely represent the subject’s normal 
situation. Adding further visits to obtain lung volumes was not practical as the 
visits for each subject were lengthy and intensive. Subjects were unlikely to 
accept further investigations as evidenced by the drop out rate in the study.
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Although this was a randomised trial, it was an open design and the 
investigators were aware which group the subject was in at the time of the 3 
and 6 month visits.
The exclusion and inclusion criteria were designed to exclude subjects 
with major comorbidities associated with obesity, that could have affected the 
study. However objective testing to investigate the presence of 
gastroesophageal reflux or cardiac disease was not performed and subjects 
may have had comorbidities that I was not aware of. As this was a longitudinal 
study these effects should have been minimised. One significant comorbidity 
in particular that is commoner in the obese population is obstructive sleep 
apnoea. I was unable to screen for this condition and therefore I may have 
included subjects with this although none of the subjects were using 
continuous positive airway pressure overnight. This potentially could be a 
ponfounding factor as it is known that obstructive sleep apnoea may 
contribute to worse asthma control and also may contribute to leptin 
resistance329. Weight loss may lead to improvement in sleep apnoea meaning 
that the longitudinal effects may not be minimised although I would not expect 
any obstructive sleep apnoea to have improved with the amount of weight 
loss achieved. The possible contribution of obstructive sleep apnoea to quality 
of life, asthma control and airway inflammation should be considered in further 
studies on weight loss in asthma.
Ex smokers were also included in the study with a definition of having 
stopping smoking >2 years prior to inclusion. I did not specify a pack year 
history as a cut off for inclusion and all subjects had a physician diagnosis of 
asthma. I accept however that this may have allowed the inclusion of some
252
subjects that may have had chronic obstructive pulmonary disease which may 
have affected the inflammatory profile of the airways. Subjects however gave 
a good history of reversible airway obstruction and only those with significant 
bronchial hyperresponsiveness were included in the study.
Subjects were taking medication and this was not withdrawn, subjects 
were advised on asthma treatment at the screening visit and medication was 
not altered by the investigators for the duration of the study, however the 
subjects may have altered their use of medication through the study. Also 
asthma exacerbations were not formally recorded but subjects may have had 
exacerbations and treatment for them. If a subject reported an exacerbation 
within 3 weeks of a study visit that visit was postponed to avoid the effect of 
the acute inflammation.
The two groups studied were designed so that one group lost 
significant weight through dietician input and a control group that did not lose 
weight. Unfortunately there were some subjects that lost weight in the control 
group that were given a healthy eating leaflet. This would be difficult to avoid 
as it would be unethical to have a control group that was given no advice or 
even encouraged to increase weight. The weight loss achieved was also 
moderate when compared to surgical intervention trials and this may not have 
been sufficient to show significant changes as have been reported in recent 
studies2,328.
Lastly, the order of investigations was designed so as to have the least 
impact on each test from the one previous to it however inevitably there may 
have been some interaction. For example sputum induction had to follow 
bronchia! responsiveness testing as sputum induction would likely cause
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bronchoconstriction, however inhalation of methacholine and subsequent 
inhalation of salbutamol may have affected the cellular content of the sputum. 
An alternative would be to increase the number of visits and do these on 
different days, however as noted previously this was not reasonable for the 
subjects who had volunteered their time. Also as asthma is a variable 
condition it would be more difficult to attribute any relationships or lack of 
thereof by measuring different variables at different time points.
Further work is required to investigate the complex relationship 
between obesity, inflammation, quality of life, airway physiology and asthma. 
There is difficulty in determining the diagnosis of asthma in the obese 
population and work is required to investigate further the best method to 
measure bronchial responsiveness in obesity. In this study I avoided deep 
inhalations in my subjects so as to avoid its bronchoprotective effect but this 
effect may not be present in obesity. The influence of obesity on lung volumes 
and how this affects measures of asthma severity also need to be explored 
further. I was unable to explore the effect of change in ERV in obesity on 
symptoms, bronchial reactivity and exhaled nitric oxide. This may be an 
important factor in determining how to investigate these subjects in future 
trials. Further exploration into how obesity affects the symptoms of patients 
with and without asthma is required to explore why many patients without 
bronchial responsiveness are diagnosed and treated for asthma in the first 
place. As I failed to find significant change in weight loss between the dietician 
and control groups larger numbers are required in future trials to achieve 
greater power.
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The inclusion of a non-asthmatic group would also add further detail on 
why the inflammatory connections behave differently in asthmatics vs non­
asthmatics. Since the design of this study it has been shown that there is 
likely to be a clearer association between systemic and local airway 
inflammation in non-asthmatic obese subjects which is not seen in asthmatic 
subjects2. This may be due to the overriding local effects of exogenous 
airborne factors such as aeroallergens which overrides the effect of the 
systemic influence of adipose tissue or the effect of inhaled medication.
Future studies should include a non-asthmatic group of subjects to explore 
these differences further to compare local factors with systemic effects of 
obesity. In view of the number of investigations and numbers of subjects 
required it was not possible to include a non-asthmatic group or non-obese 
subjects in this study.
9,4 Final statement
This study presents evidence that obese patients can have symptoms 
that mimic asthma and it is important to confirm the diagnosis with objective 
clinical investigations. This has important implications for the interpretation of 
some previous epidemiological studies and also clinically to ensure these 
patients do not receive unnecessary treatment. The patients in whom asthma 
is confirmed may benefit from a different approach aimed at improving their 
quality of life using a multidisciplinary approach to asthma management which 
includes attention to the impact of weight and encouraging weight loss rather 
than increasing anti-inflammatory medication.
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Appendix A 
Questionnaires.
SGRQ
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Subject
Number
St. George’s Hospital Respiratory Questionnaire
This questionnaire is designed to help us learn more about how your breathing affects your life. Do 
not spend too long deciding about your answers. Read each question carefully and answer by 
ticking (^) the response that best applies to you. Please answer ALL questions, as honestly as 
you can. This questionnaire will remain confidential.
Part 1
most several a few only with not at all
days a days a days a chest
week week month infections
1) Over the last month, I have coughed: □ □ □ □ □
2)Overthe last month, I[ have brought up phlegm: □ □ □ n n
(sputum)
3) Over the last month, I have had shortness of breath: □ □ □ □ □
4) Over the last month, I have had attacks of wheezing: □ □ □ □ □
5) During the last month, how many severe or very 
unpleasant attacks of chest trouble have you had?
Please tick ) one 
more than 3 attacks | |
3 attacks | j
2 attacks | |
1 attack | l
no attacks | l
£) How long did the last attack of chest trouble last for?
(go to question 7 if you had no severe attacks) Please tick ) one
a week or more | |
3 or more days l |
1 or 2 days l |
less than a day | |
7) Over the last month, in an average week, how many good days (with little chest trouble) have you had?
Please tick (v^) one 
no good days j j
1 or 2 good days | j
3 or 4 good days | |
nearly every day is good | |
every day is good | [
8) If you have a wheeze, is it worse in the morning?
Please tick (Q one 
No □
Yes j |
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Part 2
Section 1
How would you best describe your chest condition?
Please tick (/) one 
The most important problem I have
Causes me quite a lot of problems
Causes me a few problems
Causes no problem
If you have ever had paid employment:
Please
My chest trouble made me stop work altogether 
My chest trouble interferes with my work or made me change my work
My chest trouble does not affect my work
Section 2
Questions about what activities make you feel breathless these days?
Please tick in each box that
applies to vou these davs: 
True False
Sitting or lying still Q Q
Getting washed or dressed □ □
Walking around the home □ □
Walking outside on the level □ □
Walking up a flight of stairs □ □
Walking up hills □ □
Playing sports or games □ □
Section 3
Some more questions about your cough and breathlessness these days?
Please tick jn each box that
applies to vou these davs: 
True False
My cough hurts Q
My cough makes me tired □ □
I am breathless when I talk □ □
I am breathless when I bend over □ □
My cough or breathing disturbs my sleep □ □
I get exhausted easily □ □
Section 4
Questions about other effects that your chest trouble may have on you these days?
Please tick (S) in each box that 
applies to you these days:
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□ 
□ 
Q
l □ □ 
□ 
□.
True False
My cough or breathing is embarrassing in public □ □
My chest trouble is a nuisance to my family or friends □ □
1 get afraid or panic when 1 cannot get my breath □ □
1 feel that i am not in control of my chest problem □ i i
1 do not expect to get my chest any better □ □
1 have become frail or invalid because of my chest □ n
Exercise is not safe for me □ □
Everything seems too much of an effort □ □
Section 5
Questions about medication, if you are receiving no medication go straight to section 6.
Please tick in each box that
aoDlies to vou these davs: 
True False
My medication does not help me very much Q Q
1 get embarrassed using my medication in public □ □
1 have unpleasant side effects from my medication □ □
My medication interferes with my life a lot □ □
Section 6
These are questions about how your activities might be affected by your breathing.
Please tick in each box that
aoolies to vou these davs: 
True False
1 take a long time to get washed or dressed \^} []^]
1 cannot take a bath or shower, or 1 take a long time □ □
1 walk slower than other people, or 1 stop for rests □ □
Jobs such as housework take a long time, or 1 have
to stop for rests
□ □
If 1 walk up one flight of stairs, 1 have to go slowly or
stop
□ □
If 1 hurry or walk fast, 1 have to stop or slow down □ □
My breathing makes it difficult to do things such as 
walk up hills, carry things up stairs, light gardening 
such as weeding, dance, play bowls or play golf
□ □
My breathing makes it difficult to do things such as 
carry heavy loads, dig the garden or shovel snow, 
jog or walk at 5 miles per hour, play tennis or swim
□ □
My breathing makes it difficult to do things such as □ □
Very heavy manual work, run, cycle, swim fast or
play competitive sport
Section 7
We would like to know how your chest usually affects your life.
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Please tick ) in each box that 
applies to you because of your 
chest trouble:
True False
I cannot play sports or games 
I cannot go out for entertainment or recreation 
I cannot go out of the house to do the shopping 
I cannot do housework 
I cannot move far from my bed or chair
Here is a list of other activities that your chest trouble may prevent you doing. (You don’t have to 
tick these, they are just to remind you of ways in which your breathlessness may affect you):
Going for walks or walking the dog 
Doing things at home or in the garden 
Sexual intercourse
Going out to church, pub, club or place of entertainment 
Going out in bad weather or smoky rooms 
Visiting family or friends or playing with children
Please write any other important activities that your chest trouble may stop you doing:
Now would you tick in the box (one only) which you think best describes how your chest affects you:
Please tick (Y) one
It does not stop me doing anything I would like to do 
It stops me doing one or two things I would like to do 
It stops me doing most of the things I would like to do 
It stops me doing everything I would like to do
Thank you for filling in this 
questionnaire. Before you 
finish would you please check 
that you have answered all 
the questions.
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SF 36 Health Survey
Instructions:
This survey asks for your views about your health. This information will keep track of 
how you feel and how well you are able to do your usual activities.
Answer every question by marking the answer as indicated. If you are unsure about 
how to answer a question please give the best answer you can.
1. In general, would you say your health is: {tick one)
Excellent.......................................... ........ □ 1
Very Good........................................ ........□ 2
Good............................................... .........n 3
Fair................................................. ......... n 4
Poor................................................ ......... □ 5
2. Comnared to one year ago, how would you rate your health in general
now?
{tick one)
Much better than one year ago................ .........n 1
Somewhat better than one year ago.......... .........n 2
About the same as one year ago.............. ........ n 3
Somewhat worse than one year ago.......... .........□ 4
Much worse than one year ago................ .........n 5
3. The following questions are about activities you might do during a typical 
dav. Does vour health now limit you in these activities? If so, how much?
{tick one number on each line)
Activities Yes, Yes, No,
limited a limited a not limited
lot little at all
a. Vigorous activities, such as running, 
lifting heavy objects, participating in 
strenuous sports................................. ...□ 1 n 2 n 3
b. Moderate activities, such as moving a table 
pushing a vacuum cleaner, bowling or 
playing golf....................................... ...n 1 n 2 n 3
c. Lifting or carrying groceries.................. ....□ i n 2 n 3
d. Climbing several flights of stairs............ ....n i □ 2 n 3
e. Climbing one flight of stairs.................. ....n i n 2 n 3
f. Bending, kneeling, or stooping............... ....n i n 2 n 3
g. Walking more than one mile...................... .....n i n 2 □ 3
h. Walking half a mile..................................... ....□ i n 2 □ 3
i. Walking one hundred yards....................... .... n 1 □ 2 □ 3
j* Bathing or dressing yourself........................ ....n i n 2 □ 3
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4. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical 
health?
{tick one number on each line) 
YES NO
a. Cut down on the amount of time you spend on work
or other activities...........................................................ni U2
b. Accomplished less than you would like........................ □ 1 □ 2
c. Were limited in the kind of work or other activities.......□ 1 □ 2
d. Had difficulty performing the work or other activities
(for example it took extra effort).................................... □ 1 □ 2
5. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)?
{tick one number on each line) 
YES NO
a. Cut down the amount of time you spend on work
or other activities...........................................................□ 1 □ 2
b. Accomplished less than you would like........................□ 1 □ 2
c. Didn’t do work or other activities as carefully as usual. □ 1 0 2
6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbours, or groups?
{tick one)
Not at all.................................................................................................. □ 1
Slightly.....................................................................................................□ 2
Moderately...............................................................................................n 3
Quite a bit................................................................................................ □ 4
Extremely.................................................................................................□ 5
7. How much bodily pain have you had during the past 4 weeks? {tick one)
None........................................................................................................□ 1
Very mild.................................................................................................... □ 2
Mild............................................................................................................□ 3
Moderate.................................................................................................... □ 4
Severe.........................................................................................................□ 5
Very severe................................................................................................. □ 6
8. During the past 4 weeks,, how much did pain interfere with your normal 
work (including both work outside the home and housework)? {tick one)
Not at all.....................................................................................................D 1
A little bit................................................................................................... □ 2
Moderately.................................................................................................n 3
Quite a bit................................................................................................... □ 4
Extremely................................................................................................... □ 5
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9. These questions are about how you feel and how things have been with 
you during the past 4 weeks. For each question, please give one answer 
that comes closest to the way you have been feeling. How much of the time 
during the past 4 weeks:
(tick one number on each line)
All of 
the time
Most of 
the time
A good bit 
of the time
Some of 
the time
A little of 
the time
None of 
the time
a. Did you feel full of life? □ 1 □ 2 □ 3 □ 4 n 5 □ 6
b. Have you been a very nervous 
person?
n 1 n 2 n 3 □ 4 n 5 n 6
c. Have you felt so down in the dumps 
that nothing could cheer you up?
□ i n 2 □ 3 n 4 n 5 n 6
d. Have you felt calm and peaceful? □ i □ 2 n 3 n 4 □ 5 n 6
e. Did you have a lot of energy? n i n 2 n 3 n 4 n 5 □ 6
f. Have you felt downhearted and low? n i n 2 n 3 □ 4 n 5 n 6
g. Did you feel worn out? □ i □ 2 n 3 n 4 ' 1 5 n 6
h. Have you been a happy person? n i □ 2 n 3 n 4 n 5 n 6
i. Did you feel tired? □ i □ 2 n 3 □ 4 n 5 n 6
10. During the past 4 weeks, how much of the time has your physical health 
or emotional problems interfered with your social activities (like visiting
with friends, relatives, etc.)? {tick one)
All of the time.............................................................................□ 1
Most of the time..........................................................................□ 2
Some of the time.......................................................................... □ 3
A little of the time.......................................................................□ 4
None of the time.......................................................................... □ 5
11. How TRUE or FALSE is each of the following statements for you?
{tick one number on each 
line)________ ______
Definitely
true
Mostly
true
Don’t
know
Mostly
false
Definitely
false
a. I seem to get ill more easily than other people □ 1 □ 2 □ 3 n 4 n 5
b. I am as healthy as anybody I know □ 1 n 2 n 3 n 4 n 5
c. I expect my health to get worse □ 1 n 2 n 3 n 4 n 5
d. My health is excellent n i n 2 □ 3 D 4 n 5
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Impact of weight on quality of life questionnaire-iite version (IWQOL-LITE)
Please answer the following statements by circling the number that best applies to you 
in the past week. Be as honest as possible. There are no right or wrong answers.
Physical function Always
true
Usually
true
Sometimes
true
Rarely
true
Never
true
1. Because of my weight I have trouble picking 
up objects.
n i n 2 □ 3 n 4 n 5
2. Because of my weight I have trouble tying my 
shoelaces.
□ i □ 2 n 3 n 4 n 5
3. Because of my weight 1 have difficulty getting 
up from chairs.
n i n 2 □ 3 □ 4 n 5
4. Because of my weight I have trouble using 
stairs.
n i n 2 □ 3 n 4 n 5
5. Because of my weight I have difficulty putting 
on or taking off my clothes.
n i a 2 □ 3 □ 4 □ 5
6. Because of my weight I have trouble with 
mobility (getting around)
□ i □ 2 n 3 n 4 n 5
7. Because of my weight I have trouble crossing 
my legs.
n i n 2 n 3 n 4 n 5
8.1 feel short of breath with only mild exertion 
(e.g. climbing a single flight of stairs).
n i n 2 n 3 n 4 □ 5
9.1 am troubled by painful or stiff joints. □ i n 2 □ 3 n 4 □ 5
10. My ankles and lower legs are swollen at the 
end of the day.
□ i n 2 n 3 n 4 □ 5
11.1 am worried about my health. n 1 n 2 n 3 n 4 n 5
Self-esteem Always
true
Usually
true
Sometimes
true
Rarely
true
Never
true
1. Because of my weight I am self-conscious. □ 1 n 2 n 3 n 4 n 5
2. Because of my weight my self-esteem is not 
what it could be.
n i n 2 n 3 n 4 n 5
3. Because of my weight I feel unsure of myself. n i n 2 □ 3 n 4 n 5
4. Because of my weight I don’t like myself. n i n 2 n 3 n 4 n 5
5 Because of my weight I am afraid of being 
rejected.
□ i n 2 n 3 n 4 n 5
6. Because of my weight I avoid looking in 
mirrors or seeing myself in photographs.
□ 1 n 2 n 3 n 4 n 5
7. Because of my weight I am embarrassed to be 
seen in public places.
n i n 2 n 3 n 4 n 5
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Impact of weight on quality of life questionnaire-lite version (IWOOL-LITE)
Sexual Life Always
true
Usually
true
Sometimes
true
Rarely
true
Never
true
1. Because of my weight I do not enjoy sexual 
activity.
□ 1 n 2 n 3 □ 4 n 5
2. Because of my weight I have little or no sexual 
desire.
n i n 2 □ 3 n 4 n 5
3. Because of my weight I have difficulty with 
sexual performance.
n 1 □ 2 □ 3 n 4 □ 5
4. Because of my weight I avoid sexual 
encounters whenever possible.
□ 1 □ 2 n 3 □ 4 □ 5
Public Distress Always
true
Usually
true
Sometimes
true
Rarely
true
Never
true
1. Because of my weight I experience ridicule, 
teasing, or unwanted attention.
□ 1 n 2 n 3 □ 4 □ 5
2. Because of my weight I worry about fitting 
into seats in public places (e.g. theatres, cinemas, 
restaurants, cars, or aeroplanes).
n i n 2 n 3 □ 4 n 5
3. Because of my weight I worry about fitting 
through aisles or turnstiles.
n i n 2 n 3 n 4 □ 5
4. Because of weight I worry about finding chairs 
that are strong enough to hold my weight.
n i n 2 n 3 n 4 n 5
5. Because of my weight I experience 
discrimination by others.
n i □ 2 □ 3 n 4 n 5
Work (Note: for those not in paid employment, 
answer with respect to your daily activities.)
Always
true
Usually
true
Sometimes
true
Rarely
true
Never true
1. Because of my weight I have trouble getting 
things done or carrying out my responsibilities.
n i n 2 □ 3 n 4 n 5
2. Because of my weight I am less productive 
than I could be.
n i n 2 □ 3 n 4 □ 5
3. Because of my weight I don’t receive 
appropriate pay rises, promotions or recognition 
at work.
n i □ 2 □ 3 n 4 n 5
4. Because of my weight I am afraid to go for 
job interviews.
□ i □ 2 □ 3 n 4 n 5
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Impact of weight on quality of life questioimaire-lite version (IWQOL-LITE)
Food Craving
A craving is defined as an intense desire for a 
particular food that is difficult to resist.
Over the past week,
Always Often Sometimes Rarely Never
1. How often did you experience a craving for 
any of the following foods: high fat foods (such 
as fried foods, sausages), sweet things (such as 
chocolate, ice cream, biscuits) or carbohydrates 
(such as pasta, potatoes, bread)?
□ 1 □ 2 n 3 □ 4 □ 5
2. How often did you feel intense hunger no 
matter what or how much you ate?
□ 1 □ 2 n 3 n 4 n 5
3. How often were you able to eat your favorite 
foods and still feel in control of your eating?
□ 1 □ 2 n 3 n 4 n 5
4. How often did you experience an inability to 
stop eating once you started, even if you felt 
full?
□ 1 n 2 n 3 n 4 n 5
Sleep
Over the past week,
Every
day
5-6 Days 3-4 Days 1-2 Days No days
1. How often did you wake up feeling fresh and 
rested?
n 1 n 2 □ 3 n 4 □ 5
2. How often did you experience difficulty 
falling asleep?
□ i □ 2 n 3 n 4 n 5
3. How often did you experience difficulty 
staying asleep (other than for going to the 
toilet)?
□ i n 2 n 3 n 4 n 5
4. How often were you satisfied with the quality 
of your sleep?
□ i n 2 n 3 □ 4 n 5
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Appendix B
Additional material for HRQoL chapter
Differences between dietician and control groups for SF36, SGRQ and
IWQOL-Lite questionnaires.
Baseline 3 months 6 months
Rhys Functioning 3.037 (0.088) 0.101 (0.753) 0.233 (0.632)
Role Physical 6.665 (0.013)* 0.313 (0.580) 0.222 (0.640)
Bodily Pain 1.812 (0.184) 0.800 (0.378) 0.236 (0.630)
General Health 2.939 (0.093) 5.284 (0.028)* 2.077 (0.158)
Vitality 6.123 (0.017)* 0.191 (0.665) 0.391 (0.536)
Social functioning 7.393 (0.009)* 0.071 (0.791) 1.009 (0.322)
Role Emotional 0.238 (0.628) 0.077 (0.783) 0.492 (0.488)
Mental Health 2.538 (0.118) 5.842 (0.022)* 1.769 (0.192)
Physical Health 
summary
7.202 (0.010)* 0.465 (0.500) 0.225 (0.638)
Mental Health 
Summary
4.712 (0.035)* 1.213 (0.279) 1.509 (0.227)
Total 6.383 (0.015)* 0.496 (0.486) 1.148 (0.291)
Values are F statisttic & (p values) when comparing between groups for each
questionnaire domain. ANOVA 
*p<0.05
Table 42. Comparison of means (ANOVA) at each visit between dietician 
and control groups for each domain for the SF-36 HRQoL questionnaire
With Bonferroni correction (adjustment of alpha level: p<0.00625) there were
no significant differences seen.
Baseline 3 months 6 months
Symptoms 2.416(0.127) 1.843 (0.184) 0.414 (0.524)
Activity 3.340 (0.074) 0.274 (0.604) 2.323 (0.136)
Impacts 2.178 (0.146) 2.411 (0.130) 0.711 (0.405)
Total 3.597 (0.064) 1.724 (0.198) 1.352 (0.253)
Values are F statistic & (p values) when comparing between groups for each
questionnaire domain. ANOVA
*p<0.05
Table 43. Comparison of means (ANOVA) at each visit between dietician 
and control groups for each domain for the SGRQ HRQoL questionnaire
There were no significant differences between groups for any scores of any
domains for the SGRQ questionnaire.
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Baseline 3 months 4 months
Physical Function 5.208 (0.027)* 0.410(0.526) 0.074 (0.788)
Self Esteem 2.278 (0.138) 0.144 (0.707) 0.122 (0.729)
Sexual Life 0.001 (0.974) 0.209 (0.651) 1.024 (0.319)
Public Distress 0.782 (0.381) 0.001 (0.974) 0.445 (0.509)
Work 4.036 (0.050) 0.119 (0.733) 0.147 (0.704)
Total 3.228 (0.079) 0.093 (0.762) 0.003 (0.954)
Values are F statisltic & (p values) when comparing between groups for each
questionnaire domain. ANOVA 
*p<0.05
Table 44. Comparison of means (ANOVA) at each visit between dietician 
and control groups for each domain for the IWQOL-Lite HRQoL 
questionnaire
HRQoL Scores Change from baseline
SF 36
3 months 
Dietician group
3 months 
Control group
6 months 
Dietician 
group
6 months 
Control group
Phys
Functioning
10.2(12.9) 1.1 (14.3) 13.2 (14.1) 5.9(12.8)
Role Physical 37.5 (39.3)* -1.8(38.6)* 28.4 (47.7) 1.6 (35.9)
Bodily Pain 2(26.1) -3.1 (18.7) 4(25) 2.8(17.7)
General Health 1.4(15.3) 3.5(14.1) 6.6(16.7) 3.2(12.1)
Vitality 10.8 (13.4)* -1.1 (17.8)* 11.8(16.7) 1.9(12.5)
Social
functioning
18(23.7)* -3.6 (23.6)* 10.3(22.9) 1.5(17)
Role Emotional 13.4 (36.6) 14.4 (56.5) 6 (40.7) 16.7(51.6)
Mental Health -3.2(13.6) 4.9 (14.6) 0.4 (15.1) -0.3(14.9)
Physical Health 
summary
12.5 (13.3)* -0.2(14.1)* 12.9(16.8) 3(11.7)
Mental Health 
Summary
8 (13) 3.5 (17.5) 6.9 (14.3) 4.6(16.4)
Total 11.3(13.2) 1.6(16.7) 8.2 (19.2) 4.1 (13.9)
* Significant correlation p<0.05. With Bonferroni adjustment these were no 
longer significant
Table 45. Change in domain score from baseline for dietician and 
control group at 3 and 6 months for the SF-36 HRQoL questionnaire
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3 months 
Dietician group
3 months 
Control group
6 months
Dietician
group
6 months 
Control group
Symptoms -8.2 (11.2)* 0.7 (10.4)* -11.3 (10.5) -2.7 (21.2)
Activity -8.9(11.7) -2.3 (9.1) -9 (11.4) -7.7 (12.3)
Impacts -6.5(11) -4.8 (9.7) -2.9(11.8) -4.1 (14.5)
Total -7.5 (8.7) -3 (8.2) -6.1 (9.5) -4.9(12)
* Significant correlation p<0.05. With Bonferroni adjustment this was no longer 
significant.
Table 46. Change in domain score from baseline for dietician and 
control group at 3 and 6 months for the SGRQ HRQoL questionnaire
3 months 
Dietician group
3 months 
Control group
6 months
Dietician
group
6 months 
Control group
Physical
Function
7.8 (8.5) 1.3(15.8) 8.2 (14.9) 0.3 (14)
Self Esteem 6.8(19.9) 0.5(16.6) 8.6(17.5) 3.6 (21.7)
Sexual Life 5.6 (14.3) 9.8(18.3) 8.2 (17.2) 2.5 (15.3)
Public Distress 3.6(16.5) 1.8(17.5) 7.3(14.5) 5(12)
Work 7.2(11.7) 4 (14.4) 7.7 (16.4) 3.3(18.9)
Total 7.3 (8.2) 3.4(14.6) 8.7(11.2) 2.3(11.9)
* Significant correlation p<0.05. With Bonferroni adjustment this was no longer 
significant.
Table 47. Change in domain score from baseline for dietician and 
control group at 3 and 6 months for the IWQOL-Lite HRQoL 
questionnaire
Correlations between BMI and HRQoL
Baseline
Ail
subjects
Baseline
Dietician
group
Baseline
Control
group
3 months
All
subjects
3 months 
Dietician 
group
3 months
Control
group
6 months
All
subjects
6 months 
Dietician 
group
6 months
Control
group
Phys
Functioning
R= -0.215
P= 0.129
R= -0.236 
P= 0.246
R= -0.159
P= 0.447
R= -0,244
P= 0.165
R= -0.102
P= 0.669
R= -0.410
P= 0.146
R= -0.140 
P= 0.400
R= 0.124
P= 0.581
R=-0.535* 
P= 0.033
Role Physical R= -0.015
P= 0.917
R= 0.021 
P=0.917
R= 0.015
P= 0.941
R= -0.317
P= 0.068
R= -0,090
P= 0.706
R= -0.553* 
P= 0.040
R=-0,080 
P= 0.635
R=0.233
P= 0.296
R= -0.693* 
P= 0.003
Bodily Pain R= -0.232
P= 0.101
R= -0.248 
P= 0.222
R= -0.187
P= 0.371
R= -0.192
P= 0.276
R= 0.049
P= 0.838
R= -0.545* 
P= 0.044
R= -0.251
P= 0.128
R=-0.016
P= 0.944
R= -0.609* 
P= 0.012
Genera! Health R=-0,285* 
P= 0.043
R= -0.168 
P= 0.411
R= -0.387
P= 0.056
R= -0.117
P= 0.510
R= 0.044
P= 0.854
R= -0.599* 
P= 0.024
R= -0.093
P= 0.578
R= -0.002
P= 0.992
R= -0.299
P= 0.260
Vitality R=-0.079
P= 0.581
R= -0.090 
P=0.662
R= -0.003
P= 0.988
R= -0.271
P= 0.121
R= -0.226
P= 0.339
R= -0.348
P= 0.223
R= -0.233
P= 0.160
R= -0.138
P= 0.540
R= -0.382
P= 0.144
Social
functioning
R=-0.116 
P=0.417
R= -0.194 
P= 0.343
R= 0.054
P= 0.798
R=-0.335
P= 0.053
R=-0.083
P= 0.728
R=-0.695* 
P= 0.006
R= -0.125
P= 0.454
R= 0.077
P= 0.735
R= -0.554* 
P= 0.026
Role Emotional R= 0.004
P= 0.979
R= 0.090
P= 0.661
R= -0.075
P= 0.721
R= -0.338
P= 0.051
R= -0.090 
P=0.706
R= -0.677* 
P= 0.008
R= 0.009
P= 0.958
R= 0.291
P= 0.189
R= -0.527* 
P= 0.036
Mental Health R=-0.175
P= 0.221
R= -0.249 
P= 0.219
R= -0.047
P= 0.823
R= -0.145 
P= 0.415
R= -0.142
P= 0.550
R= -0.215
P= 0.460
R= -0.249
P= 0.131
R=-0.127
P= 0.575
R= -0,426
P= 0.100
Physical Health 
summary
R= -0.184
P= 0.196
R=-0.166 
P= 0.417
R= -0.157
P= 0.454
R= -0.319
P= 0.066
R=-0.092 
P=0.701
R= -0.601* 
P= 0.023
R= -0.195 
P= 0.240
R= 0.087
P= 0,702
R= -0.629* 
P= 0.009
Mental Health 
Summary
R=-0.145
P= 0.308
R=-0.117 
P= 0.570
R= -0.133
P= 0.526
R= -0.319* 
P= 0.048
R= -0.128
P= 0.590
R= -0.682* 
P= 0.007
R= -0,144 
P= 0.389
R= 0.089
P= 0.693
R= -0.519* 
P= 0.039
Total R= -0.158
P= 0.267
R=-0.150 
P= 0.466
R= -0.119
P= 0.570
R= -0.358* 
P= 0.038
R= -0.113
P= 0.637
R= -0,666* 
P= 0.009
R= -0,205 
P= 0.217
R= 0.063
P= 0,782
R= -0.613* 
P= 0.012
* Significant correlation p<0.05
Table 48. Correlations r(p) between BMI and all domains for all subjects, 
dietician and control groups at each visit for the SF-36 HRQoL 
questionnaire
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Baseline
All
subiects
Baseline
Dietician
group
Baseline
Control
group
3 months
All
subiects
3 months 
Dietician 
group
3 months 
Control 
group 
6 months
All
subiects
6 months 
Dietician 
group
6 months
Control
group
Symptoms R=-0.066 
P=0.645
R= -0.200
P= 0.326
R= 0.014
P= 0.947
R= 0.105
P= 0.548
R= -0.269
P= 0.238
R= 0.545*
P= 0.044
R= 0.210
P= 0.206
R=-0.073
P= 0.0748
R= -0.640* 
P= 0.008
Activity R= 0.111
P= 0.436
R= 0.204
P= 0.317
R= -0.009
P= 0.966
R= 0.263
P= 0.127
R= 0.176
P= 0.444
R= 0.351
P= 0.219
R= 0.290
P= 0.077
R= 0.160
P= 0.476
R= 0.476
P= 0.062
Impacts R= -0.111
P= 0.437
R= -0.182
P= 0.373
R= -0.069
P= 0.743
R= 0.096
P= 0.583
R= 0.029
P= 0.900
R= 0.232
P= 0.426
R= 0.178
P= 0.284
R= 0.085
P= 0.707
R= 0.331
P= 0.211
Total R= -0.031
P= 0.827
R=-0.079
P= 0.703
R= -0.035
P= 0.869
R= 0.185
P= 0.287
R= 0.029
P= 0.902
R= 0.386
P= 0,173
R= 0.248
P= 0.133
R= 0.095
P= 0,676
R= 0.496
P= 0,051
* Significant correlation p<0.05
Table 49. Correlations r(p) between BMI and all domains for all subjects, 
dietician and control groups at each visit for the SGRQ HRQoL 
questionnaire
Visit 2
All
subiects
Visit 2
Dietician
group
Visit 2
Control
group
Visit 3
All
subjects
Visit 3
Dietician
group
Visit 3
Control
group
Visit 4
All
subiects
Visit 4
Dietician
group
Visit 4
Control
group
Physical
Function
R= -0.437* 
P= 0.001
R“ -0.419* 
P= 0.033
R= -0.448* 
P= 0.025
R= -0.538* 
P= 0,001
R=-0.426
P= 0,061
R= -0.680* 
P= 0,011
R= -0.482* 
P= 0,002
R= -0.413
P= 0,056
R=- 0.646* 
P= 0.009
Self Esteem R= -0.282* 
P= 0.045
R=-0.154
P= 0.453
R= -0.397* 
P= 0.049
R= -0.381* 
P= 0.029
R=-0.336
P= 0.147
R= -0.474
P= 0.101
R= -0.359* 
P= 0.029
R= -0.304
P= 0.170
R= -0.475
P= 0.074
Sexual Life R= -0.175
P= 0.220
R= -0.092
P= 0.653
R= -0.255
P= 0.218
R= -0.235
P= 0.188
R=-0.209
P= 0.378
R= -0.265
P= 0.382
R= -0.246
P= 0.142
R= -0.165
P= 0.464
R= -0.457
P= 0.086
Public Distress R= -0.715* 
P= 0.000
R= -0.603 
P=0.01
R= -0.826* 
P= 0,000
R= -0.704* 
P= 0.000
R= -0.657* 
P= 0.002
R= -0.752* 
P= 0.003
R= -0.581* 
P= 0.000
R= -0.606* 
P= 0.003
R= -0.531* 
P= 0.042
Work R= -0.220
P= 0.121
R= 0.071
P= 0.732
R= -0.502* 
P= 0.011
R= -0.402* 
P= 0.020
R= -0.151
P= 0.524
R= -0.631* 
P= 0.021
R= -0.217
P= 0.196
R= 0.026
P= 0.910
R= -0.592* 
P= 0.020
Total R= -0.460* 
P= 0.001
R= -0.328
P= 0.102
R=-0.586* 
P= 0.002
R= -0.581* 
P= 0.000
R= -0.479* 
P= 0.033
R= -0.705* 
P= 0.007
R= -0.471* 
P= 0.003
R= -0.409
P= 0.059
R= -0.633* 
P= 0.011
* Significant correlation p<0,05
Table 50. Correlations r(p) between BMI and all domains for all subjects, 
dietician and control groups at each visit for the SGRQ HRQoL 
questionnaire
Correlations between change in weight and change in domain scores
between visits.
Baseline 
to 3 
months
All
subjects
Baseline 
to 3 
months 
Dietician 
group
Baseline to
3 months
Control
group
3 to 6 
months
All
subjects
3 to 6 
months 
Dietician 
group
3 to 6 
months 
Control 
group
Baseline 
to 6 
months
All
subiects
Baseline to
6 months 
Dietician 
group
Baseline 
to 6 
months 
Control 
group
Phys
Functioning
R=-0.310
P= 0.074
R=-0.116 
P= 0.625
R= -0.384
P= 0.175
R= -0.148
P= 0.435
R=-0.167
P= 0.508
R= -0.242
P= 0.449
R= -0.241
P= 0.145
R=-0.121
P= 0.593
R= -0.294
P= 0.268
Role Physical R= -0,217
P= 0.217
R= -0.096 
P= 0.687
R= -0.193
P= 0.508
R= -0.080
P= 0.673
R= 0.236
P= 0.345
R= -0.352
P= 0.262
R= 0.047
P= 0.780
R= 0.144
P= 0.524
R= 0.092
P= 0.735
Bodily Pain R=-0.155
P= 0.381
R= 0.002
P= 0.993
R= -0.325
P= 0.257
R= -0.231
P= 0.219
R= -0.320
P= 0,196
R= -0.249
P= 0.434
R= -0.102 
P= 0.542
R=-0.118
P= 0.600
R= -0.090
P= 0.741
General Health R= -0.224
P= 0.203
R= 0.137
P= 0.564
R= -0.607* 
P= 0.021
R= 0.081
P= 0.671
R= 0.380
P= 0.119
R= -0.144
P= 0.656
R= -0.020 
P= 0.904
R= 0.243
P= 0.276
R= -0.304
P= 0.253
Vitality R= -0.034
P~ 0.850
R= 0.353
P= 0.127
R= -0.145
P= 0.622
R= -0.211
P= 0.264
R= -0.108
P= 0.670
R= -0.347
P= 0,270
R= -0.010 
P=0.953
R= 0.281
P= 0.205
R= -0.213
P= 0.428
Social
functioning
R= -0.164
P= 0.354
R= -0.262 
P= 0.265
R= 0.047
P= 0.872
R= -0.027 
P= 0.886
R= 0.069
P= 0.786
R= -0.162
P= 0.615
R= -0,032 
P= 0.850
R= 0.068
P= 0.764
R= -0.060
P= 0.826
Role Emotional R= -0.070
P= 0.694
R= -0.112 
P= 0.639
R= -0.054
P= 0.854
R= 0.218
P= 0.248
R= 0.0270 
P= 0.278
R= 0.292
P= 0.357
R= 0.206
P= 0.215
R= 0.330
P= 0.134
R= 0.085
P= 0.753
Mental Health R= 0.016
P= 0.929
R- 0.108
P= 0.650
R=-0.162
P= 0.579
R= -0.133 
P= 0.484
R=-0.040
P= 0.876
R= -0.262
P= 0.411
R=-0.065 
P= 0.700
R= 0.022
P= 0.924
R=-0.143
P= 0.598
Physical Health 
summary
R= -0.282
P= 0.107
R= 0.025
P= 0.918
R= -0.420
P= 0.135
R= -0.178
P= 0.346
R= 0.081
P= 0.748
R= -0.524
P= 0.080
R= -0.050 
P= 0.764
R= 0.131
P= 0.560
R= -0.141
P= 0.602
Mental Health 
Summary
R= -0.151
P= 0.393
R= -0.044 
P= 0.852
R=-0.176
P= 0.548
R= 0.076
P= 0.689
R= 0.218
P= 0.385
R= -0.118
P= 0.714
R= 0.095
P= 0.569
R= 0.331
P= 0.133
R= -0.061
P= 0.824
Total R=-0.233
P= 0.184
R= -0.066 
P= 0.781
R= -0.261
P= 0.368
R= -0.044 
P= 0.816
R= 0.073
P= 0.774
R= -0.356
P= 0.256
R= 0.062
P= 0.713
R= 0.220
P= 0.326
R= -0.067
P= 0.806
* Significant correlation p<0.05
Table 51. Correlation r(p) of change in weight (Kg) and change in domain 
scores for all subjects, dietician and control groups between baseline to
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3 months, 3 to 6 months and baseline to 6 months for the SF-36 HRQoL 
questionnaire
Visit 3-2
All
subjects
Visit 3-2 
Dietician 
group
Visit 3-2 
Control 
group
Visit 4-3
All
subjects
Visit 4-3 
Dietician 
group
Visit 4-3 
Control 
sroup
Visit 4-2
All
subjects
Visit 4-2 
Dietician 
group
Visit 4-2 
Control 
group
Symptoms R= -0.090
P= 0.606
R= -0.300 
P= 0.187
R= -0.104
P= 0.723
R= 0.022
P= 0.905
R= -0.096
P= 0.696
R= 0.079
P= 0.806
R= 0.008
P= 0.962
R= -0.094
P= 0.679
R=-0.026
P= 0.925
Activity R= 0.058
P= 0.740
R= 0.001
P= 0.995
R= -0.005
P= 0.985
R= -0.052
P= 0.780
R= -0.036
P= 0.885
R= -0.010
P= 0.976
R= 0.114
P= 0.494
R= 0.049
P= 0.829
R= 0.172
P= 0.523
Impacts R= 0.151
P= 0.386
R= -0.151
P= 0.513
R= 0.431
P= 0.124
R=-0.106
P= 0.569
R= 0.152
P= 0.534
R= -0.250
P= 0.433
R= 0.123
P= 0.460
R= -0.057
P= 0.800
R= 0.281
P= 0.291
Total R= 0.108
P= 0.537
R= -0.162 
P= 0.482
R= 0.264
P= 0.362
R= -0.096
P= 0.609
R= 0.085
P= 0.730
R= -0.164
P= 0.611
R= 0.125
P= 0.456
R=-0.035
P= 0.877
R= 0.227
P= 0.398
* Significant correlation p<0.05
Table 52. Correlation r(p) of change in weight (Kg) and change in domain 
scores for all subjects, dietician and control groups between baseline to 
3 months, 3 to 6 months and baseline to 6 months for the SGRQ HRQoL 
questionnaire
Visit 3-2
All
subjects
Visit 3-2 
Dietician 
group
Visit 3-2 
Control 
group
Visit 4-3
All
subjects
Visit 4-3 
Dietician 
group
Visit 4-3 
Control 
group
Visit 4-2
All
subjects
Visit 4-2 
Dietician 
group
Visit 4-2 
Control 
group
Physical
Function
R= -0.399* 
P= 0.022
R=-0.213 
P= 0.367
R=-0.470
P= 0.105
R= 0.007
P= 0.972
R= -0.108
P= 0.671
R= 0.111
P= 0.746
R= -0.313 
P= 0.060
R=-0.344
P= 0.117
R= -0.240
P= 0.390
Self Esteem R=-0.511* 
P= 0,002
R= -0.383 
P= 0.096
R=-0.704* 
P= 0.007
R= -0,157
P= 0.416
R= 0.241
P= 0.335
R= -0.451
P= 0.164
R= -0.296 
P= 0.075
R=-0.101
P= 0.655
R= -0.435
P= 0.105
Sexuai Life R= -0,169 
P=0.347
R= -0.443 
P= 0.051
R=-0.014
P= 0.965
R= 0.244
P= 0.193
R= 0.111
P= 0.662
R= 0.342
P= 0.276
R= -0.286 
P= 0.086
R= -0.297
P= 0.179
R=-0.251
P= 0.366
Public Distress R= -0.237
P= 0.183
R= -0.090 
P= 0.707
R= -0.346
P= 0.247
R= 0.183
P= 0,343
R= 0.281
P= 0.258
R= 0.094
P= 0.784
R= -0.004 
P= 0.983
R= 0.104
P= 0.646
R= -0.108
P= 0.701
Work R= -0.332
P= 0.059
R= -0.030 
P= 0.899
R= -0.504
P= 0.079
R= 0,125
P= 0.517
R= 0.218 
P=0.385
R= 0.021
P= 0.950
R= 0.015
P= 0.928
R= 0.146
P= 0.516
R= -0.065
P= 0.819
Total R= -0,551* 
P= 0.001
R= -0,421
P= 0.065
R=-0.621* 
P= 0.024
R= 0.006
P= 0.975
R= 0.152
P= 0.548
R= -0.155
P= 0.650
R= -0.290 
P= 0.082
R= -0.170
P= 0.451
R= -0.359
P= 0.189
* Significant correlation p<0.05
Table 53. Correlation r(p) of change in weight (Kg) and change in domain 
scores for all subjects, dietician and control groups between baseline to 
3 months, 3 to 6 months and baseline to 6 months for the IWQOL-Lite 
HRQoL questionnaire
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Comparing groups that achieved >5% weight loss at 6 months with
those that did not
Baseline
>5%weight
loss
Baseline 
<5% weight 
loss
3 months 
>5% weight 
loss
3 months 
<5% weight 
loss
6 months 
>5% weight 
loss
6 months 
<5% weight 
loss
Rhys Functioning 61.8 (21.9) 61.6 (21.6) 70 (21.4) 65 (19.5) 73.4 (20.1) 70.7 (21.2)
Role Physical 62.5 (39.8) 52.3 (44.3) 91.7
(20.4)*
61.7
(45.2)*
75 (39.8) 72.7 (36.1)
Bodily Pain 74.7 (26.3) 60.6 (23.2) 72.5 (23.7) 64.7 (20.2) 80 (20.7)* 62.7
(25.3)*
General Health 49.1 (19.8) 51.7(19.5) 55.2 (21.4) 51.1 (209) 54 (22.4) 57.1 (21)
Vitality 51.3 (21.9) 40.9(21) 58 (23.4) 47 (19.3) 60.3 (18.8) 47.5(19.8)
Social functioning 74.4 (23.5) 67.8 (23.6) 85.9 (23.1) 70.1 (24.9) 81.4 (27.6) 74 (25.2)
Role Emotional 66.7 (43.9) 60.6 (39.4) 91.1
(26.6)*
62.3
(39.6)*
74.9 (39.5) 72.7 (43.2)
Mental Health 67.8 (19.10 66.9(15.3) 70.1 (20.5) 63.7 (21) 70.5 (21.2) 65.1 (20.1)
Physical Health 
summary
59.8 (20) 53.5 (20.7) 69.3 (16.7) 58 (17.9) 68.4(18.8) 62.2(19.4)
Mental Health 
Summary
61.8 (18.8) 57.7 (20.2) 72.1 (17.3) 58.7 (18.6) 68.2 (21.6) 63.3 (20.6)
Total 63.5 (19.5) 57.8 (20.9) 74.3
(17.2)*
60.7
(17.8)*
68.4 (22.8) 65.4 (19.5)
* significant difference p<0.05
Table 54. Mean (SD) scores for all domains for those that lost clinically 
significant weight and those that did not for each visit for the SF-36 
HRQoL questionnaire
Baseline
>5%weight
loss
Baseline 
<5% weight 
loss
3 months 
£5% weight 
loss
3 months 
<5% weight 
loss
6 months 
>5% weight 
loss
6 months 
<5% weight 
loss
Symptoms 56.2 (21.7) 66(18) 51.8(19.4) 59.2 (18.6) 50.6 (18.7) 56.9(19.6)
Activity 48.5 (24.2) 51.6 (19) 39.8 (23.5) 48.6 (17.1) 39.2 (23.4) 43.7 (20.2)
Impacts 26 (15.3) 33 (16.5) 20 (12.6) 28.5 (16) 21.9(14.6) 30 (20.9)
Total 37.8 (15.8) 44.1 (15.4) 31.3 (14.1) 39.8 (15) 31.9(15.2) 38.7 (18.7)
* significant difference p<0.05
Table 55. Mean (SD) scores for all domains for those that lost clinically 
significant weight and those that did not for each visit for the SGRQ 
HRQoL questionnaire
Visit 2
>5%weight
loss
Visit 2 
<5% weight 
loss
Visit 3 
£5% weight 
loss
Visit 3 
<5% weight 
loss
Visit 4 
>5% weight 
loss
Visit 4 
<5% weight 
loss
Physical Function 65.5 (24) 65 (19.1) 71.6 (21.6) 65.3 (17) 74.3 (19.2) 65.6 (20.6)
Self Esteem 50.4 (28.2) 54 (33) 62 (25) 48.2 (25.1) 61.4 (26.9) 55.1 (28.5)
Sexual Life 72.3 (26.8) 61.6 (32) 81.3 (25.9) 62.9 (26.6) 82.8 (25.4) 64 (29.8)
Public Distress 73.8 (27.5) 76.1 (24.1) 81.7 (21.9) 70 (26.1) 81.3 (24.4) 80.5 (24)
Work 85.2 (17.4) 74.4 (23.8) 90.8
(12.7)*
73.8
(17.4)*
90.6 (15.8) 79.5(21.8)
Total 66.8 (20.3) 64 (22.5) 74.8 (17.2) 63 (17) 75.7 (17.3) 66.6 (22.4)
* significant difference p<0.05
Table 56. Mean (SD) scores for all domains for those that lost clinically 
significant weight and those that did not for each visit for the IWQOL- 
Lite HRQoL questionnaire
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Baseline to 3 
months 
>5%weight 
loss
Baseline to 3 
months 
<5% weight 
loss
Baseline to 6 
months 
>5%weight 
loss
Baseline to 6 
months 
<5% weight 
loss
Rhys
Functioning
8.3 (10.3) 5.7(17.9) 11.6(13.5) 9.1 (14.4)
Role Physical 26.7 (32) 16.7 (45.9) 12.5 (50.8) 20.5 (40.6
Bodily Pain -3.1 (18.5) 2.2 (21.2) 5.3 (25.6) 2.1 (19.5)
General Health 5.7 (12) 0.8(16.9) 4.9(12.8) 5.4 (16.5)
Vitality 5.3(10.6) 7.3(14.6) 9.1 (14.7) 6.6 (16.6)
Social
functioning
11.6 (18.5) 6.5(22.4) 7.1 (20.3) 6.2 (21.6)
Role Emotional 26.7 (38.3) 11.2 (46.6) 8.3 (46.4) 12.1 (45.5)
Mental Health 0.3 (9.7) -0.3(16.4) 2.8(15.6) -1.8(14.4)
Physical Health 
summary
8.6 (7.2) 6.7 (16.5) 8.6(16.6) 8.8 (15)
Mental Health 
Summary
10 (9) 4.9(15.3) 6.4 (14.5) 5.6(15.8)
Total 10.2 (6.7) 6.3(16.5) 4.9(19.2) 7.5(15.7)
* significant difference p<0.05
Table 57. Change in domain score mean (sd) from baseline to 3 and 6 
months for the SF-36 HRQoL questionnaire comparison of dietician and 
control groups.
Baseline to 3 
months 
>5%weight 
loss
Baseline to 3 
months 
<5% weight 
loss
Baseline to 6 
months 
>5% weight 
loss
Baseline to 6 
months 
<5% weight 
loss
Symptoms -4.5(10) -6.5(12.4) -5.6(12.1) -9.2 (18.9)
Activity -9.1 (7.6) -5.9(13.1) -9.2 (12.7) -7.9(13.1)
Impacts -6.4 (9.3) -6.1 (11.2) -4(11.4) -2.9 (14)
Total -6.9 (6.2) -6 (9.9) -5.9 (10.3) -5.4(10.8)
* significant correlation p<0.05
Table 58. Change in domain score mean (sd) from baseline to 3 and 6 
months for the SGRQ HRQoL questionnaire comparison of dietician and 
control groups
275
Baseline to 3 
months 
>5%weight 
loss
Baseline to 3 
months 
<5% weight 
loss
Baseline to 6 
months 
>5%weight 
loss
Baseline to 6 
months 
<5% weight 
loss
Physical
Function
5.6 (6.8) 5.1 (15.9) 8.8 (15.4) 2.1 (14.1)
Self Esteem 8.6(12.9) -0.9(21.9) 10.9 (17.6) 3.2(20.1)
Sexual Life 6.3 (10.6) 9.8(19.2) 10.5(15.6) 2.4(16.6)
Public Distress 4.3(16.4) 0.6(16.5) 7.5(15.6) 5.5(11.7)
Work 4.2(10.2) 7(15.1) 5.5(14.9) 6.3 (19.3)
Total 5.9 (6.5) 5.3 (14) 8.9(11.4) 3.9 (11.9)
* significant corre ation p<0.05
Table 59. Change in domain score mean (sd) from baseline to 3 and 6 
months for the IWQOL-Lite HRQoL questionnaire comparison of 
dietician and control groups
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Exhaled Nitric oxide vs HRQoL scores
Questionnaire Baseline 3 months 6 months
SF36
FeNO 50ml Alveolar
Nitric oxide
Bronchial 
Nitric oxide
FeNO 50ml Alveolar
Nitric oxide
Bronchial 
Nitric oxide
FeNO 50ml Alveolar
Nitric oxide
Bronchia! 
Nitric oxide
Phys Functioning R=-0.252
P= 0.084
R= -134
P= 0.415
R= -0.225
P= 0.169
R= -0.269
P= 0.143
R= 0.038
P= 0.846
R= -0.417*
P= 0.027
R= -0.023
P= 0.894
R= 0.127
P= 0.503
R= -0.041
P= 0.828
Role Physical R= 0.075
P= 0.611
R= -0.037
P= 0.825
R= 0.069
P= 0.675
R=-0.161
P= 0.388
R= -0.119
P= 0.546
R= -0.182
P= 0.355
R= 0.014
P= 0.936
R= 0.055
P= 0.774
R= 0.070
P= 0.714
Bodily Pain R=-0.089
P= 0.548
R=-0.201
P= 0.221
R= -0.088
P= 0.594
R= - 0.196
P= 0.291
R= -0.337
P= 0.080
R= -0.249
P= 0.201
R= -0.251
P= 0.141
R= 0.128
P= 0.500
R= -0.276
P= 0.139
General Health R= -0.127 
P=0.391
R= 0.115
P= 0.484
R= -0.098
P= 0.551
R= -0.065
P= 0.728
R= -0.160
P= 0.416
R= -0.186
P= 0.344
R= 0.095
P= 0.583
R= -0.049
P= 0.795
R= 0.138
P= 0,466
Vitality R= -0.144
P= 0.328
R= -0.114
P= 0.489
R= -0.054
P= 0.743
R= -0.267
P= 0.147
R= 0.074
P= 0.709
R= -0.348
P= 0.070
R= 0,047
P= 0.786
R= 0.213
P= 0.258
R= 0.036
P= 0.850
Social functioning R= -0.286*
P= 0.049
R=-0.129
P= 0,433
R= -0.234
P= 0,151
R= -0.212
P= 0,253
R= 0.141
P= 0.475
R= -0.300
P= 0.122
R= 0.028
P= 0.872
R= 0.174
P= 0.357
R= -0.029
P= 0.877
Role Emotional R= -0.039
P= 0.791
R= 0.079
P= 0.634
R= -0.054
P= 0.743
R=-0.043
P= 0.817
R= -0.091
P= 0.645
R= -0.050
P= 0.802
R= 0.020
P= 0.906
R= 0.229
P= 0.223
R= -0.065
P= 0.734
Mental Health R= -0.176 
P=0,232
R= -0.010
P= 0.952
R= -0.184
P= 0.262
R=-0.059
P= 0.753
R= 0.124
P= 0.528
R= -0.202
P= 0.302
R= 0.169
P= 0.324
R= 0.206
P= 0.274
R= 0.176
P= 0.351
Physical Health summary R= -0,100 
P=0.498
R= -0.093
P= 0.575
R=-0.074
P= 0.654
R= -0,247
P= 0.181
R= -0.149
P= 0.450
R= -0.355
P= 0.064
R= -0.033
P= 0.851
R= 0.118
P= 0.536
R= -0.016
P= 0.932
Mental Health Summary R= -0.181
P= 0.218
R= -0.003
P= 0.986
R=-0.149
P= 0.365
R=-0.161
P= 0.388
R= 0.009
P= 0.964
R=-0.268
P= 0.168
R= 0.077
P= 0.655
R= 0.206
P= 0.275
R= 0.039
P= 0.839
Total R= -0.137
P= 0.353
R= -0.061
P= 0.713
R= -0.114
P= 0.488
R=-0.211
P= 0.255
R= -0.073
P= 0.711
R=-0.314
P= 0.104
R= 0.049
P= 0.775
R= 0.199
P= 0.293
R= 0.039
P= 0.838
SGRQ
Symptoms R= 0.192
P= 0.190
R= 0.138
P= 0.400
R= 0.153
P= 0.351
R= 0.146
P= 0.425
R= 0.154
P= 0.426
R= 0.179
P= 0,353
R= -0.036
P= 0.837
R= -0.181
P= 0.339
R= -0.175
P= 0.356
Activity R= 0.124
P= 0.403
R= 0,039
P= 0.813
R= 0.084
P= 0.611
R= 0.213
P= 0.241
R= -0.014
P= 0.942
R= 0.309
P= 0.103
R= -0.009
P= 0,961
R= -0.145
P= 0.443
R= -0.035
P= 0.856
Impacts R= 0.395*
P= 0.005
R= 0.217
P= 0.185
R= 0.419*
P= 0.008
R= 0.417*
P= 0,018 .
R= 0.236
P= 0.218
R= 0.505*
P= 0.005
R= 0.036
P= 0.834
R= -0.180
P= 0.342
R= -0.041
P= 0.828
Total R= 0.308*
P= 0.033
R= 0.164
P= 0.317
R= 0.295
P= 0.068
R= 0,346
P= 0.053
R= 0.157
P= 0.415
R= 0.446*
P= 0.015
R= 0.011
P= 0.951
R= -0.192
P= 0.308
R= -0.066
P= 0.730
IWQOL-Lite
Physical Function R= -0.165
P= 0.263
R= -0.304
P= 0.059
R= -.247
P= 0.129
R= -0,089
P= 0.635
R= -0.280
P= 0.149
R= -0.159
P= 0.419
R= 0.119
P= 0.495
R=0.164
P= 0.394
R= 0.180
P= 0.350
Self Esteem R= 0.058
Pb 0.696
R= 0.015
P= 0.927
R= 0.063
P= 0.704
R=-0.098
P= 0.598
R= 0.177
P= 0.368
R= -0.321
P= 0.096
R= 0.198
P= 0.254
R= 0.141
P= 0.467
R= 0.342
P= 0.070
Sexual Life R= -0.202
P= 0.168
R= -0.170
P= 0.300
Rb -0.284
P= 0.080
R= -0.297
P= 0,105
R= -0.032
P= 0.870
R= -0.429* 
P= 0,023
R= 0.008
P= 0.962
R= 0.144
P= 0.456
R= 0.078
P= 0.688
Public Distress R= -0.129
P= 0.382
R= -0.108
P= 0.515
R= -0.244
P= 0.134
R= 0.174
P= 0.349
R= 0.061
P= 0.757
R= 0.094
P= 0.634
R= 0.110
P= 0.530
R= 0.041
P= 0.834
R= 0.167
P= 0.385
Work R—0.039
P= 0,790
R= -0.131
P= 0,427
R= -0.126
P= 0,444
R= -0.092
P= 0.621
R= -0.118
P= 0.549
R=-0.157
P= 0.424
R=-0.138
P= 0.429
R= 0.069
P= 0.724
R— =0.097
P= 0,615
Total R= -0,157
P= 0.286
R= -0.190
P= 0.247
R= -0.240
P= 0.140
R= -0.096
P= 0.608
R= -0,062
P= 0.754
R= -0.246
P= 0.207
R= 0.122
P= 0.485
R= 0.142
P= 0.462
R= 0,215
P= 0.262
* significant correlation p<0.05
Table 60. Correlation r(p) between measures of exhaled nitric oxide and 
domain scores at each visit for the SF-36, SGRQ and IWQOL-Lite HRQoL 
questionnaires
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FeNO 50ml
Baseline to 6 months
Alveolar NO
Baseline to 6 months
Bronchial flux NO 
Baseline to 6 months
SF36
Rhys Functioning R= -0.172 R= -0.287 R= 0.023
P= 0.331 P= 0.184 P— 0.919
Role Physical R= -0.125 R= 0.098 R= -0.139
P= 0.481 P= 0.655 P= 0.528
Bodily Pain R= -0.101 R= 0.120 R= -0.157
P= 0.570 P= 0.586 P= 0.474
General Health ZJ II p b a> R- 0.185 R= 0.212
P= 0.927 P= 0.399 P= 0.332
Vitality R= 0.122 R= 0.239 R= 0.128
P= 0.493 P= 0.272 P= 0.559
Social functioning R= -0.082 R= -0.045 R= -0.175
P= 0.644 P= 0.837 P= 0.425
Role Emotional R= -0.068 R= -0.026 R= 0.079
P= 0.701 P= 0.907 P= 0.720
Mental Health R= 0.132 R= 0.018 R= 0.211
P= 0.456 P= 0.935 P= 0.333
Physical Health R= -0.110 R= 0,110 R= -0.052
summary P= 0.534 P= 0.617 P= 0.814
Mental Health R= -0.014 R= 0.047 R= 0.106
Summary P= 0.938 P= 0.830 P= 0.629
Total R= -0.088 R= 0.056 R= -0.006
P= 0.620 P= 0.801 P= 0.978
SGRQ
Symptoms R= 0.161 R= 0.181 R= 0.184
P= 0.363 P= 0.408 P= 0.401
Activity R= -0.176 R= -0.011 R= -0.297
P= 0.319 P= 0.962 P= 0.169
Impacts R= -0.103 R= 0.028 R= -0.249
P= 0.561 P= 0.899 P= 0.252
Total R= -0.085 R= 0.055 R= -0.227
P= 0.633 P= 0.803 P= 0.297
IWQOL-Lite
Physical Function R= 0.135 R= -0.237 R= 0.179
P= 0.453 P= 0.289 P= 0.426
Self Esteem R— 0.410* R= 0.061 R= 0.503*
P= 0.018 P= 0.787 P= 0.017
Sexual Life R= 0.113 R= -0.345 R= 0.060
P= 0.532 P= 0.116 P= 0.790
Public Distress R~ 0.089 R= -0.025 R= 0.133
P= 0.624 Tl I! p b ro P= 0.556
Work R= 0.154 R= -0.173 R= 0.157
P= 0.392 P- 0.441 P= 0.486
Total R= 0.193 R= -0.233 R= 0.210
P= 0.283 P= 0.296 P= 0.349
* significant correlation p<0.05
Table 61. Correlations between change in domain score and changes in 
measures of exhaled nitric oxide between baseline and 6 months for the 
SF-36, SGRQ and IWQOL-Lite HRQoL questionnaires
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Bronchial responsiveness and specific airway conductance
Baseline 3 months 6 months
SF36 Log10
PC45
sGaw Logic
PC45
sGaw Logic
PC45
sGaw
Rhys Functioning R= 0.006 
P= 0.969
R= - 
0.110
P= 0.451
R= - 
0.058
P= 0.753
R= - 
0.137
P= 0.456
R=~
0.252
P= 0.150
R= -0.237
P= 0.164
Role Physical R= 0.065 
P= 0.659
R= - 
0.073
P= 0.620
R= - 
0.160
P= 0.382
R= - 
0.197
P= 0.280
R= 0.071 
P= 0.688
R= -0.073
P= 0.671
Bodily Pain R=.
0.082
P= 0.579
R=.
0.075
P= 0.606
R“ - 
0.216
P= 0.235
R= - 
0.281
P= 0.119
R= 0.022 
P= 0.902
R= -0.154
P= 0.369
General Health R= 0.032 
P= 0.827
R= - 
0.002
P= 0.988
R= - 
0.014
P= 0.940
R= 0.235 
P= 0.195
R= 0.021 
P= 0.907
R= 0.149
P= 0.385
Vitality R= 0.083 
P= 0.577
R= 0.117 
P= 0.424
R= - 
0.035
P= 0.849
R=-
0.139
P= 0.448
R= - 
0.090
P= 0.611
R= -0.226
P= 0.185
Social functioning R= 0.178 
P= 0.225
R= - 
0.021
P= 0.885
R= - 
0.078
P= 0.673
R= - 
0.236
P= 0.193
R= - 
0.167
P= 0.345
R= -0.258
P= 0.129
Role Emotional R= 0.092 
P= 0.535
R= - 
0.244
P= 0.091
R= - 
0.307
P= 0.088
R= - 
0.288
P= 0.110
R— - 
0.235
P= 0.182
R= -0.271
P= 0.110
Mental Health R=
0.285*
P= 0.049
R= - 
0.083
P= 0.572
R= - 
0.114
P= 0.535
R= - 
0.029
P= 0.874
R= - 
0.332
P= 0.055
R= -0.371*
P= 0.026
Physical Health 
summary
R= 0.033 
P= 0.824
R= - 
0.048
P= 0.741
R= - 
0.136
P= 0.458
R= - 
0.154
P= 0.400
R— - 
0.037
P= 0.836
R= -0.137
P= 0.426
Mental Health 
Summary
R= 0.162 
P= 0.272
R= - 
0.101
P= 0.491
R= - 
0.178
P= 0.330
R= .
0.159
P= 0.386
R= - 
0.211
P= 0.230
R= -0.260
P= 0.126
Total R= 0.103 
P= 0.484
R= - 
0.104
P= 0.478
R= - 
0.189
P= 0.300
R= - 
0.214
P= 0.240
R= - 
0.151
P= 0.394
R= -0.128
P= 0.456
SGRQ
Symptoms R= - 
0.092
P= 0.534
R= 0.004 
P= 0.979
R= 0.010 
P= 0.955
R= 0.153 
P= 0.396
R= - 
0.116
P= 0.513
R= -0.029
P= 0.864
Activity R= 0.022 
P= 0.884
R= 0.066 
P= 0.652
R= 0.078 
P= 0.665
R= 0.154 
P= 0.392
R= 0.248 
P= 0.157
R= 0.091
P= 0.598
Impacts R= - 
0.140
P= 0.344
R= 0.027 
P= 0.855
R= - 
0.213
P= 0.234
R= - 
0.094
P= 0.604
R=-
0.007
P= 0.970
R= 0.210
P= 0.219
Total R= - 
0.091
P= 0.540
R= 0.041 
P= 0.777
R= -
0.071
P=0.696
R= 0.054 
P= 0.765
R= 0.067 
P= 0.705
R= 0.147
P= 0.392
IWQOL-Lite
Physical Function R= - 
0.016
P= 0.916
R= - 
0.006
P= 0.965
R= - 
0.258
P= 0.162
R= - 
0.236
P= 0.201
R=-
0.120
P= 0.507
R= -0.081
P= 0.645
Self Esteem R=
0.349*
P= 0.015
R= 0.200 
P= 0.168
R= 0.354 
P= 0.050
R= 0.193 
P= 0.297
R= 0.329 
P= 0.062
R= 0.049
P= 0.782
Sexual Life R= 0.010 
P= 0.945
R= - 
0.017
R= 0.139 
P= 0.455
R= 0.074 
P= 0.692
R= 0.156 
P= 0.386
R= -0.274
P= 0.112
279
P= 0.908
Public Distress R= 0.191 
P= 0.193
R= 0.067 
P= 0.645
R= - 
0.184
P= 0.322
R= - 
0.143
P= 0.444
R= 0.122 
P= 0.499
R= 0.200
P= 0.250
Work R= 0.017 
P= 0.908
R= - 
0.105
P= 0.472
R=.
0.110
P= 0.558
R= - 
0.151
P= 0.418
R- 0.227 
P= 0.203
R= -0.144
P= 0.411
Total R= 0.169 
P= 0.251
R= 0.056 
P= 0.700
R= - 
0.025
P= 0.896
R= - 
0.073
P= 0.696
R= 0.126 
P= 0.486
R= -0.062
P= 0.722
* significant correlation p<0.05
Table 62. Correlation r(p) between bronchial responsiveness, specific 
airway conductance and domain scores at each visit for the SF-36, 
SGRQ and IWQOL-Lite HRQoL questionnaires
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Log 10 PC45
Baseline to 6 months
sGaw
Baseline to 6 months
SF36
Phys Functioning R= -0.250 R= -0.187
P= 0.176 P= 0.296
Role Physical R= 0.155 R= -0.040
P= 0.404 P= 0.826
Bodily Pain R= 0.061 R= 0.131
P= 0.743 P= 0.468
General Health R= 0.089 R= 0.224
P= 0.635 P= 0.209
Vitality R= -0.185 R= 0.109
P= 0.319 P= 0.545
Social functioning R= -0.021 R= -0.044
P= 0.910 P= 0.810
Role Emotional R= 0.094 R= 0.183
P= 0.616 P= 0.309
Mental Health R= -0.176 R= -0.127
P= 0.344 P= 0.482
Physical Health summary R= 0.041 R= 0.040
P= 0.828 P= 0.826
Mental Health Summary R= -0.008 R= 0.131
P= 0.968 P= 0.468
Total R= 0.035 R= 0.135
P= 0.854 P= 0.453
SGRQ
Symptoms R= 0.159 R= 0.261
P= 0.393 P= 0.143
Activity R= 0.273 R= 0.156
P= 0.137 P= 0.387
Impacts R= 0.181 R= 0.034
P= 0.329 P= 0.849
Total R= 0.265 R= 0.156
P= 0.150 P= 0.386
IWQOL-Lite
Physical Function R= -0.175 R= -0.072
P= 0.347 P= 0.696
Self Esteem R= -0.065 R= -0.188
P= 0.730 P= 0.302
Sexual Life R= -0.469* R= -0.385*
P= 0.008 P= 0.029
Public Distress R= -0.101 R= -0.068
P= 0.590 P= 0.712
Work R= -0.261 R= -0.123
P= 0.157 P= 0.502
Total R= -0.302 R= -0.209
P= 0.099 P= 0.250
* significant correlation p<0.05
Table 63. Correlations between change in domain score and changes in 
bronchial responsiveness and specific airway conductance between 
baseline and 6 months for the SF-36, SGRQ and IWQOL-Lite HRQoL 
questionnaires
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Appendix C
Additional information for differential cell counts.
Reproducibility. Each individual slide of subjects’ sputum was counted 
twice on separate occasions by the same individual. The following Bland 
Altman plots are based on these two separate counts to check for quality of 
reproducibility.
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Fig 18. Bland Altman plots for differential cell counts of all subjects at 
each visit. Each individual cell type is shown
Correlation between change in differential cell count between visits and
change in weight % between visits.
Whole group
Baseline to 3 
months
3 months to 6 
months
Baseline to 6 
months
Neutrophils -0.364 (0.201) 0.163 (0.561) 0.144 (0.609)
Macrophages 0.396 (0.161) -0.199 (0.477) -0.025 (0.929)
Eosinophils -0.007 (0.981) 0.170 (0.545) -0.090 (0.750)
Epithelial -0.177 (0.544) -0.169 (548) -0.026 (0.926)
Lymphocytes 0.157 (0.592) -0.140 (0.620) -0.151 (0.590)
Metachromatic 0.100 (0.735) -0.359 (0.189) 0.200 (0.475)
Table 64. R (p value) shown for investigation of correlaltions of a change
in weight as percentage of starting weight and change in cell count for 
each cell type for all subjects 
Dietician Group
Baseline to 3 
months
3 months to 6 
months
Baseline to 6 
months
Neutrophils -0.770 (0.009) 0.193 (0.569) -0.311 (0.382)
Macrophages 0.674 (0.033) -0.093 (0.785) -0.094 (0.797)
Eosinophils 0.013(0.972) -0.003 (0.994) 0.503 (0.138)
Epithelial -0.162 (0.655) -0.233 (0.490) -0.413(0.235)
Lymphocytes 0.250 (0.486) 0.014 (0.967) -0.285 (0.425)
Metachromatic 0.117 (0.748) -0.173 (0.612) -0.078 (0.831)
Table 65. R (p value) shown for investigation of correlaltions of a change
in weight as percentage of starting weight and change in cell count for 
each cell type for the dietician group
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Control Group
Baseline to 3 
months
3 months to 6 
months
Baseline to 6 
months
Neutrophils 0.655 (0.345) 0.229 (0.771) 0.289 (0.638)
Macrophages -0.425 (0.575) -0.300 (0.700) -0.091 (0.884)
Eosinophils -0.051 (0.949) 0.206 (0.794) -0.283 (0.644)
Epithelial -0.269 (0.731) -0.295 (705) 0.496 (0.396)
Lymphocytes -0.041 (0.959) -0.482 (0.518) 0.165 (0.791)
Metachromatic NA* -0.407 (0.593) 0.630 (0.255)
*couid not be computed as at least one of the variables is constant
Table 66. R (p value) shown for investigation of correlations of a change 
in weight as percentage of starting weight and change in cell count for 
each cell type for the dietician group.
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Appendix D
Additional information for bronchial responsiveness
Comparing dietician and control groups.
Baseline 3 months 6 months
sGaw 0.579 (0.450) 0.513(0.479) 0.345 (0.561)
pc45 0.145 (0.706) 0.013(0.910) 0.206 (0.653)
LogPC45 0.057 (0.812) 0.186 (0.669) 0.016(0.901)
DRS 0.059 (0.809) 0.116 (0.736) 1.032 (0.317)
BRI 0.039 (0.844) 0.153 (0.698) 0.682 (0.415)
Table 67. F statistic (p values) when comparing dietician and control 
groups for each variable at each visit. ANOVA
Baseline to 3 
months
Dietician group
Baseline to 3 
months
Control group
Baseline to 6 
months
Dietician group
Baseline to 6 
months
Control group
sGaw -0.01 (0.046) 0.011 (0.029) -0.002 (0.045) 0.008 (0.042)
PC4fi 0.097 (0.339) 0.02 (0.595) 0.186 (0.651) 0.04 (0.223)
LogPC45 0.134 (0.35) 0.047 (0.541) 0.079 (0.394) 0.173 (0.329)
DRS -51.25 (26.17) -47.93 (18.55) 5.83 (18.91)* -8.87 (18.35)*
BRI -0.036 (0.097) -0.027 (0.153) 0.026 (-0.064)* 0.026 (0.102)*
* significant diflference between groups p<0.05
Table 68. Mean (sd) change from baseline for sGaw, Bronchial 
responsiveness and Bronchial reactivity from baseline to 3 and 6 
months for each group. * denotes significant difference between groups
There were no significant differences between dietician and control 
groups for changes from baseline for any variables of airway responsiveness 
or reactivity or specific airway conductance except for the dose response 
slope and bronchial reactivity index between visit 2 and visit 4.
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Change from baseline per vistt for sGaw
Dietician group 
------ Control group
Change from baseline per visit for LoqPC45
-•-Dietician group 
—Control group
Fig 23. Graphs showing change from baseline for sGaw, PC45, LogPC45, 
DRS and BRI for each visit for dietician and control groups. P values 
show comparison of means between the groups at each visit
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Baseline 3 months' 6 months
sGaw¥ R= -0.045
P= 0.758
R= -0.002
P= 0.993
R= -0.163
P= 0.342
PC45¥ R= 0.100
P= 0.497
R= 0.274
P= 0.123
R= 0.005
P= 0.977
LogPC45 R= 0.002
P= 0.990
R= 0.391
P= 0.025*
R= -0.012
P= 0.947
DRS R= -0.140
P= 0.342
R= -0.229
P= 0.192
R= 0.005
P= 0.976
BRI R= -0.158
P= 0.285
R= -0.274
P= 0.117
R= -0.018
P= 0.922
¥ = Skewed data therefore Spearman’s Correlation used 
* significant correlation p<0.05
Table 69. Correlations between measures of s Gaw, bronchial 
responsiveness, bronchial reactivity and BMI for all subjects
Dietician
group
baseline
Control group 
baseline
Dietician 
group 3 
months
Control group
3 months
Dietician 
group 6 
months
Control group 
visit 6 months
sGaw ¥ R= -0.177
P= 0.397
R= 0.109
P= 0.611
R= -0.133
P= 0.575
R= 0.138
P= 0.654
R= -0.267
P= 0.243
R= 0.029
P= 0.918
PC45 ¥ R= 0.007
P= 0.974
R= 0.241
P= 0.269
R= 0.203
P= 0.391
R- 0.280
P= 0.354
R= -0.011
P= 0.963
R= -0.014
P= 0.960
LogPC4
5
R= -0.189
P= 0.365
R= 0.235
P= 0.133
R= 0.160
P= 0.500
R= 0.659*
P= 0.014
R= -0.020
P= 0.936
R= 0.003
P= 0.990
DRS R= 0.000
P= 0.998
R= -0.323
P= 0.133
R= -0.166
P= 0.471
R= -0.322
P= 0.283
R= 0.008
P= 0.973
R= -0.035
P= 0.900
BRI R= -0.007
P= 0.972
R= -0.347
P= 0.105
R= -0.129
P= 0.576
R= -0.460
P= 0.114
R= -0.001
P= 0.996
R= -0.069
P= 0.807
¥ = Skewed data therefore Spearman’s Correlation used 
* significant correlation p<0.05
Table 70. Correlations between measures of s Gaw, bronchial 
responsiveness, bronchial reactivity and BMI for dietician and control 
groups
Baseline to 3 months Baseline to 6 months
All
subjects
Dietician
group
Control
group
All
subjects
Dietician
group
Control
group
sGaw R= 0.257
P= 0.162
R= 0.528*
P= 0.020
R= -0.159
P= 0.622
R= 0.069
P= 0.699
R= 0.268
P- 0.254
R= -0.200
P= 0.493
PC45 R= 0.050
P= 0.795
R= -0.030
P= 0.904
R= 0.112
P= 0.758
R= -0.221
P= 0.240
R= -0.445
P= 0.074
R= 0.253
P= 0.405
LogPC45 R= 0.130
P= 0.493
R~ -0.203
P= 0.405
R= 0.375
P= 0.256
R= -0.038
P= 0.838
R= -0.334
P= 0.175
R= 0.239
P= 0.431
DRS R= -0.017
P= 0.927
R= -0.035
P= 0.883
R—0.028
P= 0.934
R= -0.137
P= 0.462
R= 0.157
P= 0.534
R= -0.325
P= 0.279
BRI R= -0.109
P= 0.558
R= 0.376
P= 0.102
R= -0.432 
P= 0.184
R= -0.165
P= 0.375
R= 0.284
P= 0.254
R= -0.411
P= 0.163
* significant correlation p<0.05
Table 71. Correlation between weight loss as a percentage of starting 
weight and change in sGaw, PC45, LogPC45, DRS and BRI at 3 and 6 
months
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Corresponding change Change in FeNOSOml 
between baseline and 3 
months
Change in FeNOSOml 
between baseline and 6 
months
sGaw R= 0.122 R= 0.132
P= 0.553 P= 0.478
PC45 R= -0.077 R= -0.075
P= 0.714 P= 0.697
LogPC45 R- -0.002 R= -0.050
P= 0.991 P= 0.794
DRS R= -0.077 R= 0.218
P= 0.707 P= 0.248
BR1 R= 0.069 R= 0.202
P= 0.738 P= 0.283
Table 72. Correlations between change in exhaled nitric oxide and 
measures of bronchial responsiveness and reactivity
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